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Abstract 
 
DEVELOPMENT OF HIGH EFFICIENCY DRY POWDER INHALERS FOR USE WITH 
SPRAY DRIED FORMULATIONS 
 
By Dale Robert Farkas 
 
A dissertation submitted in partial fulfillment of the requirements for the degree of 
Doctor of Philosophy at Virginia Commonwealth University. 
 
Virginia Commonwealth University, 2017 
 
Director: Dr. P. Worth Longest 
Professor, Department of Mechanical and Nuclear Engineering and 
Department of Pharmaceutics 
 
 Dry powder inhalers (DPIs) are advantageous for delivering medication to the 
lungs for the treatment of respiratory diseases because of the stability of the powders, 
relative low cost, synchronization of inhalation and dose delivery, and many design 
options that can be used for optimization.  However, currently marketed DPIs are very 
inefficient in delivering medications to the lungs.  This study has developed multiple new 
high efficiency DPIs for use with spray dried excipient enhanced growth (EEG) powder 
formulations based on the following platforms:  capsule-based for oral inhalation, high-
dose for oral inhalation, inline with 3D rod array dispersion, and inline with capillary jet 
dispersion.  The capsule-based DPIs for oral inhalation implemented a 3D rod array for 
aerosol dispersion with optimal designs producing mass median aerodynamic diameters 
(MMADs) in the range of 1.3-1.5 µm and emitted doses in the range of 79-81%.  Keys to 
 
 
inhaler success were the orientation of the capsule and inclusion of the 3D rod array.  
For the high-dose oral inhaler, performance was similar to the optimized capsule-based 
devices, while aerosolizing a much larger mass of powder.  Surprisingly, removal of the 
fluidized bed of spheres improved performance producing a simple high dose device 
containing only a single dose sphere.  The inline device using the 3D rod array was 
effective in producing particles of approximately 1.5 µm, at flow rates consistent with 
high flow therapy using a 1 L ventilation bag as the delivery mechanism.  Using a 
capillary jet as the dispersion mechanism, further advances were made to allow for both 
delivery using a low volume (LV) of air and delivery in low flow therapy.  This easily 
adaptable platform was able to produce a high quality aerosol out of a nasal cannula 
with an ED greater than 60% and a size (~2 µm) that should produce minimal 
extrathoracic losses.  In conclusion, this study demonstrates (i) the design and 
optimization of DPIs capable of delivering EEG aerosols to the lungs using oral 
inhalation, (ii) the ability to deliver EEG aerosols using N2L aerosol administration, and 
(iii) the design of a new flexible LV-DPI device that is easily adaptable to multiple 
patients and delivery platforms, which are greatly needed in clinical environments.  
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Chapter 1 Specific Aims 
 
The goal of this research is the development of multiple dry powder inhaler (DPI) 
platforms for different applications that can effectively aerosolize excipient enhanced 
growth (EEG) and other spray dried powders to provide lung targeted delivery of inhaled 
therapeutics.  Potential pharmacotherapies that could benefit from the technology 
developed in this work include inhaled antibiotics, mucus clearance agents, anti-
inflammatories, and surfactants.  Excipient enhanced growth is a new inhalation delivery 
technique developed at VCU in which small hygroscopic aerosols are formed and 
inhaled by the patient (Hindle et al. 2012).  The initial small size of the aerosol largely 
eliminates mouth-throat depositional losses for orally inhaled medications (Son et al. 
2013a).  Furthermore, the small initial size of the aerosol enables efficient nose-to-lung 
(N2L) aerosol administration, which can be advantageous for delivering the aerosol over 
an extended period of time or delivery during non-invasive ventilation (NIV) (Longest et 
al. 2011b).  The hygroscopic excipient employed in the multi-component particles 
induces condensational growth of the particles into droplets within the lungs and 
targeted deposition.  While previous work at VCU has shown the EEG technique to 
effectively target lung deposition of different therapeutics (Hindle et al. 2012, Longest et 
al. 2012b), generating aerosols with small initial mass median aerodynamic diameters 
(MMADs), for example < 1.5 µm, from a passive DPI is highly challenging. 
2 
 
Approaches that can be used for producing small dry powder aerosols include (i) 
optimization of the powder formulation with the inclusion of dispersion enhancers and 
(ii) the development of new aerosolization devices.  The VCU Team has previously 
investigated the optimization of EEG formulations and aerosolization with existing and 
modified devices (Longest et al. 2013b, Son et al. 2013a, Son et al. 2013b).  This 
project seeks to develop new and optimal devices for the deaggregation of EEG 
formulations that produce the required small aerosols for high efficiency lung-target 
delivery of different medications. 
The developed devices are intended for traditional oral inhalation administration 
in adults as well as inline devices for N2L aerosol administration in both adults and 
children.  For most applications considered, delivering high doses with a single loading 
of the inhaler is an intended design goal.  Device modifications and optimization are 
performed through multiple iterations, using computational fluid dynamics (CFD) when it 
is most useful.  Aerosolization performance of the devices is tested using multiple in 
vitro characterization techniques, together with evaluation of aerosol transmission 
through human replica in vitro upper airway models.  Ultimately, device performance is 
characterized based on high emitted dose (ED) and small mass median aerodynamic 
diameter (MMAD) (in the range ≥70% and ≤1.5 µm, respectively), and top performing 
devices are proposed for each of the applications considered. 
The inhaler systems investigated were as follows: an orally administered DPI for 
adults and children, a high-dose oral DPI for adults and children, a high flow nasal 
cannula delivery system to be used with a standard ventilation bag, a low flow nasal 
delivery system for use in-line with a nasal cannula system, and a low volume device 
3 
 
that can be attached to multiple patient interfaces to inject the aerosol into an already 
present flow.  Each system will be designed with 3D modeling software and optimized 
as needed using a selective combination of Computational Fluid Dynamics (CFD) and 
experimental testing.  The devices will be built using rapid prototyping (3D printing) from 
both in house machines as well as from outside companies, and these devices will be 
tested in collaboration with the VCU Department of Pharmaceutics (Dr. Michael Hindle).  
Each listed system will have its own optimized lead device to be presented, for a total of 
5 final designs. 
 
Objective 1: Develop a new DPI for oral inhalation using a capsule-based drug 
loading approach and the proven 3D rod array technology. 
All prescribed DPIs in the United States and the rest of the world are very 
inefficient in delivering drug to the lungs of a patient.  Large particles exiting the inhalers 
cause high mouth-throat (MT) deposition as well as high variability in dose delivery.  To 
decrease the particle size exiting the DPI, a higher flow rate through the device is 
sometimes used, but this can also cause increased MT deposition making this method 
counterproductive (DeHaan et al. 2004).  In order to minimize MT depositional loss, a 
smaller particle size could be coupled with a relatively low flow rate.  However, small 
particle sizes entering the lung may lack sufficient momentum to deposit and may then 
be exhaled by the patient.  To remedy this situation, the small particles need to increase 
in size once they enter the lung to foster deposition, decrease losses from exhalation, 
and potentially target the site of deposition.  The EEG method, proposed and developed 
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at VCU, is designed to provide this highly desirable particle size increase once the 
aerosol is within the lungs (Hindle et al. 2012, Longest et al. 2012b).   
To deaggregate the powder for effective delivery, an inhaler geometry including a 
3D rod array in the mouthpiece was designed previously (Son et al. 2013b).  The rods 
are perpendicular to the flow and cause increased turbulence to provide the energy 
needed to break up the powder after exiting the capsule.  The parameter used to 
quantify the increase in turbulence in the system, non-dimensional specific dissipation 
(NDSD), was proposed by Longest et al. (2013b).  This parameter takes into account 
the exposure time, turbulent energy, and turbulent length scale of the flow through the 
device.  The NDSD has been shown to have a direct correlation to the particle size 
exiting a device and can assist with device optimization using CFD before performing 
experimental device characterization. 
The two proposed oral DPI designs in this study both include the 3D rod array 
technology in the mouthpiece, but have different capsule chamber orientations, with one 
being perpendicular and one being parallel with the incoming air flow.  The use of these 
inhalers is passive by design, in that user-generated inspiratory flow through the inhaler 
creates the flow needed to empty the powder from the capsule.  The tasks required for 
Objective 1 are listed below. 
 
Task 1.1: Develop prototype devices that align the capsule's primary axis perpendicular 
(VCU1 DPI or CC1-3D) and parallel (VCU3 DPI or CC90-3D) with the incoming air flow 
and provide a flow rate of 45 LPM at a 4 kPa pressure drop. 
• Status: Complete and published (Behara et al. 2014a, Behara et al. 2014b) 
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Task 1.2: Investigate the effect of hole position on capsule vibration in the VCU1 device 
using high-speed photography. Link the measured vibration outcome to aerosolization 
performance. 
• Status: Complete and published (Behara et al. 2014a) 
Task 1.3: Investigate the effects of different rod materials on aerosol deaggregation in 
the VCU1 device. 
• Status: Complete and published (Behara et al. 2014a) 
 
Objective 2: Develop an inline DPI platform that implements capsule loading and 
the 3D rod array, and is actuated by a ventilation bag or gas source for operation 
at high flow (~15 LPM) and low flow (~5 LPM). 
 A major application for both high and low flow nose-to-lung (N2L) delivery is 
administering medication while a patient is on mechanical ventilation.  Instead of using 
invasive techniques (endotracheal or tracheostomy tube), noninvasive ventilation (NIV) 
is often used to deliver both oxygen and medication to a patient. This is typically done 
using a nasal cannula, face mask, or other type of interface that is designed to 
continuously deliver oxygen in the same way as standard NIV techniques, but, when 
medication needs to be delivered, a device inline with the flow could be activated to 
produce an aerosol with the needed medication and use the flow produced by the 
ventilation bag to carry the aerosol through the system and to the patient.  The problem 
with delivering medication using this technique is the amount of tubing and connectors 
that the aerosol must pass through before reaching the patient, causing high losses. 
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The design of the high flow delivery system proposed is based on that of the 
original 3D rod array design.  While the 3D rod array itself is very similar to the oral 
inhaler design (Objective 1), the inlet and outlet were configured to connect with a 
ventilation bag gas source and small diameter outlet, as would be needed to connect 
with NIV gas delivery lines or a nasal cannula interface.  To allow for decreased flow 
rates through the devices and maintain good deaggregation of the powder, the 3D rod 
array was modified based on CFD predictions and experimental results. 
 The low flow system is very similar to the high flow device, but additional 
changes were made to the rod array to allow for a lower flow rate.  This system was 
also designed to be used with smaller tubing (4 mm vs. 10 mm), closer to that of a 
standard oxygen cannula system.  The device as well as y-connector and a nasal 
cannula are also designed to replace the commercial cannula system used in most 
hospitals in order to improve aerosol transmission.  The tasks for this objective are 
listed below. 
Task 2.1: Prototype the device platform using a critical orifice to control flow rate with 
required seals and connections for proper operation. 
• Status: Complete and published (Behara et al. 2014c) 
 
Objective 3: Develop a high dose oral inhalation DPI for use with adults or 
children that operates effectively with powder masses of 50 and 100 mg. 
To deliver a large amount of formulation (50 mg or greater with a target 
application of 100 mg) to a patient’s lungs, the previously developed DPIs using the 3D 
rod array technology would not be appropriate as the capsules in these designs cannot 
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hold the amount of powder required and is typically limited to ~25 mg for effective 
operation.  A new design based on a fluidized bed is proposed to accommodate a large 
amount of powder and deaggregate it efficiently.  The theory behind deaggregation 
using the fluidized bed design involves using small spheres to grind together and impact 
with a powder when a gas is forced through the bed (Prenni et al. 2000).  The design of 
this device includes a hollow dosing sphere and mixing balls inside of a chamber with a 
90 degree bend.  The tasks for completing this objective are shown below. 
Task 3.1: Prototype and optimize a new high dose DPI using a fluidized bed design that 
operates at pressure drops of 4 kPa (adult) and 2 kPa (diseased airways or child). 
• Status: Complete and published (Farkas et al. 2015) 
Task 3.2: Screen and test aerosolization performance of the fluidized bed DPI at 
pressure drops of 4 kPa and 2 kPa. 
• Status: Complete and published (Farkas et al. 2015) 
Task 3.3: Test performance of the fluidized bed device containing only the dose sphere 
in order to reduce device depositional losses. 
• Status: Complete and published (Farkas et al. 2015) 
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Objective 4: Develop a new low-volume capsule-based inline DPI platform 
actuated with an external (low volume) gas source such as a syringe or placebo 
MDI.  The device must be connectable to positive pressure systems such as a 
mechanical ventilation line or NIV mask and prevent the ingress of humidified air 
into the powder containment area. 
 Delivering inhaled medications to infants can be done in a number of ways: 
endotracheal tubes, face masks, nasal cannulas, etc., but due to low tidal volumes it 
can be difficult to generate a small particle aerosol and have sufficient inspiratory flow to 
deliver it to the lungs.  The design of a low volume device could be used to inject an 
aerosol into the flow path of the chosen delivery method.  The device is to be powered 
by multiple small bursts of compressed air from either a syringe or a placebo (HFA-only) 
metered dose inhaler (MDI), as well as the possibility of using a compressed air or 
oxygen source. 
The capsule device will be open along its longitudinal axis for capsule loading 
and when assembled will pierce the capsule with the same capillaries used for the inlet 
and outlet of the air and aerosol, respectively.  The use of a syringe air-source would 
require the user to refill the syringe with air after each actuation by pulling the plunger 
back into position.  Because this is a sealed system, the syringe will need to be 
removed or a three way valve will need to be positioned between the syringe outlet and 
the device to prevent powder from being pulled into the syringe and lost.  The MDI 
actuator will require an expansion chamber to evaporate the liquid HFA propellant 
before reaching the capsule to prevent aggregation of the powder.  Systems for low flow 
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nasal cannula (LFNC) delivery will be developed to administer the aerosol leaving the 
optimized device.  The tasks for completing Objective 4 are listed below. 
Task 4.1: Develop device prototypes for loaded doses in the range of 2-50 mg that 
pierce the capsule during closure and are powered by low gas volumes from a syringe 
or placebo MDI source. 
• Status: Complete and Accepted (Farkas et al. 2017) 
Task 4.2: Test device performance and develop an optimized platform and gas source. 
• Status: Complete and Accepted (Farkas et al. 2017) 
Task 4.3: Develop an optimized system and test delivery for administration during LFNC 
gas administration in an adult using steady state conditions. 
• Status: Complete and In Review 
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Chapter 2 Background 
  
The following review is organized based on the four objectives defined in Chapter 
1.  A review of controlled condensational growth techniques is presented first to connect 
the objectives, as all of the studies are aimed at producing devices to be used as 
platforms for delivering medication in this fashion.  Literature relevant to each specific 
objective is then reviewed successively. 
 
2.1 Controlled Condensational Growth Techniques 
  The excipient enhanced growth (EEG) method (Hindle et al. 2012, Longest et al. 
2012a, Longest et al. 2012b) is a possible solution to the low lung delivery efficiency of 
current commercial dry powder inhalers (DPIs).  This method requires a small particle 
size exiting the inhaler and, subsequently, entering the mouth-throat (MT) or nasal 
airways in nose-to-lung (N2L) delivery to avoid deposition in these extrathoracic 
regions.  Once the aerosol passes the extrathoracic airways, the inclusion of a 
hygroscopic excipient causes the particles to absorb the water vapor that naturally 
occurs in the lungs and increase in size fostering lung retention and potentially targeting 
the site of deposition. 
 Similar to the EEG approach is the Enhanced Condensational Growth (ECG) 
approach (Hindle et al. 2010, Longest et al. 2011a).  This approach requires the 
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introduction of humidified air into the lungs that condenses when it meets inhaled 
submicrometer particles in the airways, allowing them to increase in size and deposit 
within the lungs in a targeted manner.  Since the particles do not meet supersaturated 
air until after the nose-mouth-throat (NMT), the particles effectively bypass these 
regions, allowing for higher lung deposition and enabling targeted deposition in the 
airways by controlling the growth of the particles.  In a 2nd variation, the submicrometer 
particle and saturated humidity stream are combined at the point of inhalation, and 
inhalation velocity allows the particles to enter the lungs before appreciable size 
increase can occur.  With these ECG methods, a hygroscopic excipient is optional after 
determining the desired particle size increase. 
 Both the EEG and ECG methods have been shown, in vitro and with 
computational fluid dynamics (CFD), to effectively deliver medication to the lungs 
(Longest et al. 2011b, Tian et al. 2013).  The following studies will emphasize the EEG 
approach based on the focus of this dissertation, which is creating EEG aerosols. The 
reviewed studies will focus on the design of devices consisting of different techniques 
for aerosol generation and lung delivery using spray dried EEG aerosols and starting 
from the aggregated powder state.  Active devices, requiring an external source of air 
flow, as well as passive devices, requiring inhalation from the patient to generate the 
aerosol, will be developed in this work.  Techniques used for deaggregation in the 
devices include the use of the previously developed 3D rod array (Son et al. 2013b, 
Behara et al. 2014a, Behara et al. 2014b, Behara et al. 2014c), fluidized beds (Farkas 
et al. 2015), and the use of an air source as the primary energy for deaggregation.  
While there are many commercial DPIs available, these are not designed to deliver 
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EEG powders and are highly inefficient with most powder formulations.  For this reason, 
new devices are needed that are designed specifically for creating EEG aerosols, with 
smaller than conventional aerosol sizes, e.g., < 1.5 µm.  Furthermore, beyond the Penn 
Century Insufflator device for delivering test aerosols to animals, inline devices are not 
currently commercially available, motivating the need for new devices. 
 
2.2 Objective 1: Development of a High Efficiency Dry 
Powder Inhaler 
 
2.2.1 Handheld Dry Powder Inhalers 
 DPIs are becoming the most popular devices for delivering inhaled medication to 
the lungs (Smith et al. 2010).  A primary limitation associated with these devices is that 
most commercial DPIs use formulations of carrier particles and struggle to generate fine 
particle fractions less than 5 µm (FPF<5µm) above 40%.  These devices are also highly 
dependent on patient behavior, resulting in dramatic FPF reductions with decreasing 
flow rates (Prime et al. 1999, Islam et al. 2012, Zhou et al. 2014).  For example, the 
Flovent Diskus inhaler (GlaxoSmithKline, Raleigh, NC) was shown in vitro to have MT 
losses of 70% using a realistic airway model (Tian et al. 2011, Longest et al. 2012c).  
The mass median aerodynamic diameter (MMAD) of the Diskus inhaler was found to be 
2.99 µm at flow rate of 75 LPM, with this size increasing to 4.10 µm when lowering the 
flow rate to 37 LPM (Longest et al. 2012c). 
 With an increasing aerosol size, the chance of MT deposition also increases.  
The same holds true for an increasing device flow rate.  While the aerosol exiting the 
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DPI will most likely be smaller with a higher flow rate, the momentum will also increase, 
causing impaction on the approximately 90 degree turn at the back of the throat.  High 
efficiency delivery to the lungs can reduce side effects of drugs by decreasing MT 
deposition, thus decreasing systemic exposure.  Many future possibilities for inhaled 
medications, such as antibiotics, pain medications, and chemotherapy, have a very 
specific dosing requirement for effectiveness and come with significant side effects 
(Gagnadoux et al. 2008, Yi et al. 2010, Rubin 2011).  Because of these side effects, 
maximizing lung delivery efficiency and minimizing depositional loss in the extrathoracic 
airways is very important in order to achieve the desired pharmaceutical effect in a safe 
manner. 
A study to show MT deposition variability between normal humans was 
conducted by Delvadia et al. (2012) using the Budelin Novolizer (Meda 
Pharmaceuticals, Bishops Stortford UK).  Low, moderate, and high flow rates through 
three different MT models (small, medium, and large) were used to show intersubject 
variability in lung delivery efficiency.  Each flow rate was paired with a specific geometry 
for comparison purposes.  Flow rate increases from the small to large MT models 
showed an increase in MT deposition, as expected.  For example, using the high flow 
rate through the device and model, the losses increased (40 to 56%) as flow rate 
increased (73 to 99 LPM) when changing from the small to medium model.  However, 
the device produced less MT deposition with the high flow rate when compared to the 
low flow rate using the same model (48 vs 62%).  This 14% increase in MT deposition 
at a lower flow rate is most likely caused by the increase in aerosol size, due to reduced 
deaggregation, resulting in an increase in momentum that counteracts the decrease in 
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velocity.  While the lower device retention in this study more than offset the increase in 
MT deposition to produce a higher total lung dose (15-27% increase), the high 
deposition of 48-62% in the MT region shows there is significant room for needed 
improvement (Delvadia et al. 2012). 
In a second study by Delvadia et al. (2013), using the medium MT model 
characterized in the previous study (Delvadia et al. 2012), five commercial DPI systems 
(HandiHaler, Aerolizer, Easyhaler, Turbuhaler, and Diskhaler) were tested in vitro for 
comparison of lung dose and MT deposition between both each other as well as in vivo 
data reported in previous studies (Borgstrom et al. 1994, Vidgren et al. 1994, Meyer et 
al. 2004, Brand et al. 2007, Cass et al. 2012).  The range of lung deposition in these 
studies was between 13% with the Diskhaler (Cass et al. 2012) and greater than 30% 
with the Easyhaler (Vidgren et al. 1994, Delvadia et al. 2013).  While the HandiHaler 
was shown to have the lowest MT deposition of approximately 25-30%, device retention 
was much higher than the other devices (~60%), which resulted in a small lung dose of 
less than 20% (Brand et al. 2007, Delvadia et al. 2013).  Overall, this study showed a 
high variability in lung doses and MT deposition between different commercially 
available inhalers.  Reducing this variability is important in order to determine correct 
dosing actually received by the patient and to reduce the risk of side effects. 
 Spray dried pharmaceutical powder formulations, such as the Pulmosphere™ 
technology and the previously mentioned EEG method have improved inhaler 
performance with the use of highly dispersible compounds that contain smaller primary 
particle sizes, producing higher FPF values upon aerosolization (Sham et al. 2004, 
Geller et al. 2011, Young et al. 2013, Weers et al. 2014).  Pulmosphere™ technology is 
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an emulsion-based spray-drying process that produces less dense, porous particles 
(Geller et al. 2011).  While spray dried powders, in general, experience a reduced 
cohesive force and show an increase in dispersion, the porous surface of the 
Pulmosphere™ particles are designed to allow for even less agglomeration (Geller et al. 
2011).  Using the T-326 Inhaler, Geller et al. (2011) reported a lung dose of only 34% of 
the 80 mg loaded mass.  This was because losses of 22 and 44% occurred due to 
device retention and MT deposition, respectively. 
 Son et al. (2013a) optimized the spray drying of EEG powder formulations and 
tested aerosolization behavior with the commercially available Aerolizer.  The resulting 
aerosol performance showed the MT deposition to be minimal (<5%) while the FPF 
leaving the device was greater than 95%.  However, the flow rate for the device (90 
LPM) was considered to be too high for some patient populations (e.g., children and 
COPD patients). Because of this, the HandiHaler was chosen to be optimized for the 
EEG formulation in the study by Son et al. (2013) based on its similar aerosolization 
characteristics while using a much lower flow rate (45 LPM) at an equivalent 4 kPa 
pressure drop.  Longest et al. (2013b) demonstrated that the addition of a 3D rod array 
in the mouthpiece could increase device performance substantially by increasing the 
new Non-Dimensional Specific Dissipation (NDSD) parameter of the fluid flow.  This 
parameter was shown to have a direct correlation with the mean particle size leaving 
the inhaler (Longest et al. 2013b).  As a result, the NDSD can be used as a 
computational fluid dynamics (CFD)-based optimization and design parameter for 
developing EEG inhalers. 
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 In summary, commercial devices have been shown to perform poorly, with low 
lung doses due to high depositional losses in both the device and MT regions.  Device 
and formulation improvements have increased lung delivery efficiency, but much room 
for improvement still exists.  While the EEG formulation appears to be the best currently 
available option, the challenge of creating an initially submicrometer particle size with a 
DPI still remains. 
 
2.3 Objective 2: Development of an Inline DPI System using 
3D Rod Array Technology 
 
2.3.1 Active DPIs 
 When compared to the number of passive devices, few active devices have been 
used to form pharmaceutical aerosols (Tang et al. 2011, Laube et al. 2012, Pohlmann et 
al. 2013).  Potential applications of active devices include aerosol delivery to children 
(Laube et al. 2012), aerosol delivery to patients undergoing mechanical ventilation 
(Tang et al. 2011), nose to lung aerosol delivery (Longest et al. 2011b, Golshahi et al. 
2013), and aerosol delivery to animals (Grainger et al. 2004).  Since these devices do 
not rely on a patient to produce the needed flow through the device, they can be used in 
situations where the patient has decreased breathing capability or cannot follow the 
multiple step instructions associated with passive devices.  Everard et al. (1996) used a 
modified version of the Turbuhaler DPI to aerosolize budesonide through a 9 mm 
diameter endotracheal tube (ETT) with an active setup.  Delivery through the device and 
ETT was reported at 20%.  Tang et al. (2011) used the Osmohaler, powered by an adult 
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ventilation bag, to deliver an aerosol through both ETT and tracheostomy tubes for size 
characterization.  The setup of this experiment included a flow meter inline between the 
bag and device, as well as a one-way valve positioned between the device and 
impinger to prevent exhalation air from entering the device and corrupting the powder.  
FPF<5µm values were between 20 and 30% with an emitted dose (ED) in the range of 50-
60%.  Laube et al. (2012) used the Solovent® DPI to produce an aerosol to be 
introduced to the Sofia anatomical infant nose-throat (SAINT) model using an active 
setup that used a syringe as an airflow source.  While the device was reported to emit 
90% of the loaded dose, only 0.3-4% of that dose reached a filter used to represent the 
lungs, with most of the losses being in the cardstock spacer between the device and the 
model.  In a study by Corcoran et al. (2013), the MicroDose DPI was proposed for 
creating an aerosol using a piezoelectric system as the active means of powder 
deaggregation.  While device performance was not available in this study, 
pharmacokinetic data showed that the dose was comparable to a standard auto-injector 
pen with the same loaded dose.  From the previously mentioned studies, current active 
devices have a wide range of reported, approximate, lung delivery efficiencies (0.3-
30%).  FPFs are also very low, in the range of 20-30%, which makes them less 
desirable in the administration of EEG aerosols that require a small aerosol to penetrate 
the lungs. 
 
2.3.2 Nose-to-Lung (N2L) Aerosol Administration 
 Aerosol administration through the nose to the lungs can be an efficient way to 
deliver medication requiring continuous delivery over a long period of time, high doses 
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of medication also over a longer period of time, medication needing to be administered 
frequently, and delivery to patients under noninvasive ventilation (NIV).  However, since 
the nasal passages are very narrow, depositional losses are a concern when attempting 
to pass an aerosol through the nose to the lungs (Longest et al. 2011b).  Another 
disadvantage of N2L delivery is the powder having to pass through small diameter 
tubing and connectors that introduce flow direction (Longest et al. 2013a).  The 
connectors and tubing can provide the powder multiple deposition chances, thus 
lowering the dose available to be delivered to the patient. 
 To overcome both the nose and system connections acting as a filter for the 
aerosol, a smaller aerosol can be introduced.  Submicrometer aerosols have been 
shown using CFD as well as in vitro experiments to significantly decrease deposition 
(Longest et al. 2011b).  In this study, which used the ECG approach mentioned 
previously, NMT deposition was reduced from 72% to 14%.  Expiratory losses are also 
a concern when dealing with a small aerosol as they may not deposit before exhalation 
occurs.  Longest et al. (2011b) showed that the ECG method can provide the necessary 
particle size growth to decrease these losses as the size had more than doubled (0.9 to 
2 µm) as the aerosol reached the lungs.  Tian et al. (2014a) considered this approach in 
more detail by studying both EEG and ECG delivery techniques, using CFD, through a 
realistic NMT model using initial particles in the submicrometer range.  When using an 
aerosol with an MMAD of 0.9 µm entering the NMT, predicted lung doses for the three 
cases studied were in the range of 71-87%, much larger than the 26% delivered with an 
MMAD of 4.9 µm.  In addition, the aerosol was predicted to grow, with the EEG method, 
by 2.5-6% in diameter to prevent exhalation losses (Tian et al. 2014a). 
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 In summary, N2L delivery has many applications, including high dose delivery, 
frequent repeated doses of medication, and delivery during NIV.  Aerosol administration 
using this type of method is known to be inefficient because of both losses in delivery 
systems as well as losses in the nasal passage due to the long, narrow passages 
connecting the nose to the throat.  Streamlining of components, as well as creating 
submicrometer particles are techniques developed by our group that have been used 
with success to decrease these losses. 
 
2.4 Objective 3: High-Dose Dry Powder Inhaler Development 
 
2.4.1 Current DPI Dose Limitations 
Currently available DPIs are, for the most part, designed around delivering a small 
mass of formulation (0.5-20 mg).  While these small doses are consistent with some 
commercially available formulations, there are medications which require a much higher 
dose to be effective.  For example, antibiotics, anti-inflammatories, surfactants, and 
mucus clearance drugs all utilize higher doses (Keller et al. 2010, Ruppert et al. 2010, 
Young et al. 2013).  Using a commercial device for these types of medication would 
require multiple iterations of loading, inhalation, and reloading to obtain the correct 
dosage while also ensuring the performance of the device is unchanging.  Having to 
load multiple capsules to obtain the correct dose of medication can be tedious and may 
result in poor patient compliance, as well as decreased device performance if not done 
properly.  For some of these medications, such as antibiotics, incorrect dosing can lead 
to unwanted side effects as well as reduced effectiveness. 
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Aerosolizing a large mass of powder in a handheld device can prove difficult and 
has previously required either some sort of external power or flow source to cause 
vibrations or turbulence strong enough to disperse the powder (Corcoran et al. 2013) or 
implemented an inhaler designed for smaller doses with multiple loading cycles (Geller 
et al. 2011).  Using multiple capsules can save time compared to extended treatments, 
but loading multiple capsules is tedious, especially when it involves up to 10 loading 
cycles, such as the Bronchitol (Pharmaxis Ltd, Sydney, Australia) system (Bilton et al. 
2011). 
 
2.4.2 Current High Dose DPIs 
The Twincer inhaler is a passive device designed to deliver a loaded dose of up to 
50 mg, but higher amounts have not currently been tested (de Boer et al. 2012).  The 
ED of the device was reported to be between 90 and 95% for the dose range of 10-50 
mg.  However, the FPF<5µm range of 59 to 67% shows that a larger aerosol than desired 
for EEG delivery is leaving the device and will most likely lead to higher losses in the 
MT region.  This, coupled with the almost nonexistent FPF<1µm values that are required 
for the EEG application, makes this ineffective for EEG delivery. 
Another device, the Orbital multi-breath inhaler, was shown to deliver up to 400 mg 
of multiple powder formulations (Young et al. 2013).  This large mass was delivered 
over 16 inhalations with ED of approximately 75%, but the particle size, while 
satisfactory for formulations using a static particle size, was not ideal for EEG delivery, 
even with a flow rate of 60 LPM.  The device produced particle sizes with FPFs of 42-
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67% and MMADs of 3, 4.2, and 4 µm using Ciprofloxacin (Cipro), mannitol, and a 1:8 
Cipro-mannitol co-spray-dried powder, respectively (Young et al. 2013). 
 
2.4.3 Fluidized Beds 
Fluidized beds have been used to generate aerosols for many applications, but 
have mostly been used in large, commercial machines, not in a handheld device (Hinds 
1999).  This concept uses a collection of solids (often, spheres) that behave like a fluid 
when a gas passes through them (Prenni et al. 2000).  This fluid-like movement causes 
the solids to move around and contact each other, producing high frequency vibrations 
and a vibrating-like motion that can help deaggregate a powder. 
 Of the currently available high dose DPI designs, none have been designed 
specifically to deliver an EEG aerosol.  Because of this, the designs do not meet the 
desired performance requirements and new devices must be explored to achieve the 
needed performance.  A fluidized bed design could prove useful in delivering this large 
dose because of its good performance in commercial applications to create large 
amounts of monodisperse aerosols of small sizes (Lind et al. 2010). 
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2.5 Objective 4: Development of a Low-Volume Capsule-
Based Dry Powder Inhaler and Nose-To-Lung Delivery 
Platform 
 
2.5.1 Low Volume Uses/Benefits 
 Some patients, especially infants, require a device that uses a small volume of 
air to produce a useable aerosol.  Infants have a small tidal volume and cannot safely 
use traditional DPIs or even some of the devices that use lower flow rates to function 
because the powder would either not be deaggregated properly or it would deposit in 
the device before reaching the patient (Syedain et al. 2015).  A new low volume inline 
device is intended to effectively produce the aerosol for the patient with a small amount 
of additional air that still allows for effective delivery.  Across a range of applications 
including infant mechanical ventilation, N2L delivery during low flow oxygen 
administration, and aerosol delivery through a sealed mask in NPPV, an added gas 
volume of approximately 2-5 mL is acceptable for forming the aerosol.  This small 
volume of added air is necessary to avoid complications with subjects that have small 
tidal volumes such as infants (~50 mL).  The device should be easy to load and should 
be capable of aerosolizing typical high dose medications, all while being operated by a 
caregiver.  A potential high dose application involving the delivery of surfactants to 
infants is given below, followed by a review of existing low volume devices. 
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2.5.2 Surfactant Delivery 
 Respiratory distress syndrome in infants is usually caused by a lack of pulmonary 
surfactant production associated with preterm birth (Rey-Santano et al. 2013).  This is 
currently corrected by delivery of a liquid bolus containing surfactant to the lungs via an 
endotracheal tube (Syedain et al. 2015).  This can cause complications including 
transient hypoxia, hypercapnia, and changes in cerebral blood flow (Schipper et al. 
1997, Murdoch et al. 1998).  Delivery of surfactant in an aerosol form has been shown 
to improve lung functions similar to the use of bolus instillation.  However the aerosol 
therapy produced less adverse effects when compared to the bolus technique (Rey-
Santano et al. 2013). 
 
2.5.3 Available Low Volume Devices 
 Laube et al. (2012) used the Solovent® DPI to deliver an aerosol using a 5 mL 
syringe as the air source.  High losses, greater than 96% of the ED, in the spacer 
resulted in low lung delivery efficiency.  The average diameter of particles in the powder 
used in this study was 4.5 µm. This device was not designed to deaggregate powder 
any further, as with a 3D rod array, but it can be assumed that since larger particles are 
filtered out due to depositional losses, the average diameter was reduced before 
reaching the patient. 
 The Microjet™ device is a characteristic inter-tracheal catheter spray unit 
(requiring a liquid formulation) and was tested in one study by Syedain et al. (2015) to 
deliver a surfactant aerosol to infants through an endotracheal tube.  The device is 
small (<1 mm in diameter) and can be inserted into ETTs as small as 2 mm.  This 
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device was designed to produce an aerosol using an airflow rate in the range of 0.05 
and 0.24 LPM at high pressure (40-80 psi).  The device creates a high velocity jet 
exiting the device which is said to be reduced quickly after exiting the device to follow 
the flow stream into the patient’s lungs.  The majority of the particles leaving the device 
were in the 2.5 to 5 µm range.  While this device shows promise, the potential 
consequences of a high velocity aerosol spray exiting the device and entering the 
trachea may cause aerosol deposition in unwanted areas, as well as possible trauma, 
such as pulmonary perforations caused by the liquid jet piercing the soft lung tissue, to 
the patient. 
The DP-4M Dry Powder Insufflator™ (PennCentury, Wyndmoor, PA, USA) device 
is designed to produce an aerosol with less than 2 mL of air produced from a syringe or 
air pump.  The device has a chamber that can be hold a small amount of powder to be 
delivered through the small stainless steel tube at the end of the device.  The device 
has been used to deliver multiple powder formulations of multiple sizes (Cryan et al. 
2007, Hoppentocht et al. 2014b).  While this device is designed for endotracheal 
aerosol delivery to mice (Morello et al. 2009), it has been shown to produce a useable 
aerosol for the delivery of insulin to monkeys (Grainger et al. 2004).  The device 
retention has also been shown to be low with some formulations, while using multiple 
actuations of less than 1 mL (Hoppentocht et al. 2014b).   
 Hoppentocht et al. (2014b) performed a study to characterize the exiting aerosol 
from the same DP-4M Insufflator used in the previously mentioned studies.  
Formulations investigated include both spray-dried and micronized versions of 
tobramycin, mannitol, inulin, and colistimethate sodium.  0.5 to 3 mg doses were 
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investigated for 200, 500, and 1000 µL of air used for dispersion.  Device retention and 
particle sizes for each formulation had varying results.  MMADs ranged from less than 3 
µm to more than 30 µm, with larger particles coming from the higher loaded doses.  
Device retention ranged from less than 5%, with some tobramycin cases, to close to 
100% with some mannitol and inulin cases. 
 Existing devices each provide some characteristics of a high performance 
design, but they do not provide all of the desired capabilities.  Disadvantages of some of 
these devices include complex loading, variability of delivery efficiency between 
patients, as well as variability between performance with different powder formulations, 
high losses in delivery systems, and possible complications due to high velocity air 
streams entering the lungs.  Based on this analysis, a new low-volume inline device is 
required to effectively aerosolize and deliver EEG powder formulations that can meet 
the following performance requirements: MMAD less than 1.5 µm, FPF<5µm greater than 
90%, FPF<1µm greater than 30%, and an ED of at least 75%. 
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Figure 2.1 Chart showing the origin of the devices in this research with an expanded 
view of the overall device categories showing dispersion mechanisms for each. 
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Table 2.1 Table defining characteristics used throughout the presented research. 
Characteristic Terms Definition Typical Values 
Low Dose Powder masses typically 
delivered using 
commercial DPIs and 
asthma medicines 
0.5 – 20 mg (total 
formulation mass) 
High Dose Powder masses larger 
than typically delivered in 
commercial DPIs 
>25 mg (total formulation 
mass) 
 
Low Flow Ventilation flow rates used 
for children/infants or for 
adults without the 
requirement of added 
humidity 
1 – 8 LPM 
High Flow Ventilation flow rates 
higher than low flow 
values which typically 
require heating and 
humidifying the air flow 
patient comfort 
>10 LPM 
 
Low Volume DPI actuation air volumes 
on the order of test animal 
and infant tidal volumes or 
that are much smaller 
than adult tidal volumes 
≤10 mL 
High Volume Volumes associated with 
typical adult lung volumes 
1 – 4 L 
 
Adult Negative Pressure 
Drop 
Pressure achievable when 
a typical adult patient 
inhales through an oral 
DPI 
4 kPa 
Child Negative Pressure 
Drop 
Pressure achievable when 
a typical child patient 
inhales through an oral 
DPI 
2 kPa 
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Chapter 3 Development of a High Efficiency Dry 
Powder Inhaler for EEG Delivery 
3.1 Objective 
 The objective of this study is to develop a capsule-based high efficiency oral DPI 
intended for EEG aerosol delivery. 
 
3.2 Introduction 
 Dry powder inhalers (DPIs) prescribed to patients all over the world are inefficient 
in delivering drugs that are able to penetrate the lungs.  The excipient enhanced growth 
(EEG) method of drug delivery requires an inhaler producing a small particle size to 
function properly (Hindle et al. 2012, Longest et al. 2012b).  This small size can help to 
prevent mouth-throat (MT) deposition from impaction on the back of the throat due to 
the sudden change of direction.  The inhaler to be used should also have a higher 
resistance to keep the flow rate relatively low, thereby also helping to reduce the MT 
deposition (DeHaan et al. 2004). 
The objective of this study is to develop a high efficiency DPI intended for the 
delivery of EEG aerosols.  The optimized EEG powder formulation proposed by Son et 
al. (2013a) is used in conjunction with the previously developed 3D rod array (Son et al. 
2013b).  Capsule chamber (CC) orientations explored include parallel and perpendicular 
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to the inlet flow.  All devices are tested with a pressure drop of 4 kPa for adult inhalation 
conditions, unless otherwise stated, which produces a flow between 40-50 LPM at our 
target inhaler resistance of 0.044 
√𝑘𝑃𝑎
𝑙𝑝𝑚
.  Results are given in terms of device and capsule 
retention, emitted dose (ED), fine particle fractions less than 5 µm (FPF<5µm), fine 
particle fractions less than 1 µm (FPF<1µm), and the mass median aerodynamic diameter 
(MMAD) of the aerosol produced.  Aerosolization characteristics of a high performance 
design will consist of an MMAD less than 1.5 µm, FPF<5µm greater than 90%, FPF<1µm 
greater than 30%, and an ED at or above 75%. 
 
3.3 Devices and Methods 
Inhaler Design of the Capsule-Based High Efficiency DPIs 
The capsule based oral inhalers to be tested consist of a capsule chamber (CC) 
to house the size 3 capsule (Capsugel, Morristown, NJ) during use and a mouthpiece 
with a 3D rod array inside to assist in aerosolization of 2 mg of EEG-AS formulation.  
The VCU1 inhaler is designed around a CC that is perpendicular to the incoming flow, 
while the VCU3 design uses flow parallel to the capsule, as different orientations to 
empty the capsule.  Figure 3.1 and Figure 3.2 show examples of VCU1 and VCU3, 
respectively.  The mouthpiece for both was optimized in the study by Son et al. (2013b), 
using the 3D rod array as the deaggregation mechanism.  Both prototyped and metal 
versions of the rod array will be analyzed in this study. 
 CC designs for the VCU1 device included staggering the inlet holes from the 
centerline, as well as a single inlet hole in the middle.  The staggering of air holes, 
shown in Figure 3.3 analyzed in this study include 0, 0.41, 0.83, 1.24, and 1.65 mm 
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offset from the CC centerline.  A single, central hole was also included to be analyzed.  
Each of these CC designs use inlet hole diameters to match the desired pressure drop 
of 4 kPa across the device when used with a flow rate of 45 LPM. 
 VCU3 CC designs, shown in Figure 3.4 include 45 and 90 degree angles 
between the CC and the mouthpiece flow passage.  Each design has a central hole 
located at the top of the CC with a diameter chosen to produce a pressure drop of 4 kPa 
at a flow rate of 45 LPM.  Each design also incorporates the same 3D rod array used in 
the VCU1 device. 
The inhalers were created using Autodesk Inventor and exported as .STL files to 
be prototyped. The files were then prepared using 3D Lightyear File Preparation 
Software. The parts were built using a 3D Systems Viper SLA Prototyper (3D Systems 
Inc., Rock Hill, SC) using Accura 60 stereolithography resin (3DSystems Inc.).  Once 
the parts were prototyped, they were cleaned using a Proclean SL Part Washer (3D 
Systems Inc.) and dried in a 3D Systems dryer for approximately 90 min. 
 
High-Speed Photography 
The motion of the capsule inside of the chamber was analyzed using a Photron 
PCI R2 high-speed camera at 2000 frames per second. This helped to show the overall 
movement of the capsule as well as to determine the number of apparent chamber wall 
impactions per second. Rapid changes in capsule direction near the wall surface were 
assumed to be due to contact with the wall and counted as a capsule wall impaction.  
The impactions were counted for a total of 1,500 frames to determine the total number 
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per second. Three videos were analyzed for each device and the average impactions 
per second were calculated from the data. 
 
3.4 Results 
 The device retention and aerosolization performance for each capsule chamber 
design of VCU1 are given in Table 3.1.  CC1-4 all achieved between 64 and 68% ED 
with FPF<5µm and FPF<1µm at or above 90% and 30%, respectively.  MMADs produced 
were also similar, in the range of 1.44-1.55 µm.  While CC1-4 were not statistically 
different in terms of ED and aerosolization characteristics, CC1 achieved the lowest 
variability in device and capsule retention.  For this reason, CC1 was chosen to be 
optimized further.  In an attempt to further increase deaggregation, the prototyped, 
plastic, 3D rod array was replaced with stainless steel rods of the same dimensions.  
Table 3.2 shows the increase in aerosolization performance as the FPF<1µm increased 
5%, causing a decrease in MMAD from 1.44 to 1.30 µm.  To increase the ED of the 
device a coating of polytetrafluoroethylene (PTFE) was applied to the interior walls.  ED 
was increased from 64% to 81% while the particle size leaving the device was 
unchanged (Table 3.2).  CC1 was also compared with the Aerolizer, HandiHaler, and 
the modified HandiHaler, from the study by Son et al. (2013b), in Figure 3.5.  The 
optimized device outperformed all of the commercial devices in both delivery and 
aerosolization performance. 
 ED and aerosolization results comparing the CC90 and CC45 capsule chambers 
to the CC1 device optimized previously can be found in Table 3.3.  Both the CC90 and 
CC45 devices showed increases in FPF<5µm and ED values.  More importantly, the 
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optimized CC1 device was compared to the CC90 device across a range of different 
pressure drops which resulted in different flow rates through the devices (Table 3.4).  
An increase from 2 to 6 kPa pressure drop across the CC1 device led to an increase to 
70% from 61% ED while the CC90 only increased from 71 to 73%.  FPF<5µm also 
increased with CC1 (91 to 94%) from the pressure drop increase, with CC90 staying 
constant at 95%.  This FPF<5µm increase in CC1 corresponds to a decrease in MMAD 
from 1.63 µm at 2 kPa to 1.50 µm at 6 kPa.  CC90, again, produced a more consistent 
value, across the range of pressures, of 1.54 µm at 2 kPa and 1.48 µm at 6 kPa.  Figure 
3.6 shows a comparison of both the CC1 and CC90 devices to reported values of 
FPF<5µm and MMAD for various commercial inhalers.  Even at extremely high flow rates 
(150 LPM), the commercial devices fail to create an aerosol with an MMAD of less than 
2 µm and an FPF<5µm of greater than ~40%. 
  
33 
 
3.5 Abbreviations 
AS  Albuterol sulfate 
CC  Capsule chamber 
DPI  Dry powder inhaler 
ED  Emitted dose 
EEG  Excipient enhanced growth 
FPF  Fine particle fraction 
MMAD Mass median aerodynamic diameter 
MT  Mouth-throat 
PTFE  Polytetrafluoroethylene  
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Figure 3.1 Images of the best case VCU1 inhaler (CC1-3D) including (a) surface 
model of the composite device with an internal 3D rod array, (b) an opened device for 
capsule loading with a size 3 capsule, and (c) the prototyped device for experimental 
testing.  Panel (b) illustrates the device separated at the interface between the capsule 
chamber (CC) analyzed in this study and the previously optimized downstream flow 
passage (mouthpiece) and 3D rod array. 
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Figure 3.2 The best case VCU3 inhaler (CC90-3D) with the capsule in the (a) loaded 
(no flow), and (b) in-use (45 LPM) position. A minimum flow rate of 25-30 LPM is 
required to elevate a capsule containing 2 mg of powder above the red line marked in 
the capsule viewing window. 
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Figure 3.3 Images of the VCU1 capsule chambers: (a) top view with dimensions and 
a size 3 capsule in place, (b) side view illustrating height of all capsule chambers, and 
(c) capsule aperture position on the capsule. Air inlet holes differentiate the capsule 
chambers considered with (d) 2 inline inlets (CC1), (e) 2 inlets staggered by 1.65 mm 
(CC5), and (f) one central inlet (CC6).
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Figure 3.4 Dry powder inhalers (DPI) considered consisting of different capsule 
chambers (CC) coupled with the 3D rod array flow passage: (a) CC1-3D with two air 
inlets and the capsule oriented perpendicular to the inlet airflow; (b) CC90-3D with the 
capsule oriented parallel to the inlet airflow and a 90° angle between the CC and flow 
passage; and (c) CC45-3D with a 45° angle between the CC and flow passage.  
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Figure 3.5  Comparison of aerosolization performance [n=3; Mean (SD)] of CC1-3Dm-
PTFE with commercial and modified powder inhaler devices (batch 2 powders).  (a) 
Percent albuterol sulfate as a function of device and capsule retentions, (b) fine particle 
fractions less than 5 and 1 µm, and (c) mass median aerodynamic diameters. 
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Figure 3.6 Comparison of flow rate effects for the CC-3D inhalers and previously 
reported commercial products in terms of (a) FPF<5µm and (b) MMAD.  Salbutamol 
Diskus, Diskhaler, and Turbuhaler were considered in the study of Prime et al.17 at flow 
rates of 28-60 LPM.  Salmeterol Diskus and Formoterol Turbuhaler were considered by 
Tarsin et al. (2006), and the illustrated line represents the reported linear best fit of the 
data.
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Table 3.1 The effect of air inlet hole staggering on the mean drug deposition and 
aerosolization performance for VCU1 (CCs 1-5) coupled with the 3D rod array 
mouthpiece tested at a 4 kPa pressure drop.  Coefficient of variation (%) is shown in 
parenthesis [n=3] (Behara et al. 2014a). 
 Description CC1-3D CC2-3D CC3-3D CC4-3D CC5-3D 
      
Offset distance (mm) 0.00 0.41 0.83 1.24 1.65 
Air inlet hole diameter 
(mm) 
3.16 2.78 3.17 2.78 3.08 
Air flow rate (L min-1) 50 40 50 43 50 
      
Emitted (%)* 66.2 (1.8) 68.4 (3.6) 67.0 (10.0) 64.9 (17.3) 6.3 (63.9)** 
Capsule retention (%)* 13.7 (10.5) 13.5 (17.4) 10.1 (6.7) 14.4 (50.3) 90.4 (5.4)** 
Capsule chamber 
retention (%) 
6.1 (17.3) 5.4 (30.3) 12.0 (40.4) 9.8 (81.9) 2.1 (55.1) 
Mouthpiece retention (%)* 14.1 (4.4) 12.7 (8.0) 10.9 (21.7) 10.9 (21.2) 1.1 (37.7)** 
      
FPF<5µm/ED (%)* 93.8 (0.7) 93.6(1.1) 94.3 (3.0) 89.7 (1.0) 75.3 (16.4)** 
FPF<1µm/ED (%)* 30.9 (1.9) 32.7 (4.1) 31.7 (3.4) 28.6 (7.3) 20.8 (30.3)** 
MMAD (µm)* 1.47 (1.22) 1.46 (2.54) 1.44 (0.68) 1.55 (3.76) 1.83 (15.39)** 
      
*P<0.05 significant effect of air inlet staggering on % emitted, capsule & mouthpiece retentions, 
FPF<5µm/ED, FPF<1µm/ED and MMAD (one-way ANOVA).  
**P<0.05 significant effect of % emitted, capsule & mouthpiece retentions, FPF<5µm/ED, FPF<1µm/ED and 
MMAD compared to CC1-3D (post-hoc Tukey). 
 
Batch-1 EEG formulation combination particles generated by Büchi Nano Spray Dryer (B-90). 
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Table 3.2 Mean drug deposition and aerosolization performance of CC1 with resin or 
metal 3D rod arrays and with the PTFE coated capsule and inhaler tested at a 4 kPa 
pressure drop (equivalent to 50 L/min for each inhaler).  Coefficient of variation (%) is 
shown in parenthesis [n=3] (Behara et al. 2014a). 
Description CC1-3D CC1-3Dm CC1-3Dm-PTFE 
    
Emitted (%)* 63.8 (3.0) 64.7 (2.3) 81.4 (2.7)** 
Capsule retention (%)* 14.1 (9.0) 16.2 (4.1) 7.3 (14.2)** 
Capsule chamber retention (%)* 8.8 (15.3) 8.8 (11.0) 2.2 (25.4)** 
Mouthpiece retention (%)* 13.2 (2.7) 10.2 (3.6)** 9.1 (15.9)** 
    
FPF<5µm/ED (%) 93.9 (0.4) 94.5 (0.9) 92.7 (1.3) 
FPF<1µm/ED (%)* 32.2 (3.2) 37.3 (2.6)** 36.8 (2.3)** 
MMAD (µm)* 1.44 (1.96) 1.30 (1.74)** 1.30 (0.97)** 
    
*P<0.05 significant effect of uncoated devices built with resin and metal 3D arrays and 
PTFE coated inhaler device with metal 3D array on % emitted, capsule, capsule 
chamber & mouthpiece retentions, FPF<1µm/ED and MMAD (one-way ANOVA).  
**P<0.05 significant effect of % emitted, capsule, capsule chamber & mouthpiece 
retentions, FPF<1µm/ED and MMAD compared to CC1-3D with resin rod array (post-hoc 
Tukey). 
 
Batch-2 EEG formulation combination particles generated by Büchi Nano Spray Dryer 
(B-90). 
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Table 3.3 The effect of powder inhaler design on the mean AS deaggregation 
performance when aerosolized at a 4 kPa pressure drop.  Standard deviation is shown 
in parenthesis [n=3] (Behara et al. 2014b). 
Description CC1-3D CC90-3D CC45-3D 
    
Emitted dose (%)* 65.0 (4.1) 73.4 (4.1) 75.7 (0.4)** 
    
FPF<5µm/ED (%)* 91.4 (1.4) 95.1 (0.2)** 94.3 (0.6)** 
FPF<1µm/ED (%)* 29.2 (0.2) 31.4 (0.1)** 28.3 (0.8) 
MMAD (µm)* 1.52 (0.01) 1.49 (0.00) 1.57 (0.02)** 
    
*P<0.05 significant effect of inhaler design on % emitted, FPF<5µm/ED, FPF<1µm/ED and 
MMAD (one-way ANOVA).  
**P<0.05 significant difference compared to CC1-3D as shown in Fig. 3 (post hoc 
Tukey). 
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Table 3.4 The effect of airflow rate on aerosolization of AS using CC1-3D and CC90-3D designs.  Data shown in grey 
was duplicated from Table 3.3 for better presentation to the reader. Standard deviation is shown in parenthesis [n=3] 
(Behara et al. 2014b).  
Description CC1-3D CC90-3D 
       
Air flow rate (LPM) 35 50 61 32 45 55 
Pressure drop (kPa) 2 4 6 2 4 6 
       
Emitted dose (%)* 61.0 (1.4) 65.0 (4.1) 69.9 (1.2)** 71.2 (1.6) 73.4 (4.1) 73.2 (1.9) 
       
FPF<5µm/ED (%)*^ 91.3 (1.7) 91.4 (1.4) 94.6 (0.3)** 95.5 (0.1) 95.1 (0.2)** 95.3 (0.2) 
FPF<1µm/ED (%)*^ 27.1 (1.7) 29.2 (0.2) 28.6 (1.2) 31.4 (0.4) 31.4 (0.1) 30.0 (0.7)** 
MMAD (µm)*^ 1.63 (0.04) 1.52 (0.01)** 1.50 (0.03)** 1.54 (0.01) 1.49 (0.00)** 1.48 (0.02)** 
       
*P<0.05 significant effect for CC1-3D of air flow rate on % emitted, FPF<5µm/ED, FPF<1µm/ED and MMAD (one-way 
ANOVA).  
^ P<0.05 significant effect for CC90-3D of air flow rate on FPF<5µm/ED, FPF<1µm/ED and MMAD (one-way ANOVA). 
**P<0.05 significant difference compared to 35 LPM with CC1-3D and 32 LPM with CC90-3D, respectively 
(post hoc Tukey). 
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Chapter 4 Develop an inline DPI system using the 
3D rod array for high flow (15 LPM) and low flow (5 
LPM) 
4.1 Objective 
 The objective of this study is to develop an inline DPI system for delivering EEG 
aerosols with low depositional losses in the device and high aerosolization efficiency. 
 
4.2 Introduction 
Administration of medication to patients on mechanical ventilation can be a 
difficult problem to solve.  Non-invasive ventilation (NIV) techniques can be used to 
continuously deliver the oxygen needed by the patient without using a tracheostomy 
tube or an endotracheal tube.  This oxygen delivery system could be used to also carry 
a drug in aerosol form through the nose-mouth-throat (NMT) and into the lungs.  To 
make this type of delivery feasible, losses in tubing and connectors should be minimal 
to make sure the correct dose is being delivered to the patient (Longest et al. 2013a). 
The objective of this study is to design an active DPI system capable of 
delivering an EEG aerosol efficiently in terms of powder deaggregation and low system 
retention.  The system to be considered is an inline device with a flow control orifice, a 
capsule chamber, and a 3D rod array connected to a high flow nasal cannula (HFNC), 
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previously optimized by Longest et al. (2013a), with tubing.  Flow control orifice size, 
airflow rate, and 3D rod array designs will be varied to produce an optimized system.  
The CC90 device developed by Behara et al. (2014b) will also be used in the system as 
a comparison.  Aerosolization characteristics of a high performance design will consist 
of an MMAD less than 1.5 µm, FPF<5µm greater than 90%, FPF<1µm greater than 30%, 
and an ED at or above 75%. 
 
4.3 Devices and Methods 
Experimental Setup 
A schematic showing the experimental setup used in this study is shown in 
Figure 4.1.  A standard 1 L ventilation bag (Adult Manual Resuscitator, Legend Medical 
Devices, South El Monte, California) was connected to the devices using 10 mm 
connective tubing with a flow meter (Sensirion EM1, Sensirion AG, Stafa, Switzerland) 
between the two for flow rate monitoring.  The device was connected to the HFNC using 
the same style 10 mm tubing. 
The Low Flow Nasal Cannula (LFNC) system, shown in Figure 4.2, uses a 
continuous flow through the device to deliver an aerosol through tubing, a streamlined-
Y, and a streamlined nasal cannula.  The particle size exiting the nasal cannula will be 
characterized first, then the optimized system will be connected to a realistic NMT 
model to investigate the depositional losses and approximate lung dose. 
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Estimated Flow Values 
To capture the flow profiles through each device, the flow meter was used during 
experiments to record the flow from the ventilation bag in 0.02 second intervals.  The 
ventilation bag was squeezed by hand to produce the flow through the system.  The 
inlets of the devices to be studied are 2.0 mm, 2.3 mm, 3.1 mm, and 3.6 mm and the 
max flow rates through each are 10, 22, 38, and 41 LPM, respectively, depending on 
the rod array configuration used (232, 212, 343, or 565) as the dispersion mechanism.  
To characterize the flow, multiple methods were used for each of the devices and these 
values are given in Table 4.1 and Table 4.2.  Total average flow rates were calculated 
as the time average of all recorded data points.  This method is useful in estimating the 
total volume of air passed through each device, but the value given is most likely an 
underestimation of the effective aerosolization flow rate.  To account for this 
underestimation, the root-mean-square (RMS) of the plateau values was taken.  The 
plateau was estimated, using an iterative process, to be approximately 70% of the 
plateau average.  The upper range of the flow rate was estimated by the Q90 method, 
which determined the flow rate that 90% of the total recorded flow values were under.  
The max flow rate for each device was also recorded, but this value was only achieved 
for a small amount of time during actuation. 
 
Inhaler Design 
The devices, shown in Figure 4.3, were created using Autodesk Inventor and 
exported as .STL files to be prototyped. The files were then prepared using 3D 
Lightyear File Preparation Software. The parts were built using a 3D Systems Viper SLA 
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Prototyper (3D Systems Inc., Rock Hill, SC) using Accura 60 stereolithography resin 
(3DSystems Inc.).  Once the parts were prototyped, they were cleaned using a Proclean 
SL Part Washer (3D Systems Inc.) and dried in a 3D Systems dryer for approximately 
90 min.  Both systems were designed to house a size 3 capsule filled with 2 mg of EEG-
AS formulation. 
 Figure 4.4a shows the device connected to the High Flow Nasal Cannula (HFNC) 
using a length of tubing, while Figure 4.4b shows the device prototyped with the HFNC 
directly attached.  For comparison, the previously developed CC90 device was 
prototyped with the HFNC directly attached (Figure 4.5).  A front view of the HFNC is 
given in Figure 4.6 to show the two separate inlets, one, streamlined, for the aerosol 
and one for the humidified air.  To optimize the inline devices, different capsule piercing 
locations were also investigated (Figure 4.7). 
 The LFNC system, illustrated in Figure 4.2, uses a continuous flow through a 
device similar to that used in the HFNC therapy.  This device was designed to operate 
at a lower flow rate (~5 LPM) while still creating a high quality aerosol to pass through 
tubing and connectors and out of a custom nasal cannula.  A commercial Y-connector 
and cannula, illustrated in Figure 4.8a-b, are also explored in this study.  Custom Y-
connectors and cannulas, using 2 and 4 mm tubing, are shown in Figure 4.8c-f and are 
compared to the commercial devices using device retention and particle sizing data.  
The different cases to be investigated are given in Table 4.3. 
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4.4 Results 
 Based on Table 4.4, the best performing device, denoted 3.1-565-ECG (3.1 mm 
inlet-565 rod array), achieved an ED of 71% with an MMAD of 1.39 µm (Case 3).  
FPF<5µm values were lower than desired (83%), but were still high.  A PTFE coating, 
similar to the coating of the CC1 device from Objective 1, was applied to increase the 
delivery efficiency and the comparison of the devices is given in Table 4.5.  ED was 
increased to 78% and the aerosolization performance remained similar to the device 
without the coating.  The device was also compared to the previously developed CC90 
device that was adapted to connect to the ECG cannula and the results are shown in 
Table 4.6.  While the aerosolization performance was similar between the devices, the 
ED of the inline device was 5% higher (71% vs. 66%) than the adapted CC90 device.  
Different rod array configurations were tested and compared to the 3.1-565 device.  
Table 4.7 shows that the 2.3-343 device achieved a 4% higher ED, but the lower flow 
rate caused a decrease in aerosolization performance shown by the higher MMAD 
value.  The 2.3-212 device was, all around, less effective than the 3.1-565 device, 
producing a 2% less ED and an MMAD 0.2 µm larger. 
 The 2.0-232 inline DPI used in the LFNC delivery system was able to produce a 
small particle size using only a flow rate of 5-10 LPM.  The results of system retention 
and particle size leaving the cannula are given in Table 4.8.  The system using 4 mm 
tubing from the Y-connector to the cannula showed a much lower retention than the 
commercial system (<2% vs. 21%).  The commercial system did produce a higher FPF 
for both less than 5 and 1 µm.  This data could, however, be skewed due to losses of 
larger particles in the system.  The optimized system was attached to a NMT model with 
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a mannequin head used to create the realistic attachment of the system around the ears 
and into the nostrils.  The results using both 5 and 10 LPM through the device and 30 
and 45 LPM through the NMT model are given in Table 4.9.  Losses in the device, 
including capsule retention, were above 20%, with the lower flow through the device 
producing the highest losses.  NMT losses were no higher than 3%, but the lower flow 
rate of 30 LPM produced losses in the range of 1%. 
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4.5 Abbreviations 
AS  Albuterol sulfate 
CM  Commercial 
DPI  Dry powder inhaler 
ED  Emitted dose 
EEG  Excipient enhanced growth 
FPF  Fine particle fraction 
HFNC  High flow nasal cannula 
HPMC Hydroxypropyl methylcellulose 
LFNC  Low flow nasal cannula 
MMAD Mass median aerodynamic diameter 
MT  Mouth-throat 
NIV  Noninvasive ventilation 
NMT  Nose-mouth-throat 
PTFE  Polytetrafluoroethylene 
RMS  Root mean square 
SL  Streamlined  
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Figure 4.1 The active dry powder inhaler (DPI) system including a ventilation bag, 
flow meter (for experimental testing only), inline DPI (containing a flow control orifice 
and 3D rod array), and streamlined nasal cannula.  
52 
 
 
Figure 4.2 Schematic drawing of the inline LFNC system showing the device 
connected to the Y-connector and cannula.  
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Figure 4.3 Inline DPI devices consisting of a flow control orifice (2.3 – 3.6 mm 
diameter), a capsule chamber, restraining mesh, 3D rod array and flow passage that 
connects to 10 mm diameter ventilator tubing.  Different flow control orifice size and rod 
array pattern configurations were considered including (a) 3.6 mm orifice and 5-6-5 rod 
array pattern, (b) 3.1 mm orifice and 5-6-5 rod array pattern, (c) 2.3 mm orifice and 3-4-
3 rod array pattern, and (d) 2.3 mm orifice and 2-1-2 rod array pattern.  
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Figure 4.4 Illustration of the DPI (a) with and (b) without connective tubing leading to 
the ECG cannula.  The length of the connective tubing in Panel (a) is not draw to scale.  
In the experiments, only the 3.6-565 DPI contained a 13 cm length of 10 mm diameter 
connective tubing between the device and ECG cannula.  The other devices 
implemented a much shorter (~1 cm) length or eliminated the connective tubing.  
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Figure 4.5 Connection of the previously optimized passive CC90-3D inhaler used for 
oral inhalation to the ECG cannula.  In this setup, the CC90-3D inhaler was operated by 
connecting the flow delivery line to the inlet orifice above the capsule chamber.  
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Figure 4.6 Divided ECG cannula for dual stream aerosol delivery during HFNC 
therapy.  During aerosol administration, the aerosol stream from the DPI enters one 
side of the cannula and flows through a streamlined passage into one nasal prong.  
High flow therapy (heated and humidified) gas enters the other nasal prong. 
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Figure 4.7 Capsule piercing apertures with different configurations denoted (a) Case 
1, (b) Case 2, (c) Case 3, (d) Case 4, and (e) Case 5.  Direction of flow during operation 
and the restraining mesh are illustrated in Panel (a). Apertures with a diameter of 0.5 
mm were located at the top (or bottom) of the capsule, midway the head (or base) 
curvature, and at the start of the head (or base) curvature.  
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Figure 4.8 Illustration showing (a) Commercial (CM) 2mm Y-connector, (b) CM 
cannula, (c) Streamlined (SL) 2mm Y-connector, (d) SL 2 mm cannula, (e) SL 4mm Y-
connector, and (f) SL 4mm cannula  
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Table 4.1 Air flow characteristics for the 3.6-565-ECG and 3.1-565-ECG devices based on total average flow, RMS, 
and Q90 metrics (n≥3; Mean±SD).  The maximum instantaneous flow rate recorded is also reported (Behara et al. 2014c). 
 
Method 
3.6-565-ECG 3.1-565-ECG 
Flow rate  
(LPM) 
Duration  
(s) 
Maximum flow 
(LPM) 
Flow rate  
(LPM) 
Duration  
(s) 
Maximum flow 
(LPM) 
       
Total average 25.4 (1.6) 1.1 (0.2) 40.9 (2.6) 21.5 (1.8) 1.7 (0.3) 37.7 (2.4) 
RMS 35.2 (1.9) 0.7 (0.1) 27.2 (1.9) 1.1 (0.0) 
Q90 39.6 (2.2) 1.1 (0.2) 33.0 (2.3) 1.7 (0.3) 
       
Total average: Average all flow values for entire bag squeeze. 
 
RMS: root-mean-squared average of flow in the plateau of the flow rate profile. 
 
Q90: Flow rate below which 90% of all measured values occur. 
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Table 4.2 Air flow characteristics for the 2.3-343-ECG and 2.3-212-ECG devices based on total average flow, RMS, 
and Q90 metrics (n≥3; Mean±SD).  The maximum instantaneous flow rate recorded is also reported (Behara et al. 2014c). 
 
Method 
2.3-343-ECG 2.3-212-ECG 
Flow rate  
(LPM) 
Duration  
(s) 
Maximum flow 
(LPM) 
Flow rate  
(LPM) 
Duration  
(s) 
Maximum flow 
(LPM) 
       
Total average 10.8 (1.2) 3.4 (0.6) 21.6 (0.7) 8.0 (0.9) 3.5 (0.8) 14.0 (0.6) 
RMS 14.7 (0.9) 2.0 (0.3) 11.6 (0.6) 1.5 (0.3) 
Q90 18.1 (1.1) 3.4 (0.6) 13.1 (0.6) 3.5 (0.8) 
       
Total average: Average all flow values for entire bag squeeze. 
 
RMS: root-mean-squared average of flow in the plateau of the flow rate profile. 
 
Q90: Flow rate below which 90% of all measured values occur. 
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Table 4.3 Descriptions of experimental cases used with the 2.0-232 inline DPI 
device using commercial (CM) or streamlined (SL) Y-connectors and cannulas with 
continuous flow or ventilation bag modes of actuation. 
Cases Y-connector Cannula Device flow 
rate 
(LPM) 
NMT-TB flow 
rate (LPM) 
0 CM-2mm CM-2mm 5 45a 
1 SL-2mm CM-2mm 5 45a 
2 SL-4mm CM-2mm 5 45a 
3 SL-4mm SL-2mm 5 45a 
4 SL-4mm SL-4mm 5 45a 
5 SL-4mm SL-4mm 5 45b 
6 SL-4mm SL-4mm 10 45b 
7 SL-4mm SL-4mm 5 30b 
8 SL-4mm SL-4mm 10 30b 
9c SL-4mm SL-4mm 5 45b 
a  Aerosol from cannula was directed into the NGI. 
b  Aerosol from the cannula was directed into the nasal inlet of the NMT-TB model. 
c  Ventilation bag actuated case with device flow rate calculated as a root-mean-square 
(RMS) approximation over time with three actuations of the bag. 
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Table 4.4 The effect of capsule piercing configuration on the mean AS device retention and aerosolization 
performance at the exit of the ECG cannula for five different capsule piercing cases when the 1 liter bag was squeezed 
four times through 3.1-565-ECG device.  The device was connected to a streamlined ECG cannula positioned at the 
entrance to the NGI. The standard deviation (SD) is shown in parenthesis [n=3] (Behara et al. 2014c). 
Description Case 1 Case 2 Case 3 Case 4 Case 5 
      
ED (%)* 76.5 (0.9) 79.2 (0.7) 71.1 (1.0)** 73.9 (2.4) 70.9 (2.6)** 
      
Capsule (%)* 7.1 (0.5) 6.3 (0.7) 8.5 (0.7) 7.5 (0.4) 9.5 (1.6)** 
CC (%)* 3.3 (0.8) 1.2 (0.1)** 6.8 (1.0)** 4.7 (0.7) 7.6 (0.6)** 
Flow passage (%) 8.7 (0.4) 8.8 (0.2) 9.6 (0.6) 9.1 (0.4) 8.2 (0.7) 
Connecting tubing (~1 cm) (%) 1.8 (0.2) 1.8 (0.1) 1.6 (0.3) 1.5 (0.1) 1.6 (0.3) 
ECG Cannula (%) 2.6 (0.3) 2.7 (0.2) 2.3 (0.2) 3.3 (2.0) 2.1 (0.0) 
      
FPF<5µm/ED (%)* 78.1 (3.7) 71.6 (4.6) 83.1 (1.4) 81.8 (4.7) 80.4 (4.7) 
FPF<1µm/ED (%)* 23.7 (2.7) 20.5 (2.3) 30.3 (1.6) 27.6 (3.3) 27.7 (3.9) 
MMAD (µm)* 1.55 (0.06) 1.62 (0.04) 1.39 (0.05)** 1.48 (0.06) 1.45 (0.08) 
*P<0.05 significant effect of capsule piercing on % ED, capsule and CC drug retention, FPF<5µm/ED, FPF<1µm/ED and MMAD 
(one-way ANOVA).  
 
**P<0.05 significant effect compared to Case 1 (post-hoc Tukey). 
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Table 4.5 The effect of coating the device and capsule with PTFE on the mean AS 
emitted dose and aerosolization performance for the 3.1-565-ECG device using Case 3 
piercing with two bag actuations [n=3; Mean(SD)] (Behara et al. 2014c). 
Description No PTFE PTFE 
   
ED (%) 72.1 (2.5) 78.2 (0.9)* 
   
FPF<5µm/ED (%) 77.6 (8.3) 78.9 (5.8) 
FPF<1µm/ED (%) 26.1 (5.4) 25.8 (3.8) 
MMAD (µm) 1.48 (0.11) 1.47 (0.07) 
   
*p<0.05 significant difference between no PTFE and PTFE coating for ED (independent 
samples t-test). 
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Table 4.6 Comparison between the mean AS emitted dose and aerosolization 
performance for the 3.1-565-ECG and CC90-3D devices (four bag actuations) (Behara et 
al. 2014c). 
Description 3.1-565-ECG CC90-ECG 
   
ED (%) 71.1 (1.0) 66.4 (2.2)* 
   
FPF<5µm/ED (%) 83.1 (1.4) 85.6 (0.7)* 
FPF<1µm/ED (%) 30.3 (1.6) 30.9 (0.6) 
MMAD (µm) 1.39 (0.05) 1.42 (0.01) 
   
*p<0.05 significant difference between the devices for ED and FPF<5µm/ED (independent 
samples t-test). 
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Table 4.7 The effect of orifice size (3.1 vs. 2.3 mm) and 3D rod configuration on the 
mean AS emitted dose and aerosolization performance with four bag actuations 
(Behara et al. 2014c). 
Description 3.1-565-ECG 2.3-343-ECG 2.3-212-ECG 
    
ED (%) 71.1 (1.0) 75.3 (2.5) 68.8 (4.4) 
    
FPF<5µm/ED (%)* 83.1 (1.4) 65.4 (6.4)** 60.2 (8.5)** 
FPF<1µm/ED (%)* 30.3 (1.6) 20.7 (3.0)** 21.1 (4.7)** 
MMAD (µm)* 1.39 (0.05) 1.64 (0.07)** 1.59 (0.07)** 
    
*P<0.05 significant effect of device on % FPF<5µm/ED, FPF<1µm/ED and MMAD (one-way 
ANOVA).  
 
**P<0.05 significant differences compared to 3.1-565-ECG (post-hoc Tukey). 
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Table 4.8 Emptying, deposition, and aerosolization characteristics exiting the 
cannula for the AS formulation in the 2.0-232 inline DPI operated with continuous flow 
through the device of 5 LPM and a NGI flow rate of 45 LPM [n=3; Mean (SD)].  Testing 
was performed by Dr. S. R. Behara. 
Description Case 0 
CM2CM2 
Case 1 
SL2CM2 
Case 2 
SL4CM2 
Case 3 
SL4SL2 
Case 4 
SL4SL4 
      
Emitted dose (%)a 73.9 (1.2) 73.1 (3.0) 70.6 (1.9) 81.3 (5.6) 76.6 (3.9) 
      
Capsule retention (%) 5.0 (0.4) 5.1 (1.3) 4.8 (0.8) 4.1 (0.3) 4.3 (1.4) 
Capsule chamber (%) 8.1 (0.5) 9.8 (0.8) 11.0 (0.3) 9.6 (0.8) 9.5 (2.3) 
Flow passage (%)b 12.9 (1.6) 12.1 (1.9) 13.6 (1.9) 5.0 (6.0) 9.6 (1.9) 
      
Y-connector (%) 9.8 (1.4) 4.0 (1.0) 4.0 (1.4) 3.6 (0.6) 3.6 (0.8) 
Tubing (%) 11.2 (1.3) 15.0 (1.6) 9.7 (2.1) 11.2 (0.8) 10.5 (3.5) 
Cannula (%) 21.0 (3.3) 16.6 (2.2) 21.4 (3.3) 13.2 (0.4) 1.6 (0.3) 
      
FPF<5µm/ED (%)* 95.7 (1.5) 94.1 (1.2) 92.6 (1.2) 87.1 (0.5) 85.3 (3.1) 
FPF<1µm/ED (%)* 17.5 (1.5) 11.2 (2.9) 13.1 (2.8) 6.1 (1.3) 4.3 (0.6) 
MMAD (µm)* 1.79 (0.03) 1.95 (0.07) 1.93 (0.08) 2.15 (0.03) 2.22 (0.02) 
*P<0.05 significant effect of device on % FPF<5µm/ED, FPF<1µm/ED and MMAD (one-way ANOVA).  
a Percentage of the loaded dose leaving the inline DPI device 
b Includes the 3D rod array and DPI flow passage 
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Table 4.9 Emptying, deposition, and aerosolization characteristics exiting the NMT 
for the AS formulation in the 2.0-232 inline DPI operated at continuous flow rates of 5 or 
10 LPM with NMT flow rates of 30 or 45 LPM [n=3; Mean (SD)].  Testing was performed 
by Dr. S. R. Behara. 
Description Case 5 
5/45 
Case 6 
10/45 
Case 7 
5/30 
Case 8 
10/30 
     
Emitted dose (%)a 71.0 (2.2) 79.6 (1.2) 71.3 (6.5) 73.5 (1.9) 
     
Capsule retention (%) 6.1 (1.7) 4.0 (0.5) 7.3 (0.6) 5.2 (0.8) 
Capsule chamber (%) 11.9 (2.3) 7.6 (0.7) 10.3 (3.4) 9.7 (0.9) 
Flow passage (%)b 11.0 (1.3) 8.7 (1.0) 11.2 (2.8) 11.6 (1.9) 
     
Y-connector (%) 3.7 (0.3) 5.0 (1.0) 4.3 (1.6) 4.8 (0.7) 
Tubing (%) 9.1 (1.7) 10.8 (0.3) 9.7 (1.5) 7.9 (0.5) 
Cannula (%) 1.1 (0.1) 1.7 (0.2) 1.5 (0.2) 1.6 (0.3) 
     
NMT (%) 2.8 (0.8) 3.0 (0.3) 1.5 (0.8) 1.1 (0.3) 
Upper TB (%) 0.0 (0.1) 0.1 (0.1) 0.0 (0.0) 0.0 (0.0) 
Lung chamber (%) 2.0 (1.5) 4.2 (1.6) 4.4 (2.2) 2.2 (0.5) 
     
FPF<5µm/ED (%)* 82.3 (4.1) 80.7 (3.9) 83.0 (6.3) 90.1 (2.6) 
FPF<1µm/ED (%)* 2.0 (1.8) 5.9 (3.0) 3.3 (5.6) 10.0 (2.5) 
MMAD (µm)* 2.24 (0.07) 2.12 (0.09) 2.23 (0.19) 2.11 (0.08) 
*P<0.05 significant effect of device on % FPF<5µm/ED, FPF<1µm/ED and MMAD (one-way 
ANOVA).  
a Percentage of the loaded dose leaving the inline DPI device 
b Includes the 3D rod array and DPI flow passage 
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Chapter 5 Develop a New High-Dose Dry Powder 
Inhaler (DPI) Based on a Fluidized Bed Design 
5.1 Objective 
 The objective of this study is to develop a high efficiency, high-dose DPI intended 
for EEG aerosol delivery using a concept similar to a classic fluidized bed aerosol 
generator. 
 
5.2 Introduction 
 Dry powder inhalers (DPIs) continue to gain market share and are becoming the 
most prescribed devices for delivering inhaled medications to the lungs (Smith et al. 
2010).  Recent studies have demonstrated high efficiency performance of three 
dimensional (3D) rod array DPIs with aerosol fine particle fractions (FPF) < 5 µm 
greater than 90%, mouth-throat depositional loss <5%, and little sensitivity to inhalation 
flow rate (Son et al. 2013b, Behara et al. 2014a, Behara et al. 2014b).  However, these 
DPI development studies and high efficiency devices were tested with relatively low 
doses of drug.  For these devices to deliver a large dose medication, like an inhalable 
antibiotic, multiple capsules may need to be used to administer a therapeutic dose.  In 
the recent study by Behara et al. (2014b), a DPI was developed that could produce an 
aerosol with a mass median aerodynamic diameter (MMAD) of approximately 1.50 µm, 
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an emitted dose (ED) greater than 75%, and FPF less than 5 µm and 1 µm (FPF<5µm/ED 
and FPF<1µm/ED) of 95% and 31%, respectively, at an inhalation flow rate of 45 LPM and 
a pressure drop of 4 kPa using an excipient enhanced growth (EEG) powder 
formulation.  In comparison, most commercial DPIs typically employ carrier-particle 
based formulations (i.e. lactose blends) that struggle to generate FPF<5µm above 40% 
and produce lower values at low flow making dispersion highly dependent on inhalation 
flow rate (Prime et al. 1999, Islam et al. 2012, Zhou et al. 2014).  However, spray dried 
formulations (i.e. PulmosphereTM, EEG) have frequently improved inhaler performance 
by decreasing particle sizes, thus increasing FPF<5µm values (Sham et al. 2004, Geller 
et al. 2011, Young et al. 2013, Weers et al. 2014).  The high efficiency performance 
achieved by Behara et al. (2014b) was performed with a 2 mg formulation mass, which 
is consistent with inhaled medications such as β2-agonists and corticosteroids.  
However, delivery of higher dose medicines with these new high efficiency devices may 
require loading and actuating multiple powder capsules.  Repeated loading and 
delivering the medications over multiple cycles is time consuming and may result in 
poor patient compliance (Smith et al. 2010) and potential variability in delivery 
efficiency. 
Potential pharmaceutical applications that require high-doses of drug include most 
inhaled antibiotics (e.g., tobramycin), non-steroidal anti-inflammatories (e.g., disodium 
cromoglycate), mucus clearance agents (e.g., mannitol), and surfactants (e.g., 
survanta) (Keller et al. 2010, Ruppert et al. 2010, Young et al. 2013).  To deliver these 
high-dose inhaled medications, three approaches may be employed: (i) use active DPIs 
often requiring multiple dose loadings, (ii) implement single capsule passive devices 
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and load multiple capsules, and (iii) develop new passive devices intended for high-
dose medications.  Active DPIs provide a power source to assist with aerosolizing the 
large powder mass.  For example, the MicroDose DPI (MicroDose Therapeutx, Inc., 
Monmouth Junction, NJ) utilizes a vibrating piezoelectric system to form an aerosol from 
a foil dosing blister that can contain up to approximately 400 mg of powder (Corcoran et 
al. 2013).  Aerosolization performance with active devices is typically good; however, 
the implementation of a power source typically increases device cost and complexity 
(Islam et al. 2012, Zhou et al. 2014).  Currently, the most widely used strategy for 
delivering high-doses of inhaled medications is a capsule-based device with multiple 
cycles of loading and actuation.  For example, the Podhaler (Novartis Pharmaceuticals, 
San Carlos, CA) inhaler is used to effectively deliver a 112 mg dose of tobramycin to 
cystic fibrosis patients (Geller et al. 2011).  This approach provides a significant time 
savings compared with nebulized delivery, which typically requires 15-20 minutes per 
treatment; however, the patient is required to load and actuate 4 separate capsules 
(Geller et al. 2011).  Furthermore, mouth-throat depositional loss is reported to be >40% 
with the PulmoSphere formulation and Podhaler combination.  For the delivery of 
mannitol as a mucus clearance enhancer, Bronchitol (Pharmaxis Ltd, Sydney, Australia) 
is currently delivered as 10 separate capsules containing 40 mg each (Bilton et al. 
2011). 
High-dose devices can be classified as delivering 50 mg of powder and above.  
Ideally, the same device should also be capable of delivering lower masses in the range 
of 10 or 25 mg.  The Twincer inhaler is a passive device that can be operated with a 
loaded mass up to approximately 50 mg; however, higher masses have not been 
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reported (de Boer et al. 2012).  Recently, the Orbital multi-breath inhaler was introduced 
as a true high powder mass platform capable of delivering doses up to 400 mg over a 
series of 16 inhalations (Young et al. 2013).  With high powder mass devices, multiple 
inhalations with a single dose loading are considering advantageous to avoid 
overloading the oropharynx and upper airways with deposited powder during a single 
inhalation.  The Orbital was found to produce aerosols with MMADs of 3, 4.2, and 4 µm 
using ciprofloxacin (Cipro), mannitol, and a 1:8 Cipro-mannitol co-spray-dried powder, 
respectively (Young et al. 2013).  Fine particle fractions were in the range of 42-67% 
and mouth-throat (MT) depositional loss was not reported at the tested inhalation flow 
rate of 60 LPM. 
A concept that has previously not been reported for the efficient aerosolization and 
delivery of pharmaceutical powders in a handheld device is that of a fluidized bed.  The 
fluidized bed concept consists of a collection of small spheres, or other solids, that have 
fluid-like movement when a gas is forced through them (Prenni et al. 2000).  Chaotic 
motion of the spheres induces turbulence and collisions that can effectively 
deaggregate a powder as it passes through the bed.  This approach was previously 
reported in a large scale device used to produce test aerosols for evaluating filters and 
aerosol characterization equipment (Hinds 1999).  Fluidized beds have also been used 
to meter and fill dose containment units used in inhalers, such as blisters and capsules 
(Zhu et al. 2006).  However, a miniature fluidized bed in an inhaler has not previously 
been considered and may provide an effective approach for producing high efficiency 
aerosolization of high-dose medications.   
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 The objective of this study is to develop a high efficiency, high-dose DPI intended 
for EEG aerosol delivery using a concept similar to a classic fluidized bed aerosol 
generator (Hinds 1999, Prenni et al. 2000, Lind et al. 2010).  The inhaler contains the 
fluidized bed, which consists of small light-weight mixing balls.  Designs include 
introduction of the powder directly to the fluidized bed and containment of the powder in 
a separate dosing sphere that is placed in the fluidized bed.  The effect of the mixing 
balls is also considered by removing them from the design and only including the dose 
sphere.  A series of in vitro experiments was conducted to select leading design 
conditions, optimize the design, and evaluate aerosolization characteristics compared 
with existing high efficiency devices at different flow conditions that reflect the inhalation 
capabilities of adults and children.   
 
5.3 Materials and Methods 
Overview 
To develop and optimize the fluidized bed (FB) -DPI, a number of screening 
experiments were first conducted.  The proposed design, shown in Figure 5.1, consists 
of a chamber with an off-center inlet for airflow to enter from the top, approximately sixty 
PTFE mixing balls that are 4.76 mm in diameter (McMaster-Carr, Elmhurst, Illinois), a 
powder dosing sphere with an outer diameter of 12 mm, an inner diameter of 10 mm, 
and four 0.5 mm holes for the powder to exit, a mixing chamber, a mesh to retain the 
mixing balls, and a mouthpiece.  The effects of different mixing ball sizes, air inlets, 
mixing chamber sizes, and number of holes in the powder dosing sphere were 
evaluated in search of an optimized design.  The inlet, chamber size, and ball size were 
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optimized to produce the maximum vibrational amplitude, as measured using a 
piezoelectric force sensor.  Next, the powder dosing sphere was optimized based on 
emptying over time to produce a consistent amount of powder leaving the device during 
each inhalation using a readily available spray dried mannitol powder.  Performance of 
the proposed device was then compared to a previously developed high efficiency DPI 
for EEG aerosol delivery (i.e., the CC90-3D inhaler) (Behara et al. 2014b).  The FB-DPI 
was tested using 25 mg of an EEG ciprofloxacin (EEG-Cipro) formulation for 
comparison with a single 25 mg capsule used in the previously developed CC90-3D 
device.  The FB-DPI was also tested using 100 mg of the EEG-Cipro formulation, at a 
characteristic adult pressure drop of 4 kPa, and 50 mg using a representative pediatric 
pressure drop of 2 kPa.  Results of aerosolization are given in terms of dosing sphere 
(or capsule) and device retention, ED, FPF<5µm/ED and FPF<1µm/ED, and the MMAD of the 
aerosol.  Based on previous studies, high efficiency performance for the delivery of EEG 
formulations will be defined by the production of an aerosol with the following 
characteristics: an MMAD of approximately 1.50 µm, FPF<5µm/ED above 90%, FPF<1µm/ED 
above 30%, and an ED of approximately 75% while using a relatively large mass (25-
100 mg) of powder (Behara et al. 2014a, Behara et al. 2014b). 
 
Materials 
Ciprofloxacin hydrochloride (Cipro) was purchased from Spectrum Chemicals 
(Gardena, CA) and Pearlitol® PF-Mannitol was donated from Roquette Pharma 
(Lestrem, France).  Poloxamer 188 (Leutrol F68) was donated from BASF Corporation 
(Florham Park, NJ).  L-leucine and all other reagents were purchased from Sigma 
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Chemical Co. (St. Louis, MO).  Hydroxypropyl methylcellulose (HPMC) capsules (size 
3) were donated from Qualicaps (Whitsett, NC).  
 
Inhaler design 
 A fluidized bed can be created by inducing fluid motion through an array 
consisting of many solids, usually of similar size and material.  As the fluid, which is 
typically air, moves through the bed of solids, the entire structure begins to behave 
similar to a fluid rather than a solid structure (Green 1997).  For creation of the high-
dose "fluidized bed" style DPI, small PTFE mixing balls are used to assist with the 
emptying of the device as well as the deaggregation of the powder.  Inhalation air is 
drawn through the mixing balls from an inlet jet, causing them to move chaotically within 
the mixing chamber, which empties the powder dosing sphere and breaks up 
agglomerates of powder.  The basic design of the proposed inhaler is shown in Figure 
5.1.  The design consists of the mixing chamber, an air inlet from the top, a mesh 
preventing inhalation of the small mixing balls and dosing sphere, and a mouthpiece.  
The edges on the inside of the device were rounded to prevent powder buildup in 
corners that the mixing balls could not reach.  The air inlet configurations to be 
evaluated are shown in Figure 5.2 and labeled Inlets 1-6.  Inlets directed from the 
bottom of the chamber were also considered, but were found to be ineffective in 
comparison to the top inlets. 
 Approaches to introduce the formulation into the inhaler were direct addition of 
the powder mass on top of the fluidized bed or containment of the powder in a dosing 
sphere.  The initial prototyped design of the dosing sphere had inner and outer 
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diameters of 10 and 12 mm, respectively.  To release the powder, the dosing sphere 
had either 2, 4, 6 or 8 circular openings (holes) with diameters of 0.5 mm each.   The 
sphere was built in two halves which were assembled after placing the powder inside.  
The first hole was placed at a 20 degree offset from the center bisection of the sphere, 
with a second hole opposite of this at 180 degrees.  For the 4 hole design there are two 
sets of two holes with center lines that intersect each other in the center of the sphere.  
For the six and eight hole spheres, the holes were placed at equal intervals around the 
outside of the sphere, so that for the six hole sphere, there would be three holes on both 
the top and bottom halves and for the eight hole sphere there would be four holes on 
each half.  Furthermore, a fifth hole configuration, shown in Figure 5.3, was considered 
that implemented 4 holes oriented in a way such that the center lines of the holes 
intersected in the center of the sphere, but the center lines were offset 90 degrees when 
looking from the top or bottom of the sphere.  The dosing sphere was intended to 
provide high emission from the device while uniformly releasing the powder over four 
inhalations. 
The inhalers and dosing spheres were created using Autodesk Inventor and 
exported as .STL files to be prototyped. The files were then prepared using 3D 
Lightyear Software. The parts were built using a 3D Systems Viper SLA System (3D 
Systems Inc., Rock Hill, SC) using Accura 60 stereolithography resin (3D Systems Inc.). 
Once the parts were prototyped, they were cleaned using a Proclean SL Part Washer 
(3D Systems Inc.) and dried in a 3D Systems UV-light dryer for 90 minutes.  The parts 
were then sanded to provide a smooth finish. 
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After prototyping and cleaning, the inhaler devices (but not dosing spheres) were 
coated with a commercial polytetrafluoroethylene (PTFE) suspension (LU™708, 
Sprayon Products, Cleveland, OH), which is a high contact angle (or low surface 
energy) material.  A suspension of PTFE was sprayed inside the entire device to form a 
thin coating.  Compressed air was blown through the coated portions until the surface 
appeared dry.  This coating was applied to reduce the powder buildup on the walls of 
the device and to reduce static charge buildup due to a difference in the material of the 
mixing balls and the prototyped chamber. 
 
Evaluation of Vibrational Amplitude 
 To optimize the mixing chamber diameter (15, 20, or 25 mm), inlet configuration, 
and mixing ball size (3.18, 3.97, or 4.76 mm), a screening method was used.  A 
polyvinylidene fluoride (PVDF) piezoelectric force sensor (LDT1-028K; Measurement 
Specialties, Hampton, VA) was fixed to the outside of the chamber of the devices to 
measure the intensity of vibration caused by the impaction of the spheres inside the DPI 
at a steady state flow rate of 45 LPM (4 kPa pressure drop).  The positive and negative 
leads were then connected to an oscilloscope probe.  The intensity of the vibration was 
measured by reading the voltage output values on the oscilloscope.  Peak-to-peak 
voltage averages were used to measure the intensity of vibrations within the inhaler and 
labeled the vibrational amplitude. 
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Powder formulations 
Formulations employed were a commercially available spray dried mannitol 
powder for rapid screening of emitted dose (ED) at high-mass loadings and a spray 
dried EEG formulation of the antibiotic ciprofloxacin.  The spray dried mannitol powder 
was PEARLITOL 25C (Roquette Pharma, Lestrem, France) with a reported primary 
particle mean diameter of 25 µm.  While larger in particle size than the EEG-Cipro 
formulation, the PEARLITOL powder was selected for use in the screening studies as it 
is highly dispersible, similar to EEG formulations, and readily available for high-mass 
testing of the inhaler emptying characteristics without having the potential 
pharmacological effects of the EEG-Cipro formulation. 
An EEG formulation of co-spray dried mannitol and ciprofloxacin was prepared 
using the approach described by Son et al. (2013a)  Briefly, a 20% ethanol in water 
mixture containing 0.5 % w/v of solutes consisting of Cipro, mannitol, L-leucine and 
poloxamer 188 in a ratio of 30:48:20:2 (w/w %) was spray dried using a Büchi Nano 
spray dryer B-90 (Büchi Laboratory-Techniques, Flawil, Switzerland).  The powder 
formulation was generated using an airflow rate of 120 LPM, 100% liquid flow rate using 
the 4 µm nozzle diameter at an air inlet temperature of 70 oC. The resulting air outlet 
temperature and spray dryer pressure were 40 oC and 35 mbar, respectively. Powder 
was collected from the electrostatic precipitator of the spray dryer and was stored in a 
desiccator until it was used. The powder yield was about 50-60%. Approximately 1 mg 
of powder was dissolved in 100 mL of deionized water and analyzed for content 
uniformity (n=3) of Cipro in the formulation using the USP HPLC method for Cipro. To 
protect the powder formulations from the effects of ambient humidity, powders were 
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stored in a desiccator to prevent moisture ingress and aerosolized following brief 
exposure to environmental RH conditions.   
As previously described, the EEG approach is intended to generate an aerosol 
with a very small initial MMAD, typically 1.5 µm or below, and high FPF (Son et al. 
2013a).  Due to small size of the aerosolized particles, MT or extrathoracic deposition is 
minimal (Son et al. 2013a).  Once inside the airways, the EEG particles take up water 
due to the inclusion of the hygroscopic excipient and become significantly larger 
droplets (Hindle et al. 2012).  This size increase of the droplets is used to ensure 
aerosol deposition within the lungs, which would be largely exhaled without size 
increase, and potentially control the region of drug delivery (Tian et al. 2013). 
 
Evaluation of device emptying 
 The device with the highest vibrational amplitude was selected and implemented 
for evaluation of ED from the five different dosing spheres.  Initial screening was 
conducted with 100 mg of the PEARLITOL 25C formulation loaded into the dosing 
sphere and placed in the selected FB-DPI. A vacuum pump, flow controller and inline 
filter were connected in series to the mouthpiece of the inhaler and the FB-DPI was 
actuated using an inhalation flow rate of 60 LPM for 4 seconds producing an inhaled 
volume of 4 L.  The corresponding pressure drop over the device was 4 kPa.  Four 
inhalation cycles were used to evaluate the inhaler.  The ED in these screening 
experiments using PEARLITOL 25C was calculated by weighing the FB-DPI before and 
after testing.  Emptying of the inhaler over time was also tested using a 25 mg mass of 
spray dried EEG-Cipro powder using four inhalations and analyzed by weight.  This 
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relatively low mass was employed to provide a conservatively low estimate of emptying, 
as percent ED is expected to increase as loaded mass is increased. 
 
Evaluation of previously developed capsule-based EEG DPIs at higher loaded mass 
The previous study of Behara et al. (2014b) developed the CC90-3D rod array 
DPI for use with EEG formulations and showed high efficiency performance with a 2 mg 
loaded mass.  In the current study, performance of the CC90-3D device is evaluated with 
25 mg of the EEG-Cipro formulation, which is the approximate maximum that can be 
placed in a single size 3 HPMC capsule (Qualicaps, Whitsett, NC).  The loaded 
capsules were then pierced using a 0.5 mm needle in the optimum configuration as 
determined by Behara et al. (2014b) and placed in the CC90-3D inhaler.  The powder 
was then aerosolized into a Next Generation Impactor (NGI; MSP Corp., Shoreview, 
MN) using a 2 or 4 kPa pressure drop across the device, which corresponded to flow 
rates of 32 LPM or 45 LPM, respectively.  For the adult 4 kPa pressure drop, powders 
were aerosolized until a total air volume of 4 L was drawn through the inhaler at ambient 
conditions (10-45% RH and 20-24 oC).  For the pediatric 2 kPa pressure drop, the 
powder was aerosolized until a total volume of 1.5 L was drawn through the device.  
Four inhalation cycles were pulled through the device for the adult and pediatric 
pressure drops. 
 
Evaluation of fluidized bed high-dose device (FB-DPI) 
 To characterize the aerosolization performance of the FB-DPI, EEG-Cipro 
formulation weights of 25, 50, and 100 mg were considered.  Evaluation of 25 mg was 
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used for direct comparison with the CC90-3D inhaler whereas 50 and 100 mg were 
considered as high-doses for pediatric and adult applications, respectively.  The 
appropriate mass was weighted and placed in the prototyped dosing sphere, which was 
then loaded into the FB-DPI.  The powder was then aerosolized into the NGI at an 
airflow rate corresponding to both a 2 and 4 kPa pressure drop across the device.  For 
the adult 4 kPa pressure drop, powders were aerosolized at 60 LPM until a total air 
volume of 4 L was drawn through the inhaler.  For the pediatric 2 kPa pressure drop, the 
powder was aerosolized at 45 LPM until a total volume of 1.5 L was drawn through the 
device, which is consistent with in vivo data for an approximately 7-year-old child(ICRP 
1994, Tiddens et al. 2006).  As in the other cases, 4 inhalation cycles were implemented 
for each test. All measurements with the EEG-Cipro formulation were made with three 
replicates.   
 
Particle size characterization 
 The stages of the impactor were coated with silicone spray to minimize particle 
bounce and re-entrainment. The powders were aerosolized with the DPI in a horizontal 
position attached to the pre-separator on the NGI using a rubber mold made specifically 
for the mouthpiece of this inhaler to ensure a perfect seal.  To allow for horizontal 
positioning of the inhaler, as it would be used by a patient, and avoid the use of an 
induction port, the NGI was positioned on its side (oriented vertically).  This positioning 
of the NGI is not expected to affect sizing performance due to the reliance on impaction 
and not sedimentation for aerosol capture.  To assess the total aerosol size distribution 
in the absence of a lactose carrier, the USP induction port was not used in this research 
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and development study.  After aerosolization, drug retained in the dosing sphere or 
capsule, device, and the drug collected on the pre-separator, impaction plates and the 
filter were extracted by washing with deionized water for quantitative HPLC analysis.  
The cut-off diameters of each NGI stage at a specific airflow rate were calculated using 
the formula specified in USP 35 (Chapter 601, Apparatus 5).  
 
Device retention, emitted dose, and calculation of aerosol metrics 
When using the EEG-Cipro formulation, the loaded Cipro dose was determined 
from the initial weight of the powder taken for aerosolization and the percent of Cipro 
content in the EEG formulation as measured by content uniformity. The mass of Cipro 
retained in the dosing sphere, or capsule, and device was determined by HPLC and 
expressed as a percentage of the loaded Cipro dose. Emitted dose was calculated by 
subtracting the mass of Cipro retained in the dosing sphere and device from the loaded 
Cipro dose.  FPF of the EEG formulation (FPF<5µm/ED) and sub-micrometer FPF 
(FPF<1µm/ED) were defined as the fraction less than 5 µm and 1 µm, respectively, 
expressed as a percentage of the ED.  MMAD, FPF<5µm/ED and FPF<1µm/ED were 
calculated from linear regression equations resulting from cumulative percentage mass 
vs. cut-off diameter of the respective stages on the NGI plots. 
 
5.4 Results 
Effects of chamber size and inlet configuration on vibrational amplitude 
 Results for the optimization of the chamber size, inlet configuration, and mixing 
ball size are shown in Table 5.1.  These values are the peak-to-peak voltage averages 
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output from the piezoelectric averaged over five repetitions (vibrational amplitude).  The 
results were verified visually and indicated that the designs with the highest vibrational 
amplitude values produced the highest amount of ball movement.  The three different 
mixing ball sizes, along with the 25 mm chamber and Inlet 5 (Figure 5.2e) produced the 
most active ball movement.  The different mixing ball sizes did not show any significant 
difference in the ball movement of the optimum system (Table 5.1), so the largest ball 
size, 4.76 mm, was selected.  Based on this evaluation of maximum vibrational 
amplitude at a constant inhalation flow rate, the leading design used in the subsequent 
experiments implemented a 25 mm chamber diameter with airflow Inlet 5 and 4.76 mm 
mixing balls. 
 
Effect of powder dose sphere on emitted dose 
 The initial emptying results using PEARLITOL 25C are shown in Table 5.2 and 
include the total ED from the inhaler and the percentage of the powder released from 
the dosing sphere after a total of 4 inhalations at 60 LPM for 4 seconds.  All of the 
designs, excluding the 2 hole design, performed well in terms of ED, however this test 
provided no information as to the emptying of the inhaler during each individual 
inhalation. The design goal was to produce relatively uniform release of the powder over 
each of the 4 inhalations. 
Table 5.3 illustrates the cumulative dose emptying for each of the 4 inhalation 
cycles achieved by each configuration of the dosing sphere.  The 2 hole design 
achieved a consistent release, but the overall ED was low at 58.8%.  Without the dose 
sphere, nearly the entire ED was released in the first inhalation (80.5%), and only 
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increased to 81.4% with 4 inhalations.  The 4 and 6 hole designs outperformed the 4 
Hole-90° design in terms of overall emptying in this test, but the 4 Hole-90° design 
produced the more consistent release of the powder that was desired.  Specifically, for 
the 4 and 6 hole designs 61.3% and 85.4% of the powder was released in the first 
breath, respectively.  The 4 Hole-90° only released 36.9% of the powder in the first 
breath, then 63.3%, cumulatively, in the second breath.  Based on both good emptying 
and consistent release, the 4 Hole-90o design was selected for subsequent 
experiments.  The final design of the dosing sphere for the adult pressure drop, shown 
in Figure 5.3, consisted of an outside diameter of 12 mm, inside diameter of 10 mm, and 
four 0.5 mm holes with centerlines that intersect perpendicularly through the middle of 
the ball (4 Hole-90o design).  The dosing sphere for the pediatric pressure drop was of 
the same design, but with an inside diameter of 8 mm and an outside diameter of 9.4 
mm to keep the ball as light as possible.  These designs were implemented in the final 
testing of the aerosolization performance of the device using the EEG-Cipro formulation. 
 
Results of CC90-3D inhaler with high-dose 
 For this high-dose study, the CC90-3D inhaler was very effective at deaggregating 
the EEG-Cipro powder with the adult pressure drop of 4 kPa, even at its maximum fill 
mass of 25 mg, as shown in Table 5.4.  As expected with the larger mass, as well as 
using multiple inhalations, the ED increased to 88.6% while the MMAD was found to be 
1.55 µm, only a slight increase over the previous study of Behara et al. (2014b)  
FPF<5µm/ED and FPF<1µm/ED values were similar to the previous study with only a slight 
drop in the FPF<1µm/ED value from 31.4%, as reported previously, to 28.8% with the 
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larger mass (Behara et al. 2014b).  However, when the pediatric pressure drop was 
used with the 25 mg formulation mass, there appeared to be insufficient airflow to 
levitate the capsule and produce the aerosol.  In contrast, the previous study of Behara 
et al. (2014b) which implemented a 2 mg mass, showed consistent performance of the 
device across pressure drops of 2-6 kPa.  As a pressure drop of 2 kPa and formulation 
weight of 25 mg is outside of the initial design criteria of the CC90-3D inhaler and ED 
performance was poor, these results are not presented.  However, it is expected that 
the CC90-3D inhaler can be modified to perform well under these conditions by 
optimization of the airflow inlet size and capsule chamber dimensions to allow for 
levitation of the capsule at reduced flow rates. 
 
Results of the high-dose fluidized bed device (FB-DPI) 
 The high-dose device was tested using 25 mg of the EEG-Cipro powder 
formulation for comparison with the CC90-3D inhaler and the results are displayed in 
Table 5.4.  The aerosolization performance of the device at the adult pressure drop was 
similar to that of the CC90-3D inhaler with a MMAD of 1.53 µm and a FPF<5µm/ED and 
FPF<1µm/ED of 93.8% and 31.3%, respectively.  However, the ED of 59.8% was 
significantly lower than with the CC90-3D device with 25 mg of powder.  The ED of the 
FB-DPI increased to 71.4% when 100 mg was used while still achieving a 1.53 µm 
MMAD, as well as a FPF<5µm/ED of 93.3% and FPF<1µm/ED of 36.4% as shown in Table 
5.5.  The pediatric pressure drop and 25 mg loaded mass produced an ED of 57.5%, 
with only 12.4% retention in the dosing sphere, but 30.2% device retention.  As 
expected with a lower flow rate, the MMAD increased to 1.81 µm and the FPF<1µm/ED 
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decreased to 20.0%, but the FPF<5µm/ED remained similar at 93.0%.  The design of the 
dosing sphere for the pediatric pressure drop limited the maximum mass to 50 mg 
instead of 100 mg with the adult model.  The results for the pediatric pressure drop 
using 50 mg of powder are compared to the adult pressure drop at 100 mg in Table 5.5.  
At 2 kPa and 50 mg loaded mass with the pediatric dose sphere, the device produced 
an ED of 59.8%, a MMAD of 1.80 µm, a FPF<5µm/ED of 92.3%, and a FPF<1µm/ED of 
21.8%, which is comparable to the 25 mg data. 
In a final set of experiments, the mixing balls were removed from the system and 
the motion of the dosing sphere alone was used to deaggregate and aerosolize the 
powder.  Results at a 4 kPa pressure drop with the adult dose delivery sphere and 25 
mg loaded mass are displayed in Table 5.6 for the FB-DPI without the mixing balls.  
Results indicated an ED of 73.8% without the mixing balls, which was significantly 
(p<0.05; t-test) improved compared to the similar case with the balls (59.8%; Table 5.5, 
FB-DPI 4 kPa).  However, there were no significant changes in the aerosol quality when 
the balls were removed with an MMAD of 1.53 µm, FPF<5µm/ED of 95.1%, and FPF<1µm/ED 
of 31.4%. 
 
5.5 Discussion 
 A primary outcome of this study is the first evaluation of an inhaler based on a 
fluidized bed design. The design of the inhaler incorporating mixing balls caused a 
significant decrease in the aerosol ED compared to the inhaler without the mixing balls 
with more drug retention in both the dosing sphere and the device (absolute difference 
of 16%), but the MMAD was unaffected by the presence of the mixing balls.  This is 
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likely because of the increased surface area, provided by the mixing balls, to which the 
powder could adhere.  The movement of the dose sphere was potentially hindered by 
the mixing balls, thus increasing the retention in the dosing sphere. 
 The previously developed CC90-3D inhaler was able to produce a very high 
quality aerosol with a 25 mg loaded mass at the adult pressure drop of 4 kPa.  
However, 4 capsules and 4 inhalations per capsule would be required to achieve the 
same nominal loaded formulation mass as the 100 mg FB-DPI device.  The 
performance of the CC90-3D device became extremely limited at the pediatric pressure 
drop with a weight of 25 mg, which was beyond the initial design parameters of the 
inhaler.  It is expected that the capsule chamber of the CC90-3D inhaler can be 
redesigned to allow for effective operation at this higher formulation weight compared 
with the 2 mg weight considered by Behara et al. (2014b) however, this optimization is 
beyond the scope of the current study. 
Compared with the previously developed CC90-3D inhaler at a formulation weight 
of 25 mg and adult pressure drop of 4 kPa, the optimal FB-DPI device produced nearly 
identical aerosol characteristics but the ED was reduced from 88.6% to 59.8% (Table 
5.4).  The clear advantage of the FB-DPI is the ability to increase the loaded mass to 
100 mg as considered in Table 5.5.  Increasing the loaded mass to 100 mg at the adult 
pressure drop did not change the aerosolization characteristics and increased the ED to 
71.4%.  This increase in ED associated with increased loaded mass is due to the 
internal surface area of the dosing sphere, which is larger than the internal surface area 
of the capsules used in the CC90-3D inhaler, in order to hold more powder. 
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By using a combination of the fluidized bed device and the EEG powder 
formulation, the FB-DPI was able to produce an aerosol much smaller than that of the 
ORBITAL device using the co-spray-dried formulation, with an MMAD less than half the 
size (1.53 µm vs 4.0 µm) and with much higher FPFs (93.8% vs. 42%)(Young et al. 
2013).  It should be noted that the primary particle size of the EEG-Cipro formulation 
was submicrometer sized unlike the 2.9 µm ORBITAL formulation. The ED of the FB-
DPI after four inhalations was approximately 71.4% compared with the ORBITAL device 
that appeared to emit approximately 75% of its dose at four inhalations.  The ORBITAL 
was also able to deliver a formulation mass of up to 400 mg, which could offset the 
expected higher mouth-throat depositional loss associated with using a larger aerosol 
MMAD. 
The optimum fluidized bed device that resulted from this study had the following 
characteristics: 25 mm chamber diameter, Inlet #5, 4.76 mm mixing ball diameter, and 
the 4 Hole-90° dose sphere.  This device was able to produce a 1.53 µm MMAD aerosol 
with a FPF<5µm/ED of 93.3%, a FPF<1µm/ED of 36.4%, and an ED of 71.4% when used at 
the adult pressure drop and maximum tested formulation weight of 100 mg.  When used 
at the pediatric pressure drop, the device was able to produce a 1.80 µm MMAD aerosol 
with a FPF<5µm/ED of 92.3%, a FPF<1µm/ED of 21.8%, and an ED of 59.8% using the 
maximum tested pediatric formulation weight of 50 mg.  In both the adult and pediatric 
cases, the small aerosol (i.e. MMAD < 2 µm) is expected to produce low MT 
depositional loss.  For example, Son et al. (2013a) previously demonstrated that an 
EEG aerosol with a MMAD of approximately 1 µm produced a MT depositional loss of 
<5%, compared with 80% for a commercial formulation and inhaler.  Using a 3D rod 
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array DPI and EEG formulation, MT depositional loss was reduced to <3% (Son et al. 
2013b).  For the adult inhalation conditions, the shortcoming of the optimized FB-DPI is 
the ED of 71.4%, whereas previous high efficiency DPIs have achieved ED values 
>75% (Behara et al. 2014a, Behara et al. 2014b).  Testing the device without the mixing 
balls indicated that ED could be increased without altering the performance.  This was 
an interesting finding considering that fluidized beds are known to contribute to powder 
deaggregation and are often used in industry to produce high quality fine aerosols 
(Hinds 1999).  An additional test of the vibrational amplitude without the mixing balls but 
including the dose sphere indicated a value of 566.4, which is higher than the values 
reported in Table 5.1 for the FB-DPI designs with mixing balls and supports an 
association between the measured vibrational amplitude and DPI performance.  In 
contrast, increased vibrational frequency created by the mixing balls may reduce 
vibrational amplitude and limit ED.  Furthermore, the use of smaller mixing balls, as with 
the studies of Lind et al. (2010) and Prenni et al. (2000) for packed beds, may further 
decrease ED due to increased surface area of the spheres as a whole and likely 
increased vibrational frequency.  As a result, the high dose device can be simplified and 
improved by removing the mixing balls and only retaining the dosing sphere and inhaler 
body.  These findings motivate further study of the high dose DPI in order to maximize 
ED and deaggregation with the simplest possible device.  However, this optimization is 
beyond the scope of the current study, which was intended to characterize the 
performance of an inhaler that was based on using the well recognized approach of a 
fluidized bed for aerosol deaggregation.  As previously described, the use of CFD 
simulations together with concurrent in vitro experiments can be applied to further 
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optimize the device design in a quantitative manner (Longest et al. 2009, Hindle et al. 
2013, Longest et al. 2013b). 
Considering the pediatric delivery conditions and 50 mg formulation weight, 
performance of the FB-DPI appears acceptable.  Shortcomings of the device at 2 kPa 
appear to be an ED of ~60% and a small increase in particle size with a MMAD of 1.8 
µm.  A recent study of commercial inhalers tested under pediatric delivery conditions 
produced MT deposition values of 60-80% (Below et al. 2013).  In contrast, our 
preliminary MT deposition results with EEG formulations and pediatric airway conditions 
indicate losses <10%.  Based on results for the FB-DPI device at 100 mg and 4 kPa, it 
is expected that removing the mixing balls from the pediatric inhaler will again improve 
ED.  Further decreases in MMAD, if needed, can likely be achieved through 
optimization of the dosing sphere (e.g., hole position and size) and modifying the 
number of required inhalations. 
Limitations of the current study include use of vibrational amplitude and Pearlitol 
powder to screen the initial designs.  Vibrational amplitude was found to be highest in 
the case without the mixing spheres, which implies that use of this parameter as a 
screening tool for DPI performance may be valuable.  However, vibrational frequency 
was not considered and could potentially reduce ED as in the study of Behara et al. 
(2014a)  The highly dispersive EEG formulations were expected to deaggregate like 
much larger Pearlitol particles; however, this association has not been proven.  In the 
sizing experiments, neither an induction port nor a mouth-throat geometry was used in 
order to best quantify the size distribution of the aerosol leaving the inhaler and entering 
the respiratory tract.  It was not our intent to perform compendial quality control 
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experiments; however, it is expected that the preseparator captures the drug that would 
have deposited in the induction port (or mouth-throat) considering that it has a smaller 
cutoff size.  As a result, it is expected that FPF calculations were not biased based on 
exclusion of the MT geometry.  In addition, while the stages of the NGI were coated with 
a silicone spray, as suggested by USP, it is acknowledged that with the higher masses 
of powder used in this study, particle bounce may not have been completely prevented.  
Some small powder deposits were seen on the nozzles of the NGI after experiments 
which suggest some particle bounce may be present, which may lead to small changes 
in the particle size distribution (Rissler et al. 2009, Grasmeijer et al. 2012).  
Additional limitations of this study include the investigation of a single chamber 
design and orientation, the evaluation of the device only with an inlet at the top of the 
chamber, and the evaluation of a single EEG drug formulation.  Other chamber designs 
could prove to be more effective at lowering the device retention, but could also have a 
negative effect on the particle size.  Positioning the inlet on the side or the back of the 
inhaler could also have an effect on the performance of the device and needs to be 
studied further for confirmation.  The EEG-Cipro powder was the only formulation 
studied, but the data from the CC90-3D device was similar to the EEG-Albuterol Sulfate 
(AS) formulation used in the study by Behara et al. (2014b). 
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5.6 Abbreviations 
AS  Albuterol sulfate 
Cipro  Ciprofloxacin hydrochloride 
DPI  Dry powder inhaler 
ED  Emitted dose 
EEG  Excipient enhanced growth 
FB  Fluidized bed 
FPF  Fine particle fraction 
HPLC  High-performance liquid chromatography 
HPMC Hydroxypropyl methylcellulose 
MMAD Mass median aerodynamic diameter 
MT  Mouth-throat 
PTFE  Polytetrafluoroethylene 
PVDF  Polyvinylidene fluoride 
SD  Standard deviation  
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Figure 5.1 Image of fluidized bed dry powder inhaler (FB-DPI) showing the air inlet, 
mixing chamber, mixing balls, restraining mesh and mouthpiece.  
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Figure 5.2 Images of the inlet configurations: (a) Inlet 1 attached to inhaler showing 
flow direction, (b) Inlet 2, (c) Inlet 3, (d) Inlet 4, (e) Inlet 5, and (f) Inlet 6.  
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Figure 5.3 Images showing the dosing sphere developed for this device: (a) side view 
of the two halves separated, (b) isometric view of the two halves separated, and (c) 
assembled dose sphere with the 4 Hole-90° design.  
95 
 
Table 5.1 Peak-to-Peak Voltage averages (vibrational amplitude) for chamber sizes, 
mixing ball sizes, and inlet configurations.  The standard deviation (SD) is shown in 
parenthesis [n=5]. 
Chamber size 
Mixing ball 
size 
Inlet configuration 
2 3 4 5 
      
15mm 
3.18 mm 144 (43.8) 224.8 (33.4) 375.1 (57.4) 379.2 (75.8) 
3.97 mm N/A 253.6 (75.0) 360.0 (52.4) 299.2 (97.0) 
4.76 mm N/A N/A 208.8 (75.8) 291.2 (96.7) 
      
20mm 
3.18 mm 168.4 (25.1) 190.8 (25.9) 362.4 (72.5) 273.6 (43.2) 
3.97 mm 114.8 (23.9) 176.8 (70.3) 380.0 (59.5) 311.2 (48.8) 
4.76 mm 115.2 (36.2) 284.8 (59.2) 377.6 (83.3) 371.2 (33.8) 
      
25mm 
3.18 mm 120.8 (36.1) 206.0 (22.5) 280.8 (48.9) 409.6 (40.1) 
3.97 mm 178.8 (25.8) 240.8 (64.1) 207.2 (33.0) 483.2 (40.2) 
4.76 mm 144.8 (33.4) 266.4 (54.4) 166.0 (52.7) 442.4 (69.1) 
All values given in millivolts (mV). 
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Table 5.2 Screening of dosing sphere emptying by weight using 100 mg of 
PEARLITOL 25 C [n=1]. 
Description No dosing 
sphere 
2 
Hole 
4 
Hole 
4 Hole-
90° 
6 
Hole 
8 
Hole 
       
ED (%) 92.2 44.9 84.0 92.9 88.0 90.2 
Dosing sphere released (%) N/A 50.3 97.7 96.9 97.9 98.8 
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Table 5.3 Screening of dosing sphere emptying by weight as a function of inhalation 
number using 100 mg of EEG-Cipro formulation (Batch 1 and Batch 2) [n=1]. 
Cumulative % Released from 
Dosing Sphere 
No dose 
sphere 
2 
Hole 
4 
Hole 
4 Hole-
90° 
6 
Hole 
      
1st inhalation (%) 80.5 18.4 61.3 36.9 85.4 
2nd inhalation (%) 81.3 37.4 91.2 63.3 94.7 
3rd inhalation (%) 81.3 48.6 94.2 76.3 95.9 
4th inhalation (%) 81.4 58.8 96.0 82.0 96.5 
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Table 5.4 Comparison of aerosolization using the previously developed inhaler CC90-3D to the new fluidized bed (FB) -
DPI with 25 mg of EEG-Cipro (Batches 11 and 12).  The standard deviation (SD) is shown in parenthesis [n=3]. 
Description CC90-3D 4 kPa FB-DPI 4 kPa FB-DPI 2 kPa 
    
ED (%)* 88.6 (1.4) 59.8 (2.9)** 57.5 (4.4) ** 
    
Capsule/Sphere (%)* 3.4 (2.1) 21.1 (4.4) ** 12.4 (3.7) ** 
Device (%)* 8.0 (1.2) 19.1 (1.6) ** 30.2 (1.6) ** 
    
FPF<5µm/ED (%) 94.8 (0.4) 93.8 (1.4) 93.0 (1.6) 
FPF<1µm/ED (%)* 28.8 (1.7) 31.3 (1.6) 20.0 (1.6) ** 
MMAD (µm)* 1.55 (0.04) 1.53 (0.01) 1.81 (0.03) ** 
* p <0.05 significant effect of inhaler on % ED, capsule/sphere retention, device retention, FPF<1µm/ED  and MMAD 
(one-way ANOVA) 
** p<0.05 significant difference compared to CC90-3D (post hoc Tukey) 
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Table 5.5 Comparison of the FB-DPI at adult and pediatric flow rates using 
maximum designed mass in the dosing sphere using the EEG-Cipro formulation 
(Batches 11 and 12).  The standard deviation (SD) is shown in parenthesis [n=3]. 
Description 4 kPa - 100mg 2 kPa - 50mg 
   
ED (%) 71.4 (2.1) 59.8 (1.73)* 
   
Capsule/Sphere (%) 13.3 (3.0) 16.8 (1.8) 
Device (%) 15.3 (1.5) 23.4 (0.7)* 
   
FPF<5µm/ED (%) 93.3 (0.3) 92.3 (0.4) 
FPF<1µm/ED (%) 36.4 (2.9) 21.8 (1.5)* 
MMAD (µm) 1.53 (0.10) 1.80 (0.07)* 
* p <0.05 significant different from 4kPa - 100mg (student t-test) 
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Table 5.6 Performance of the FB-DPI without mixing balls using 25 mg of EEG-Cipro 
(Batches 11 and 12). The standard deviation (SD) is shown in parenthesis [n=3]. 
Description Without mixing balls 
  
ED (%) 73.8 (1.9) 
  
Capsule/Sphere (%) 11.4 (2.1) 
Device (%) 14.7 (0.2) 
  
FPF<5µm/ED (%) 95.1 (2.1) 
FPF<1µm/ED (%) 31.4 (1.3) 
MMAD (µm) 1.53 (0.04) 
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Chapter 6 Develop a low-volume capsule-based 
inline DPI actuated by an external gas source to be 
used with multiple delivery platforms 
6.1 Objective 
 The objective of this study is to design a low-air-volume device to deliver EEG 
aerosols.  The device should have the capability to be mounted to multiple delivery 
platforms such as an NIV face mask and inline with an external respiratory gas source. 
 
6.2 Introduction 
 Inline dry powder inhalers (DPIs) are actuated by a stream of gas that is passed 
through the device from an external positive pressure source (Everard et al. 1996, Tang 
et al. 2011, Behara et al. 2014c, Walenga et al. 2017).  These devices are useful for 
generating and delivering an aerosol to patients that may not be able to use a DPI such 
as children younger than approximately 5 or 6 years old (Rubin 2011, Laube et al. 2012, 
Goralski et al. 2014).  The positive pressure gas source can be used to assist with deep 
inspiration and help maintain a breath hold in individuals with compromised lung 
function.  This deep positive pressure inspiration may enable the aerosol to penetrate 
further into the lungs compared with negative pressure inhalation through a high 
resistance device.  Inline DPIs can be connected directly into both noninvasive and 
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invasive mechanical ventilation systems allowing for the simultaneous delivery of 
respiratory gas support and therapeutic aerosols (Dhand 2005, Tang et al. 2011, Hess 
2015, Longest et al. 2015, Walenga et al. 2017).  Furthermore, inline DPIs are 
frequently used to deliver test aerosols to animals when evaluating the safety and 
efficacy of inhaled medications (Grainger et al. 2004, Duret et al. 2012). 
Based on the ability to deliver a positive pressure breath, inline DPIs have 
previously been proposed as stand-alone devices to deliver respiratory therapies to 
children.  For example, Manion et al. (2012) proposed the PuffhalerTM, which consists of 
a squeeze bulb, burst valve, blister powder storage and reservoir mask.  With spray 
dried formulations, fine particle fractions (FPF) less than 5.8 µm were 40-60% and 
emitted dose (ED; as a percentage of loaded mass) was near 50%, with a majority of 
the aerosol lost in the optimized reservoir bag.  Laube et al. (2012) reported use of the 
SoloventTM inline DPI that consists of an air syringe positive pressure gas source, 
capsule, spacer and mask.  With the SoloventTM connected directly to an infant nose-
throat model and delivering air volumes of 50-200 mL, the percent of loaded drug found 
on the throat filter (which approximates lung delivery) was 0.28 - 3.87%, with the 
majority of drug lost in the spacer reservoir. These findings indicate that a reservoir or 
spacer should be avoided if possible when delivering aerosols to children using inline 
DPIs.  Hence, the aerosol should be generated very quickly during inhalation and 
require a much smaller volume of air for effective aerosolization. 
The PennCenturyTM DP-4 Dry Powder Insufflator is an inline DPI that has been 
used for over a decade to deliver aerosols to test animals and cell cultures.  For the 
widely used mouse and rat PennCenturyTM devices, the loaded dose is in the range of 
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1-5 mg of powder and recommended air volumes are 0.2 and 2 mL, respectively.  
Aerosolization performance depends on a wide range of factors, including the 
formulation, loaded mass, and air volume (Duret et al. 2012, Hoppentocht et al. 2014a).  
For spray dried formulations under optimal conditions, device retention is approximately 
20% and emitted mass median aerodynamic diameters (MMAD) of mannitol powder 
approach values achieved by specialized lab testing equipment such as the Sympatec 
RODOS dispersion unit (Hoppentocht et al. 2014a).  Inclusion of a drug molecule such 
as tobramycin in the spray dried formulation increases the PennCenturyTM MMAD by a 
factor of approximately 2 compared with RODOS dispersion.  Loading of the 
PennCenturyTM device requires a small spatula and can be time consuming, highlighting 
the laboratory testing intent of this design.  Furthermore, variability in performance 
increases as loaded dose increases beyond 1 mg (Hoppentocht et al. 2014a). 
Studies of inline DPIs intended for human use have reported the delivery of 
albuterol sulfate,(Behara et al. 2014c, Longest et al. 2014b) mannitol,(Tang et al. 2011) 
budesonide,(Everard et al. 1996, Pornputtapitak et al. 2014) surfactants,(Pohlmann et 
al. 2013) and various antibiotics (Manion et al. 2012, Longest et al. 2015).  Tang et al. 
(2011) placed the Osmohaler DPI in an airtight container that enabled actuation with a 
manual ventilation bag and was connected to a straight endotracheal tube (ETT).  The 
manual ventilation bag was used to generate peak flow rates in the range of 87 - 133 
L/min (LPM) to aerosolize high dose capsules containing 40 to 80 mg of mannitol 
powder (AridolTM).  Delivery efficiency to the distal end of the ETT was 50 to 60% of the 
loaded dose and the associated MMAD was approximately 7 µm.  Based on this study, 
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it appears that very high flow rates (~100 LPM) and large air volumes (multiple 
squeezes of an adult ventilation bag) are required to aerosolize high doses of powder. 
For high dose surfactant aerosol delivery, Pohlmann et al. (2013) recently 
presented a design that passed pulses of air directly through a powder bed.  Using 
pressure pulses consisting of 10-30 mL of air and a spray dried surfactant formulation, 
high masses of powder could be aerosolized producing aerosols in the range of 3 to 3.5 
µm.  These findings indicate that passing controlled volumes of air directly through a 
powder reservoir can effectively aerosolize a highly dispersible spray dried formulation.  
However, the air delivery system of Pohlmann et al. (2013) appears complex and, as 
stated by the authors, the very high masses of aerosol require humidity to coat the 
particles with water prior to inhalation.  Delivery efficiency to the end of a conducting 
tube and prior to nasal prongs was 55% of the aerosolized dose (Pohlmann et al. 2013). 
Our group has recently developed a new inline DPI consisting of a flow control 
orifice, capsule chamber and three dimensional (3D) rod array (Behara et al. 2014c).  
As described in Longest et al.,(Longest et al. 2013b) the 3D rod array maximizes 
aerosol deaggregation compared with other approaches for a set amount of input power 
by maximizing turbulent energy in the small turbulent eddies.  The inline DPI is powered 
by a manual ventilation bag and the flow rate through the device is controlled by the 
orifice size.  For a spray dried excipient enhanced growth (EEG) formulation (Hindle et 
al. 2012, Son et al. 2013a) of albuterol sulfate, a device with a 2.3 mm flow control 
orifice and 3-4-3 rod array pattern (2.3-343 inline DPI) produced a flow rate of only 10 
LPM with ED (as a percentage of loaded dose) and MMAD values of approximately 
75% and 1.6 µm (Behara et al. 2014c).  Longest et al. (2015) considered a spray dried 
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formulation of ciprofloxacin in the same device and reported an ED from a streamlined 
nasal cannula(Longest et al. 2013a) of approximately 70% with an MMAD of 1.4 µm.  
Based on the EEG approach, the nasal deposition was <2% leading to high efficiency 
nose-to-lung (N2L) aerosol delivery.  In the conference publication of Longest et al. 
(2014b), we reported a device with a 2.0 mm flow control orifice and 2-3-2 rod array 
pattern (2.0-232 inline DPI) that aerosolized albuterol sulfate at a flow rate of only 5 
LPM for use with low flow nasal cannula oxygen. 
Advantages of the previously developed 3D rod array inline DPI include high ED 
and excellent deaggregation (Behara et al. 2014c, Longest et al. 2014b, Longest et al. 
2015).  The capsule-based platform makes the device easy to load.  Due to the use of 
the flow control orifice, the device is not sensitive to bag pressure above a nominal 
amount.  However, as flow rate is reduced to 5 LPM and below, it becomes increasingly 
difficult to achieve an MMAD near 1.5 µm,(Longest et al. 2014b) which is desirable for 
high efficiency nose-to-lung aerosol delivery and use of the EEG approach.  The typical 
air volume for each of these devices was 1 L per actuation.  Furthermore, performance 
is dependent upon capsule piercing pattern, (Behara et al. 2014c) and capsule piercing 
can be difficult inside a positive pressure device.  Finally, higher masses of powder 
become more difficult to aerosolize at lower flow rates. 
There appears to be a need for an inline DPI device that can aerosolize relatively 
large (10 mg and above) masses of spray dried powder formulations using very low 
dispersion air volumes (~10 mL per actuation).  High powder masses are required for 
the aerosol delivery of most antibiotics, surfactants, non-steroidal anti-inflammatories, 
and many biopharmaceuticals.  These high doses are required in adults and children, 
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where, for example, Morley et al. (1981) delivered 25 mg capsules of dry powder 
surfactant to preterm infants with respiratory distress syndrome.  Low dispersion air 
volume through the device enables application in both high flow and low flow settings.  
A 10 mL air volume is viewed as the upper end of ventilation that can be delivered to a 
late preterm infant (Jauernig et al. 2008, Walsh et al. 2010, Sunbul et al. 2014).  
Furthermore, injection of 10 mL of air should not interfere with most noninvasive or 
invasive mechanical ventilation systems.  The inline DPI device should be airtight and 
operate on positive pressure to allow connection to mechanical ventilation systems or 
sealed patient interfaces like streamlined nasal cannula (Longest et al. 2013a, Longest 
et al. 2013c) or a face mask (Walenga et al. 2017).  Importantly, the device should be 
easy to load and minimize usage steps (Smith et al. 2010). 
The objective of this study is to develop and characterize a new inline DPI for 
aerosolizing spray dried formulations with powder masses of 10 mg and higher using an 
air volume of 10 mL per actuation.  The device will be developed based on knowledge 
gained from our previous work with high efficiency DPIs (Behara et al. 2014a, Behara et 
al. 2014c, Behara et al. 2014b, Longest et al. 2015) and rapid screening using 3D 
printing technology.  In vitro aerosol experiments will be used to determine regional 
device retention, ED and to characterize the aerosol.  Initial device performance will be 
based on 10 mg powder loading, and, for a lead design, a significantly higher powder 
mass will be tested.  Aerosol plume size will also be assessed to aid in future 
incorporation of the device into positive pressure systems with low depositional losses.  
High efficiency performance is expected based on our previous DPI experience (Behara 
et al. 2014a, Behara et al. 2014c, Behara et al. 2014b, Longest et al. 2015).  
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Specifically, high efficiency performance for the delivery of EEG formulations will be 
defined by the production of an aerosol with the following characteristics: an MMAD of 
less than 1.5 µm, fine particle fraction (FPF) less than 5 µm as a percentage of ED 
(FPF<5µm/ED) above 90%, FPF<1µm/ED above 30% and an ED greater than 75%.  The 
challenge is, clearly, to now achieve this level of DPI performance with a device that 
requires only 10 mL of dispersion air per actuation and is easy to load and operate. 
 
6.3 Materials and Methods 
Overview 
In contrast with our previous inline DPIs that are intended to operate with relatively 
high dispersion air volumes (Behara et al. 2014c, Longest et al. 2015), the low air 
volume (or LV) devices developed in this study pass all of the available airflow through 
a capsule dose containment unit.  The air source is a simple syringe connected via a 
luer-lock fitting and filled with 10 mL of room air that is operated manually.  Based on 
experiments with a number of preliminary concepts, the two leading LV designs are 
presented as Figure 6.1 and Figure 6.2, respectively. A common feature in both devices 
is that metal capillary tubes pierce the capsule when the device is closed, forming an 
airtight flow path through the device.  In one design, the airflow pathway is in a single 
direction, or straight through (ST) the capsule and device (Figure 6.1).  In the second 
design, the capillary-based inlet and outlet are on a single side (SS) of the capsule, 
resulting in a near 180-degree turn in the airflow path.  In both designs, the outlet 
capillary directs aerosol through a flow channel with a final diameter of 7 mm. These 
two leading designs are optimized and compared in this study based on modifications to 
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the inlet and outlet capillary properties.  To improve dispersion of the 10 mg powder 
mass, we also introduce the concept of a dispersion ball placed inside the capsule.  Use 
of a lightweight polytetrafluoroethylene (PTFE) dispersion ball is expected to create 
vibrational motion as observed in Farkas et al. (2015) to enhance capsule emptying.  As 
a representative EEG formulation, the new inline DPIs are tested with a previously 
described (Son et al. 2013a, Son et al. 2013b) EEG formulation of albuterol sulfate.  
Using this formulation, previous inline DPIs have produced MMAD values as low as 
1.47 µm with an ED value of 78.2% using high dispersion air volumes with 
approximately 1 L of air per actuation. The primary particle size of the EEG formulation 
is tested using a Sympatec (Sympatec GmbH, Clausthal-Zellerfeld, Germany) laser 
diffraction system with a RODOS aerosol dispersion accessory, which uses a pressure 
drop of 4 bar (400 kPa) to disperse a small amount of the powder.  Aerosol 
characterization from the devices is based on drug quantification using high 
performance liquid chromatography (HPLC) analysis of the various DPI components to 
determine the emitted dose and by cascade impaction using the Next Generation 
Impactor (NGI), to determine the fine particle fraction and MMAD.  Further details of the 
devices, formulation and characterization studies are provided in the following sections. 
 
Materials 
 Albuterol Sulfate (AS) USP was purchased from Spectrum Chemicals (Gardena, 
CA) and Pearlitol® PF-Mannitol was donated from Roquette Pharma (Lestrem, France).  
Poloxamer 188 (Leutrol F68) was donated from BASF Corporation (Florham Park, NJ).  
L-leucine and all other reagents were purchased from Sigma Chemical Co. (St. Louis, 
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MO).  Quali-V, Hydroxypropyl methylcellulose (HPMC) capsules (size 0) were donated 
from Qualicaps (Whitsett, NC). 
 Spray dried albuterol sulfate EEG formulations were produced using the 
optimized method described by Son et al. (2013a) Three batches of spray dried 
formulations were employed for these studies. The primary particle size for each of the 
spray drying batches was determined using a laser diffraction method with a Sympatec 
ASPIROS/RODOS dry dispersing unit and HELOS laser diffraction sensor.  
 
Inhaler Design 
 Both inhaler designs (ST and SS) are opened at approximately midway the 
capsule chamber, the capsule is loaded into one of the halves, and the capillaries pierce 
the capsule when the device is re-assembled.  A bayonet fitting and o-rings have been 
employed to ensure an airtight seal in the capsule chamber.  Both inhaler designs 
investigated in this study use a standard luer-lock to a connect the syringe to deliver 
dispersion air through a single 0.6 mm inlet capillary and into a size 0 capsule which 
has a volume of 0.68 mL.  The capillary remains in place during dispersion as the air 
inside of the syringe is forced through the capillary into the powder bed within the 
capsule. The powder is entrained and is carried through the outlet capillary 
configuration.  Designs of the outlet capillaries are shown in cross section (to scale with 
respect to each other) in Figure 6.3.  The Straight-Through (ST) design, shown in Figure 
6.1, is designed with the inlet and outlet capillaries on opposite ends of the capsule, 
both centered on the capsules longitudinal axis.  The Single-Sided (SS) design, shown 
in Figure 6.2, is oriented with both the inlet and outlet capillaries piercing through the 
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head of the capsule.  The capillaries of the SS design are angled at ~8 degrees towards 
the centerline of the longitudinal axis of the capsule, so that the capillary central axes 
intersect halfway between the middle and the bottom of the capsule.  This angle was 
selected to increase turbulent dispersion within the capsule. 
The inhaler designs were created using Autodesk Inventor and exported as .STL 
files to be prototyped. The files were then prepared using Objet Studio preparation 
software and were built using a Stratasys Objet24 3D Printer (Stratasys Ltd., Eden 
Prairie, MN) using VeroWhitePlus material.  Support material was cleaned away from 
the model material using a Stratasys waterjet cleaning station and the devices were 
allowed to fully dry before use.  The capillaries used in the devices were custom cut 
from lengths of stainless steel (SAE 304) capillary tubing and were angled on one side 
to allow for easy piercing of the capsule upon insertion.  The capillaries were then 
secured into place using water resistant epoxy and allowed to cure fully before use.  It is 
noted that the sharpened capillaries are sufficiently recessed inside the capsule 
chamber of the device to facilitate safe assembly. 
 
Evaluation of LV devices 
 Aerosolization performance of the LV-DPIs was characterized using 10 mg of 
EEG-AS powder formulation, which was accurately weighed and manually filled into 
size 0 capsules.  This mass of powder filled approximately 3% of the capsule volume.  
Capsules were then placed in one half of the LV-DPI device and the capsule was 
pierced when the two halves were sealed together. After the devices were assembled, a 
10 mL syringe was filled with room air and then connected via the luer-lock onto the LV-
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DPI inlet.  To maintain a consistent distance from the outlet of the devices to the inlet of 
the NGI for aerosol sizing, a custom adaptor was fabricated which held the LV-DPIs 
approximately 3 cm away from the NGI preseparator inlet. The powders were 
aerosolized with the LV-DPI in a horizontal position as shown in Figure 6.1 and Figure 
6.2 with the gravity vector pointing down the page.  As minimal size change is expected 
in the aerosol under ambient temperature and relative humidity (RH) conditions, 
experiments were conducted with ambient air (T = 22 ± 3 oC and RH = 50 ± 5 %) with 
the NGI at room temperature.  To allow for horizontal positioning of the inhaler, the NGI 
was positioned on its side (oriented vertically) to test both the ST and SS devices. The 
NGI was operated at 45 L/min and the preseparator and individual stages were coated 
with MOLYKOTE® 316 silicone spray (Dow Corning, Midland, MI) to minimize particle 
bounce and re-entrainment.  The flowrate of 45 LPM was chosen to ensure collection of 
the aerosol, which exited the device 3 cm away from the preseparator inlet, and 
maintain reasonable stage cutoff diameters for evaluating a small size aerosol.  To 
actuate the DPI, the plunger of the syringe was depressed quickly (~0.2 seconds to 
empty) to aerosolize the powder into the inlet of the NGI.  The syringe was then 
disconnected from the inhaler, refilled with room air, and reconnected to the device for a 
total of 5 actuations.  Using the optimized device, an additional study was performed 
using 50 mg of powder to evaluate the effect of higher powder mass loadings.  A slower 
syringe emptying test (~0.5 seconds to empty) was also made with a 10 mg loaded 
mass using the optimized device to simulate extreme variability between users.  Syringe 
emptying times were determined using a single operator and high speed photography 
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(1000 frames/sec).  All measurements were made with three replicates for each design 
configuration. 
  
Aerosol performance characterization methods 
After aerosolization, drug masses retained in the capsule, device, and the drug 
collected on the preseparator, impaction plates and the filter of the NGI were recovered 
by washing with appropriate volumes of deionized water and quantified by HPLC 
analysis.  The mass of AS retained in the capsule and device, determined by HPLC, 
was expressed as a percentage of the nominal AS dose. The emitted dose was 
calculated by subtracting the mass of AS retained in the capsule and device from the 
nominal AS dose. 
In order to determine the nominal dose of AS in the EEG-AS formulation, known 
masses of the formulation were dissolved in 100 mL of water and the mean amount of 
AS per mg of formulation was determined using HPLC analysis. For each aerosolization 
experiment, the measured formulation AS content and the mass of formulation loaded 
into the capsule was used to determine the nominal dose of AS.  
The cut-off diameters of each NGI stage at the operating flow rate of 45 LPM 
were calculated using the formula specified in USP 35 (Chapter 601, Apparatus 5) and 
were used to calculate MMAD and fine particle fractions of the delivered aerosol. Fine 
particle fraction of the EEG formulation (FPF<5µm/ED) and sub-micrometer FPF 
(FPF<1µm/ED) were defined as the fraction less than 5 µm and 1 µm, respectively, 
expressed as a percentage of the ED.  MMAD, FPF<5µm/ED and FPF<1µm/ED were 
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calculated by linear interpolation using a plot of cumulative percentage drug mass vs. 
cut-off diameter. 
 
Aerosol Plume Characterization 
 The plume characteristics of aerosols generated by the different studied outlet 
orientations was also investigated.  To measure the plume characteristics, the device 
was loaded and actuated as described above (evaluation of LV devices). The outlet of 
the device was positioned such that the aerosol was emitted against a black 
background labelled with marks in both the vertical and horizontal directions to provide 
a scale.  A camera (Pextax K-30) was positioned to capture images at 30 fps. For 
comparison, a still image recorded when the plunger was fully depressed was used to 
determine the horizontal and vertical spreads of the plume, which were calculated using 
the scale marks.  This information will help with future implementation of the device into 
a continuous flow path for use in an inhaler or for aerosol administration during 
mechanical ventilation. 
 
6.4 Results 
EEG Formulation Dispersion Characterization  
 The dispersion characteristics and primary particle size for each of the batches of 
EEG-AS formulation employed in this study was determined using a Sympatec laser 
diffraction setup. When comparing the novel LV-DPIs over a period of time, it was 
important to determine the batch to batch consistency of the EEG-AS powder 
formulation using a consistent method of dispersion (ASPIROS/RODOS unit).  For 
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comparison to the aerosolization performance determined by the NGI, the geometric 
sizes determined by the laser diffraction method were converted to aerodynamic 
diameters using a theoretical EEG-AS particle density of 1.393 g/cm3 (Longest et al. 
2011a).  Figure 6.4 shows the mean particle size distribution for the three batches of 
EEG-AS formulation used in this study. The mean (SD) MMAD and FPF values were 
calculated from this data and are also shown in Figure 6.4.  The overall mean MMAD 
was 1.29 µm calculated from the laser diffraction sizing with the ASPIROS/RODOS 
dispersion unit.  The coefficient of variation for the MMAD for the three batches was 7% 
indicating the relative reproducibility of the spray drying process to produce a small 
sized powder formulation. The mean FPF<5µm/ED and FPF<1µm/ED across batches were 
found to be 99.3% and 33.8%, respectively with coefficients of variability of 0.8 % and 
7.6 %, respectively. These results represent very high efficiency aerosol dispersion that 
was achieved using a benchtop dispersion unit operating at relatively high pressure.  
Low coefficients of variability provided further confidence that batch-to-batch variability 
is low for the powder formulations employed in this study. 
 
Effect of Outlet on Straight-Through Design 
 The Straight-Through (ST) design is the simplest of the two investigated, with a 
single inlet and outlet centered on the longitudinal axis of the capsule.  A single 0.6 mm 
inlet capillary was used for each design in order to create a high velocity jet to aid in 
powder dispersion.  The performance results of the ST design are provided in Table 1.  
The first outlet tested, shown in Figure 6.3a, used a 0.6 mm capillary identical to the 
inlet capillary.  This outlet produced a small aerosol, with a mean MMAD (n=3) of 1.57 
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µm, but almost half (49.6%) of the powder stayed inside the capsule, with only 44.8% of 
the total loaded powder mass emitted from the device. Increasing the outlet capillary 
size was expected to increase the ED while reducing the amount of deaggregation that 
was achieved.  However, when the diameter was increased to 1.17 mm (shown in 
Figure 6.3b), the MMAD was not significantly different (1.64 µm) while the ED 
significantly increased to 57.3% (Table 6.1) compared to the 0.6 mm outlet.  Four 0.6 
mm outlet capillaries (Figure 6.3c) were then placed in a circular pattern around the 
longitudinal axis of the capsule, as close together as possible.  The four-fold increase in 
cross-sectional area versus the single 0.6 mm outlet was expected to increase the ED 
while the small diameter of each individual capillary would improve deaggregation.  The 
mean FPF<5µm/ED and FPF<1µm/ED values of 96.4% and 24.2%, respectively, as well as a 
MMAD of 1.57 µm mirrored that of the single 0.6 mm outlet (Table 6.1) and were not 
significantly different. The ED was significantly increased to 55.9% with four outlets from 
44.8% with one 0.6 mm outlet, but the capsule retention was still very high.  The 
addition of a small PTFE ball, 2.4 mm in diameter, inside the capsule was incorporated 
to help decrease the capsule powder retention by increasing vibration to prevent 
powder sticking to the walls.  The ball addition resulted in a 6% absolute increase in ED 
without changing the emitted aerosol particle size (Table 6.1) compared to four outlets 
and no ball.  A statistical comparison (post-hoc Tukey) of the 4x0.6 mm outlet case with 
and without the ball indicated no change (p≥0.05).  The ST design with 4×0.6 mm outlet 
and ball performed the best in terms of emitted dose while maintaining good powder 
dispersion. However, the capsule drug retention (28.9%) was still high and the ED was 
lower (61.9%) than the performance requirement of 75% that was initially set. 
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Effect of Outlet on Single-Sided Design 
 To help with increasing the ED, a more complex design was tested with the inlet 
and outlet on the same end of the capsule.  This Single-Sided (SS) device, with 
performance results shown in Table 2, was designed to use the same 0.6 mm inlet as 
the ST design, as well as the same outlet configurations.  Only the orientation of the 
capillaries piercing the capsule was changed to assist in ED, and to potentially prevent 
a negative effect on the emitted aerosol particle size.  Using the single 0.6 mm outlet in 
the SS design, the ED increased by more than 30% (absolute difference; compared to 
ST), resulting in 77.7% of the dose being emitted after five actuations. However, the 
mean MMAD increased to 2.19 µm with the SS design from 1.57 µm with the ST 
design.  Capsule retention was 17.8% with the SS 0.6 mm outlet, which still appeared 
relatively high.  Increasing the outlet capillary diameter to 1.17 mm for the SS device 
successfully decreased the capsule retention to 5.8% (Table 6.2).  However, the FPF 
values decreased significantly compared to the 0.6 mm outlet, corresponding with an 
increased MMAD value of 3.12 µm.  The 4x0.6 mm outlet with and with the PTFE ball 
were also tested with this configuration in an attempt to lower the particle size without 
compromising ED.  Using these outlet configurations did not significantly alter the ED or 
MMAD compared to the 0.6 mm outlet. Also, with the SS configuration, addition of the 
ball did not have a significant effect on the ED or the MMAD when comparing the results 
of the 4x0.6 mm outlet with and without the ball.  To find a compromise between the ED 
produced by the 1.17 mm outlet and the dispersion produced by the 0.6 mm outlet, an 
outlet diameter of 0.89 mm was selected.  The 0.89 mm diameter outlet capillary was 
able to emit 84.8% of the loaded powder, which was not significantly different than the 
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ED from the 1.17 mm outlet. Powder dispersion was also comparable to the 0.6 mm 
outlet with an MMAD of 2.13 µm.  An FPF<5µm/ED of 89.3% and an FPF<1µm/ED value of 
14.7% was observed with the 0.89 mm outlet. 
Comparison of ST and SS Devices 
 The best performing ST and SS devices were then analyzed in a side-by-side 
comparison, shown in Table 6.3.  The ST device was able to produce an aerosol with a 
significantly smaller MMAD (1.56 µm vs. 2.13 µm) and with a significantly higher 
FPF<1µm/ED value (25.1% vs. 14.7%), compared to the SS device.  However, capsule 
retention was 20% lower (absolute difference) with the SS device, resulting in a 
significantly larger ED (84.8% vs. 61.9%).  Although not all of the desired performance 
metrics were achieved with the SS-0.89 mm device, it was chosen as a best case in this 
study for further investigation. 
 
Comparison of SS-0.89mm Device Using Varying Actuation Conditions 
 Using the SS-0.89mm device as the leading design for this study, further testing 
was conducted in terms of increased powder mass and increased actuation time.  A 
high dose test of 50 mg of the same EEG-AS powder formulation was conducted, as 
well as a test using the original 10 mg loaded dose, but with a slower depression of the 
syringe lasting approximately 0.5 seconds (versus ~0.2 sec originally).  The results of 
these tests are presented in Table 6.4 and Table 6.5 alongside the original data from 
the optimized device.  With the larger loaded mass, ED increased approximately 8%, 
but this also resulted in a 0.9 µm increase in MMAD (Table 6.4).  This increase in 
MMAD also corresponded in a decrease in FPF values.  Slower actuation of the device 
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resulted in a 10% absolute increase in ED and a 0.6 µm increase in MMAD (Table 6.5).  
Fine particle fraction (FPF<5µm/ED) decreased as expected with a larger aerosol, but 
FPF<1µm/ED did not change from the original value. 
 
Effect of Outlet on Plume Size 
 Using the SS device, each outlet configuration was tested delivering the aerosol 
into an open environment.  Powder was aerosolized with the outlet facing vertically 
upward and captured on video, with the frames at the point in time that the syringe 
plunger was fully depressed used to measure the plume characteristics (Figure 6.5).  A 
vertical orientation was implemented such that maximum entrainment of the plume 
acting against gravity could be determined in future analysis.  Particle size experiments 
with the device oriented vertically and with the impactor suspended upside down 
indicated a negligible change in aerosol size compared with a horizontal device 
orientation.  From the images in Figure 6.5, the measurements of the plume dimensions 
were taken and simplified to show height, width and angle, and these simplified 
diagrams are shown in Figure 6.6.  The 0.6 mm outlet produced the largest plume, in 
terms of both height and width, while the 4x0.6 mm outlet produced the smallest.  Since 
the cross sectional area of the 4x0.6 mm outlet is four times larger, the velocity of the 
particles leaving the device should be four times less, carrying them away from the 
outlet slower as was observed.  However, the velocity of the 1.17 mm outlet should be 
slower than the 0.89 mm outlet, but the results of the test show that the plume is closer 
to the device for the smaller of the two outlets at the moment the syringe is empty.  This 
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may be due to inaccuracy of this visual measurement method, or complexity of a 
transient multiphase turbulent jet entering a quiescent environment. 
  
6.5 Discussion 
The outcome of this study is the development of an easy to use DPI powered by 
only a small volume of air.  This device has the potential to be implemented into several 
types of delivery systems because of its use of a positive pressure air source to create 
an aerosol of very high quality.  The optimum device that emerged from this study was a 
capsule-based LV-DPI with a single inlet, designed to be connected to a standard luer-
lock syringe, and an aerosol single outlet that was 7 mm in diameter at the distal end 
(Figure 6.2), to decrease loss of the exiting particles.  An inlet capillary 0.6 mm in 
diameter and an outlet capillary 0.89 mm, located on the same end of the capsule, were 
used to pierce the capsule while remaining in place to administer the five actuations of 
10 mL air volume through the capsule containing the powder to be aerosolized. 
Even with the combination of the best performing inhaler design and the EEG-AS 
powder formulation, the optimized device was not able to meet all of the desired 
performance metrics with the five actuations of 10 mL air volume in this study.  
However, the SS device was able to emit almost all of the loaded dose with close to 
90% being smaller than a 5 µm aerodynamic diameter.  Best case performance with a 
10 mg loaded dose of powder, included an ED of 84.8%, MMAD of 2.13 µm, FPF<5µm/ED 
of 89.3%, and FPF<1µm/ED of 14.7%.  In comparison, the targeted ideal design 
characteristics were an ED of greater than 75%, MMAD of 1.5 µm, FPF<5µm/ED of greater 
than 90%, and FPF<1µm/ED greater than 30%. 
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An inline device developed by Pohlmann et al. (2013) was able to emit 55% of 
the loaded powder mass to produce an aerosol with an MMAD of 3.16 µm using 14 mL 
compressed air volume.  However, FPFs were much lower than those that are required 
for the EEG aerosol applications (less than 10% FPF<1µm/ED).  The ability of the 
Pohlmann et al. (2013) device to store and deliver a larger powder mass (up to 3 
grams) could partially offset the larger depositional losses generated by the larger 
particle size, but this would mean more wasted medication.  By comparison, the 
Puffhaler was able to emit 60% of the loaded dose using a manually operated squeeze 
bulb, but was only able to achieve a maximum of 21% of the particles under 3.3 µm 
(Manion et al. 2012).  The FPF<3.3µm/ED for the SS-0.89 mm device in this study was 
calculated to be 79%.  The PennCentury insufflator (DP-4M) was designed to deliver 
small amounts of drug using less than 2 mL of air for dispersion.  While device drug 
retention and particle size varied greatly depending on powder formulation, the device 
was shown to have the ability to emit ~90% of loaded powder masses in the range of 1-
3 mg (Hoppentocht et al. 2014a).  The DP-4M was able to disperse some powder 
formulations to a size resembling that of the RODOS dispersed aerosol.  However, with 
the addition of drug to the formulation, effectiveness of the device to disperse the 
aerosol was decreased.  The best reported performance of the DP-4 device from 
Hoppentocht et al.,(2014b) with a powder formulation containing drug was obtained 
using a spray-dried formulation of colistimethate sodium.  With an air volume of 1 mL 
from the pressurized air pump and a powder mass of 3 mg, this device/formulation 
combination produced an ED close to 90% and a median particle size of approximately 
4 µm. 
121 
 
The recently developed 3-4-3 3D rod array device proposed by our group was 
able to produce a high quality aerosol with a loaded dose of 2 mg and an air volume of 
1 L per actuation (Behara et al. 2014c).  An ED of 75%, coupled with an MMAD of 1.6 
µm, produced by the 3D rod array device indicate very good performance, but 
FPF<5µm/ED and FPF<1µm/ED values of 65% and 21%, respectively, were lower than 
targeted (Behara et al. 2014c).  In comparison, the SS-0.89 mm device was able to emit 
10% more of the loaded dose with a higher percentage of the dose smaller than 5 µm.  
It is noted that the SS-0.89 mm device aerosolized 5 times the amount of powder using 
1% of the air volume of the 3-4-3 3D rod array device per actuation (5% of the total 
dispersion air volume). 
A potential concern with the device is exposure of the EEG hygroscopic powder 
to humidity and connection of the device to humidified ventilation systems.  As 
implemented in this study, the device and EEG powder performed well when operated 
with room condition air (T = 22 ± 3 oC; RH = 50 ± 5 %) as intended.  Performance of the 
device with excess humidity air in the syringe (e.g. RH > 70%) was not considered.  It is 
noted that the device is intended to be used in pressurized and humidified systems, 
when needed.  The 10 mL syringe containing room air provides the device air source 
and prevents backflow of humidified air through the device.  Future designs of the 
device will prevent the need to remove the syringe with each air refilling.  As a result, 
the device can be connected to a positive pressure humidified system without water 
vapor entering the capsule and degrading the powder quality.  A similar positive 
pressure device operated with a manual ventilation bag (containing room air) was used 
in the study of Walenga et al. (2017)  by our group in which a 3D rod array inline DPI 
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was connected to a noninvasive positive pressure ventilation mask that was supplied 
with humidified airflow.  The device performed well even in the presence of the 
humidified ventilation flow.  Furthermore, the aerosol was delivered into the airways at 
an adequate velocity that prevented significant size growth prior to entry into the lungs 
(Walenga et al. 2017). 
A potential shortcoming of the newly developed LV-DPIs is the ability to control 
the plume size exiting the device for use in future delivery systems.  If the momentum of 
the particles generated by the device is too high, depositional losses will increase 
significantly before the aerosol can be carried to the patient.  Slowing of the air flow 
through the syringe was shown to have a negative effect on the overall size of the 
aerosol (MMAD increase of 0.6 µm; Table 6.5), but also showed an increase in ED with 
a similar fraction of submicrometer particles.  Another potential limitation of this active 
style DPI is the requirement to coordinate actuation with inhalation.  However, this 
coordination can be signaled or automated and will depend on the application in which 
the device is used.  Future improvements in filling of the air syringe to increase ease of 
use are planned. 
Syringe emptying times may be partially dependent on the operator of the device.  
To maintain a simple low-cost device, the air syringes were emptied by hand in all 
cases.  The fast emptying time of 0.2 s was easy to achieve by the operator depressing 
the air syringe as quickly as possible.  In contrast, the operator had to practice with the 
device to reliably produce the slower 0.5 s emptying time.  However, difficulty with 
producing an emptying time of 0.5 s is not a concern given that the fast emptying time of 
0.2 s performed better.  A flow control orifice as in the study of Behara et al. (2014c) can 
123 
 
be used on future designs if it becomes necessary to limit variability in syringe emptying 
time among operators. 
Additional limitations present in this study will be further explored in the future. 
Delivery to a realistic lung model was not investigated, but will be considered after 
developing a delivery system and interface to administer the aerosol to a patient.  
Further optimization of the device will also be considered when implementing the 
delivery system, but it is expected that only small changes are needed, if any, to 
improve aerosol penetration through the delivery system.  Only a single drug 
formulation was tested in this study, EEG-AS, but other EEG formulations, such as 
Ciprofloxacin have been used in previous DPI development studies with similar 
performance to AS (Farkas et al. 2015). 
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6.6 Abbreviations 
3D Two dimensional 
AS Albuterol sulfate 
DPI Dry powder inhaler 
ED Emitted dose 
EEG Excipient enhanced growth 
ETT Endotracheal tube 
FPF Fine particle fraction 
HPLC High performance liquid chromatography 
HPMC Hydroxypropyl methylcellulose 
LPM Liters per minute 
LV Low volume 
MMAD Mass median aerodynamic diameters 
N2L Nose-to-lung 
NGI Next Generation Impactor 
PTFE Polytetrafluoroethylene 
SS Single-sided 
ST Straight-through   
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Figure 6.1 Axial cross section of the assembled Straight-Through (ST) device 
showing the inlet and outlet capillaries inside of the capsule. 
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Figure 6.2 Axial cross section of the assembled Single-Sided (SS) device showing 
the inlet and outlet capillaries inside of the capsule. 
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Figure 6.3 Cross-sectional view of the outlet capillaries with the following internal 
diameters: a) 0.6 mm, b) 1.17 mm, c) 4x0.6 mm, and d) 0.89 mm. 
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Figure 6.4 Average cumulative particle size distribution of the three powder batches 
as a function of aerodynamic diameter (converted based on a formulation density of 
1.393 g/cm3).  Average MMAD and fine particle fractions (bottom right) are shown with 
standard deviations (SD) given in parentheses. 
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Figure 6.5 Still images taken at the moment of complete syringe actuation showing 
plume of aerosol particles leaving the SS device for each outlet case: a) 0.6 mm, b) 
0.89 mm, c) 1.17 mm, and d) 4x0.6 mm. 
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Figure 6.6 Simplified images showing height, width, and approximate angle of 
particle plume after device actuation based on visual inspection of pictures: a) 0.6 mm, 
b) 0.89 mm, c) 1.17 mm, and d) 4x0.6 mm.  
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Table 6.1 Optimization of Straight-Through (ST) LV DPI device outlet internal 
diameter.  Mean aerosol characteristics with standard deviations (SD) shown in 
parenthesis [n=3]. 
Description 0.6mm 1.17mm 4x0.6mm 
4x0.6mm 
w/ ball 
     
ED (%)* 44.8 (4.8) 57.3 (4.9)** 55.9 (4.2)** 61.9 (2.0)** 
     
Capsule (%)* 49.6 (4.9) 35.0 (6.0)** 35.6 (2.6)** 28.9 (2.2)** 
Device (%) 5.6 (0.3) 7.7 (1.6) 8.5 (1.6) 9.2 (1.5) 
     
FPF<5µm/ED (%) 95.7 (1.2) 93.7 (1.3) 96.4 (0.3) 95.2 (1.4) 
FPF<1µm/ED (%) 22.4 (0.9) 23.8 (6.0) 24.2 (0.7) 25.1 (2.8) 
MMAD (µm) 1.57 (0.04) 1.64 (0.09) 1.57 (0.01) 1.56 (0.03) 
*p<0.05 significant effect of device outlet diameter on % ED and % capsule drug 
retention (one-way ANOVA).  
 
**p<0.05 significant difference compared to 0.6mm outlet (post-hoc Tukey). 
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Table 6.2 Optimization of Single-Sided (SS) LV DPI device outlet internal diameter.  
Mean aerosol characteristics with standard deviations (SD) shown in parenthesis [n=3]. 
Description 0.6mm 0.89mm 1.17mm 4x0.6mm 
4x0.6mm 
w/ ball 
      
ED (%) 77.7 (6.3) 84.8 (3.0) 87.9 (2.4) 82.0 (7.3) 80.3 (4.4) 
      
Capsule (%)* 17.8 (5.7) 8.8 (2.0)** 5.8 (1.1)** 9.5 (5.5) 10.6 (3.1) 
Device (%)* 4.5 (1.4)  6.4 (1.7) 6.3 (1.3) 8.5 (2.0) 9.1 (1.5)** 
      
FPF<5µm/ED (%)* 83.2 (3.8) 89.3 (0.5) 61.6 (8.9)** 67.2 (4.5)** 68.5 (2.3)** 
FPF<1µm/ED (%)* 14.1 (1.1) 14.7 (1.1) 9.6 (1.4)** 11.8 (1.1) 12.4 (0.9) 
MMAD (µm)* 2.19 (0.18) 2.13 (0.07) 3.12 (0.40)** 2.80 (0.23) 2.72 (0.11) 
*p<0.05 significant effect of device outlet on % capsule and device drug retention, 
FPF<5µm/ED, FPF<1µm/ED and MMAD (one-way ANOVA).  
 
**p<0.05 significant difference compared to 0.6mm outlet (post-hoc Tukey). 
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Table 6.3 Comparison of ST and SS optimized devices.  Mean aerosol 
characteristics with standard deviations (SD) shown in parenthesis [n=3]. 
Description ST-4x0.6mm w/ ball SS-0.89mm 
   
ED (%) 61.9 (2.0) 84.8 (3.0)* 
   
Capsule (%) 28.9 (2.2) 8.8 (2.0)* 
Device (%) 9.2 (1.5) 6.4 (1.7) 
   
FPF<5µm/ED (%) 95.2 (1.4) 89.3 (0.5)* 
FPF<1µm/ED (%) 25.1 (2.8) 14.7 (1.1)* 
MMAD (µm) 1.56 (0.03) 2.13 (0.07)* 
*p <0.05 significant difference between ST-4x0.6mm w/ ball and SS-0.89mm (student 
t-test) 
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Table 6.4 Comparison of optimized SS device using the original 10 mg dose and a 
higher dose of 50 mg.  Mean aerosol characteristics with standard deviations (SD) 
shown in parenthesis [n=3]. 
Description 10 mg 50 mg 
   
ED (%) 84.8 (3.0) 92.5 (2.7)* 
   
Capsule (%) 8.8 (2.0) 4.6 (2.0)* 
Device (%) 6.4 (1.7) 2.9 (0.7)* 
   
FPF<5µm/ED (%) 89.3 (0.5) 74.2 (6.2)* 
FPF<1µm/ED (%) 14.7 (1.1) 9.2 (0.8)* 
MMAD (µm) 2.13 (0.07) 3.01 (0.21)* 
*p <0.05 significant difference between 10 mg and 50 mg (student t-test) 
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Table 6.5 Comparison of optimized SS device using the original 0.2 s actuation and 
with a slower device actuation (0.5 sec).  Mean aerosol characteristics with standard 
deviations (SD) shown in parenthesis [n=3]. 
Description 10 mg-0.2 sec 10 mg-0.5 sec 
   
ED (%) 84.8 (3.0) 95.6 (2.0)* 
   
Capsule (%) 8.8 (2.0) 3.0 (1.4)* 
Device (%) 6.4 (1.7) 1.3 (0.6)* 
   
FPF<5µm/ED (%) 89.3 (0.5) 73.0 (1.7)* 
FPF<1µm/ED (%) 14.7 (1.1) 13.4 (1.0) 
MMAD (µm) 2.13 (0.07) 2.71 (0.04)* 
*p <0.05 significant difference between 10 mg-0.2 sec and 10 mg-0.5 sec (student t-
test) 
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Chapter 7 Application of an Inline Dry Powder 
Inhaler to Deliver High Dose Pharmaceutical Aerosols 
during Low Flow Nasal Cannula Therapy 
7.1 Objective 
The objective of this study is to further develop an inline DPI, based on previous 
work, that requires low air volume (LV-DPI) to efficiently deliver pharmaceutical aerosols 
to adults during LFNC therapy. 
 
7.2 Introduction 
Inline dry powder inhalers (DPIs) create a pharmaceutical aerosol using a gas 
stream supplied from a positive pressure source, such as an air syringe or manual 
ventilation bag (Everard et al. 1996, Laube et al. 2012, Behara et al. 2014c, 
Pornputtapitak et al. 2014, Longest et al. 2015).  Advantages of these devices 
compared with conventional inhalation driven DPIs include high quality aerosol 
generation (Behara et al. 2014c), use in subjects that cannot generate sufficient 
inspiratory flow (Laube et al. 2012), reproducible aerosol delivery (Longest et al. 2015), 
and assistance with deep inspiration and breath hold (Tang et al. 2011).  As aerosol 
generation is not dependent on patient inspiratory effort and following inspiration 
instructions, inline devices may be useful for administering aerosols to infants and 
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young children (Laube et al. 2012, Pohlmann et al. 2013). Based on operation with a 
positive pressure gas source, these devices can also be used to administer aerosols 
during invasive and noninvasive ventilation (Everard et al. 1996, Tang et al. 2011, 
Longest et al. 2015). 
A vast majority of studies considering aerosol delivery during mechanical 
ventilation have implemented nebulizers and metered dose inhalers (Miller et al. 2003, 
Dhand 2008, Ari et al. 2012, Dhand 2012, Hess 2015).  In contrast, few studies have 
considered DPI delivery during mechanical ventilation (Everard et al. 1996, Tang et al. 
2011, Walenga et al. 2017).  This limited use may be because of the perception that 
humidity in the ventilation system will degrade the powder quality and aerosolization 
performance (Dhand 2005).  However, successful inline DPI devices for use with 
humidified systems have separated the humidified ventilation and DPI actuation gas 
streams (Walenga et al. 2017).  This approach enables the implementation of DPIs in 
mechanical ventilation systems, with the associated advantages of rapid dose delivery, 
capability to administer high dose inhaled medications, reduced expense compared with 
many nebulizer systems, and stable well established drug formulations. 
Everard et al. (Everard et al. 1996) published one of the first successful studies of 
a DPI used in a mechanical ventilation system.  In this study the budesonide Turbohaler 
was placed in an airtight container with an air inlet from a mechanical ventilation bag 
and an aerosol outlet leading to a 9 mm endotracheal tube (ETT).  Under adult 
ventilation conditions, 20% of the initial drug mass was delivered to the end of the ETT.  
Pornputtapitak et al. (2014) aerosolized nanoclusters of budesonide nanoparticles using 
a positive pressure inline device positioned between a mechanical ventilator Y-
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connector and ETT.  The emitted dose fraction for one way flow was 65%, but was 
decreased as relative humidity (RH) increased to a clinically used value.  Tang et al. 
(Tang et al. 2011) used a containment chamber and the Osmohaler actuated with a 
mechanical ventilation bag to aerosolize mannitol powder.  Delivery efficiencies to the 
end of adult tracheal tubes were approximately 50-60% of the loaded dose.  Feng et al. 
(Feng et al. 2017) adapted this system for operation with airflow from a mechanical 
ventilator by bypassing the humidifier with a three-way valve resulting in a delivery 
efficiency of approximately 25% of the loaded powder mass to the end of an ETT.  Our 
group has proposed an inline DPI actuated with a manual ventilation bag that employs 
excipient enhanced growth (EEG) spray dried aerosol formulations (Son et al. 2013a, 
Son et al. 2013b) and a 3D rod array structure (Longest et al. 2013b) to maximize 
aerosol dispersion (Behara et al. 2014c, Longest et al. 2014b, Longest et al. 2015).  
Behara et al. (Behara et al. 2014c) demonstrated that this device produced a high 
quality aerosol with best case mass median aerodynamic diameter (MMAD) less than 
1.5 µm and device emitted doses (ED) greater than 70%.  In vitro estimated lung 
delivery efficiency as a fraction of capsule loaded dose was >60% for a nasal cannula 
interface (Longest et al. 2015) and 80-90% for use with a noninvasive positive pressure 
ventilation mask (Walenga et al. 2017). 
Low flow oxygen nasal cannula therapy, or LFNC therapy, delivers blended oxygen 
to the nasal cavity at gas flow rates up to ~8 LPM in adults and ~1 LPM in children to 
treat hypoxemia (Ward 2013).  With LFNC therapy, the ventilation gas is typically not 
heated or humidified to maintain system simplicity and the flow rate remains low to 
avoid nasal discomfort associated with cold temperature and drying.  To remain 
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unobtrusive, small diameter tubing and small nasal cannula bore sizes are used, 
typically with internal diameters (IDs) in the range of 2-4 mm.  Patients receiving LFNC 
therapy and other forms of noninvasive ventilation often require pharmaceutical 
aerosols for the treatment of underlying lung conditions.  Simultaneous administration of 
a pharmaceutical aerosol through noninvasive ventilation systems and into the lungs 
(nose-to-lung or N2L delivery) is viewed as convenient and prevents the removal of 
ventilator support during aerosol delivery (Hess 2007, Bhashyam et al. 2008, Dhand 
2012).  However, aerosol delivery efficiency through small diameter tubing and cannula 
systems is known to be very low, with typical values in the range of 0.6 – 2.5% even at 
flow rates of 2 – 5 L/min (LPM) (Perry et al. 2013, Sunbul et al. 2014). 
Based on previous studies, a number of factors are expected to significantly 
improve aerosol delivery efficiency during LFNC therapy and noninvasive ventilation in 
general.  Small particle pharmaceutical aerosols have been shown to effectively 
penetrate nasal cannula systems and enable efficient N2L delivery (Golshahi et al. 
2013, Longest et al. 2013c, Golshahi et al. 2014a, Golshahi et al. 2014b, Zeman et al. 
2017).  It was previously demonstrated that “streamlined” ventilation components can 
significantly improve the penetration of pharmaceutical aerosols, especially in nasal 
cannula systems for N2L delivery (Longest et al. 2013a, Longest et al. 2013c, Longest 
et al. 2014b).  For an inline DPI, a small amount of air volume should be used to 
generate the aerosol as higher air flows will create impaction in the small diameter 
tubing and potentially exceed the subject’s inhalation flow rate.  Finally, the aerosol 
should be created in short bursts to enable synchronization with inhalation and 
maximize the probability of the aerosol entering the lungs.  Previously proposed inline 
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DPI and nasal cannula systems can satisfy some of these requirements (Behara et al. 
2014c).  However, the relatively large gas volumes (~1 L) that are used with these 
devices may prevent their effective use in the LFNC system without significant efforts to 
limit and synchronize aerosol formation time with inspiration. 
As an alternative to inline DPIs operated with large gas volumes, our group has 
recently proposed a low volume (LV) DPI design that operates on approximately 10 ml 
of room air per actuation.  In this design, hollow capillary tubes are used to pierce the 
capsule containing the powder and form a continuous flow passage through the device.  
As a result, the entire 10 ml of actuation air passes through the device and capsule to 
form the aerosol.  Air jets formed by the capillaries inside the capsule create significant 
turbulence and deaggregate the powder.  A simple syringe with a luer-lock connector 
filled with room air was used to provide the 10 ml actuations and was compressed in 
approximately 0.2 s resulting in a short burst of 3 LPM flow.  A straight-through design, 
with inlet and outlet capillaries on opposite ends of the capsule together with an EEG 
powder formulation produced a device emitted dose of 62%, mass median aerodynamic 
diameter (MMAD) of 1.6 µm and a fine particle fraction (FPF) less than 5 µm of 95.2%.  
Based on device attributes, the LV-DPI is expected to perform well in delivering aerosol 
during LFNC.  Specifically, the small aerosol size should effectively penetrate the small 
diameter nasal cannula.  The device flow rate of 3 LPM is not expected to interfere with 
gas delivery or cause excessive deposition in the LFNC system.  Finally, the very rapid 
aerosol generation should enable effective synchronization with inspiratory flow. 
The objective of this study is to develop an inline DPI that requires low air volume 
(LV-DPI) to efficiently deliver pharmaceutical aerosols to adults during LFNC therapy.  
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Devices will be produced with 3D printing and evaluated in terms of regional deposition, 
emitted drug fraction and aerosolization using a loaded powder mass of 10 mg.  As in 
previous studies, high efficiency performance for the delivery of EEG formulations will 
be defined by the production of an aerosol with the following characteristics: an MMAD 
of less than 1.5 µm, fine particle fraction (FPF) less than 5 µm as a percentage of ED 
(FPF<5µm/ED) above 90%, FPF<1µm/ED above 30% and a device ED greater than 75%.  To 
achieve this performance, the previous LV-DPI straight-through design will first be 
improved to increase device emitted dose while maintaining small aerosol size.  A 
spacer design is then developed to integrate the aerosol plume into the LFNC system 
with minimal aerosol loss.  Finally, aerosol transmission through a complete LFNC 
system is considered with realistic tubing curvatures.  Considering the extremely small 
tubing and cannula diameters of the LFNC system, effective delivery through the 
cannula interface is extremely challenging.  However, it is expected that small particle 
EEG aerosols and streamlined ventilation components will significantly improve aerosol 
transmission.  Considering that transmission efficiency through similar small diameter 
nasal cannula systems under LFNC conditions is on the order of 1% and below, 
achieving a 60% cannula ED of the initially loaded drug powder will be a significant 
advancement. 
 
7.3 Materials and Methods 
Overview 
 The low air volume devices developed in this study are based on our previous 
work developing a LV-DPI, which was evaluated based on the aerosol characteristics at 
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the device exit.  The next logical step is to integrate the LV-DPI into a system to deliver 
the aerosol to a human subject.  LFNC therapy was selected as a challenging system 
for the simultaneous delivery of high dose inhaled medications.  From our previous 
study (Farkas et al. 2017),the straight-through (ST) devices are able to produce a high 
quality aerosol, so this design is chosen as the starting point for continued development.  
Considering that the previous emitted dose from the device was 62%, further 
improvements are sought in this study to increase the total system emitted dose.  The 
air source for the LV-DPI is a manually operated 10 mL syringe that is threaded onto the 
device using an airtight luer-lock connection.  A 3-way stopcock is attached between the 
syringe and device to prevent airflow through the device in the wrong direction while 
connected to the positive pressure system when the air syringe is refilled.  Based on the 
previous study (Farkas et al. 2017), the optimal outlet capillary diameter is chosen to be 
0.89 mm for all cases as both the aerosol characteristics and the plume characteristics 
are expected to be favorable for introduction into the LFNC system.  As a representative 
EEG formulation, the new inline DPIs are tested with a previously described EEG 
formulation of albuterol sulfate (Son et al. 2013a, Son et al. 2013b).  The primary 
particle size of the EEG formulation was tested using a Sympatec (Sympatec GmbH, 
Clausthal-Zellerfeld, Germany) laser diffraction system with a RODOS aerosol 
dispersion accessory, which uses a pressure drop of 4 bar (400 kPa) to disperse a 
small amount of powder.  Aerosol characterization from the LV-DPI systems are based 
on drug quantification using high performance liquid chromatography (HPLC) analysis 
of the various components (LV-DPI, spacer and cannula interface) to determine the 
emitted dose and by cascade impaction using the Next Generation Impactor (NGI), to 
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determine the fine particle fraction and MMAD.  Further details of the devices, 
formulation and characterization studies are provided in the following sections. 
Materials 
 Albuterol Sulfate (AS) USP was purchased from Spectrum Chemicals (Gardena, 
CA) and Pearlitol® PF-Mannitol was donated from Roquette Pharma (Lestrem, France).  
Poloxamer 188 (Leutrol F68) was donated from BASF Corporation (Florham Park, NJ).  
L-leucine and all other reagents were purchased from Sigma Chemical Co. (St. Louis, 
MO).  Quali-V, Hydroxypropyl methylcellulose (HPMC) capsules (size 0) were donated 
from Qualicaps (Whitsett, NC). 
 A single batch of spray dried albuterol sulfate EEG formulation was produced 
using the optimized method described by Son et al. (2013a).  The primary particle size 
for the spray dried batch was determined using a laser diffraction method with a 
Sympatec ASPIROS/RODOS dry dispersing unit and HELOS laser diffraction sensor.  
 
Inhaler Design 
The straight-through device containing a 0.6 mm capillary inlet (0.6mm_v1) is 
shown in Figure 7.1a while the device containing three 0.6 mm capillaries 
(3x0.6mm_v1) is shown in Figure 7.1b.  The 3x0.6mm inlet was designed to have three 
jets of air come in contact with the powder, effectively pushing a wall of air to reduce the 
chance of powder getting stuck behind the inlet capillaries where the air flow is reduced 
significantly.  Images comparing the 0.6 mm and 3x0.6 mm inlet cross sections are 
shown in Figure 7.1e and Figure 7.1f, respectively.  The capillaries were originally 
inserted approximately 6 mm into the capsule.  After observations of where the losses 
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were occurring in the devices, it was determined that a significant amount of the powder 
was depositing behind the inlet capillary openings, keeping the airflow from carrying it to 
the outlet.  It was thought that decreasing the insertion distance of the capillaries as far 
as possible would be beneficial, so the distance was decreased step by step until it no 
longer created a reliable piercing of the capsule. The retraction distance was 
determined to be 4 mm, leaving 2 mm inserted into the capsule.  These devices, 
denoted 0.6mm_v2 and 3x0.6mm_v2, are shown in Figure 7.1c and Figure 7.1d, 
respectively. 
The inhaler designs were created using Autodesk Inventor and exported as .STL 
files to be prototyped. The files were then prepared using Objet Studio preparation 
software and were built using a Stratasys Objet24 3D Printer (Stratasys Ltd., Eden 
Prairie, MN) using VeroWhitePlus material at a 32 µm resolution.  Support material was 
cleaned away from the model material using a Stratasys waterjet cleaning station and 
the devices were allowed to fully dry before use.  The capillaries used in the devices 
were custom cut from lengths of stainless steel (SAE 304) capillary tubing and were 
angled on one side to allow for easy piercing of the capsule upon insertion.  When the 
capillary pierces the capsule using the single side sharpening, a small flap of the 
capsule material is left hanging inside of the capsule.  With the retracted outlet capillary, 
it was thought that this flap would cover the outlet, blocking the flow and increasing 
capsule retention.  To prevent this blockage, the capillary was sharpened on both sides 
to create two smaller flaps, one on each side of the capillary.  The capillaries were then 
secured into place using water resistant epoxy and allowed to cure fully before use.  It is 
noted that the sharpened capillaries are sufficiently recessed inside of the device to 
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allow for safe assembly.  A rendering of the assembled best case device for this study is 
shown in Figure 7.2. 
 
Spacer Designs 
 The Spacer 1 design (Figure 7.3a) was constructed with the intent to keep the 
incoming ventilation gas flow separated from the aerosol plume until the plume had 
expanded for several centimeters.  The ventilation gas flow passed through a narrow slit 
(~ 1 mm wide) for 10 mm in order to unify the flow.  The ventilation gas then entered a 
mixing chamber region, which was 25 mm in diameter and 45 mm long, next to the 
outer wall with the intent of inward flow motion and reducing wall deposition.  The total 
volume of spacer 1 was 40.4 cm3, which at a flow rate of 5 LPM is expected to add 
approximately 0.5 s of travel time to the particles.   The interior walls were made as 
smooth as possible and all connections were streamlined to avoid unwanted powder 
losses.   
 Spacer 2, shown in Figure 7.3b, was designed to reduce the aerosol plume size 
by introducing uniform flow as soon as it exits the device.  Recirculation was believed to 
be responsible for a portion of the losses in the Spacer 1 design.  To promote uniform 
flow through the spacer, a series of cylindrical rods, 1.75 mm in diameter and spaced 
with a 1 mm gap between, was introduced to the incoming air flow.  Six of these arrays 
are stacked together along the central axis of the spacer, in a 3D grid formation, so that 
each vertical array was followed by a horizontal array.  Also, the vertical and horizontal 
arrays that make up the third and fourth set of arrays are offset so that the centers of 
the rods are positioned in the center of the gap of the array in front and behind that are 
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oriented in the same direction, so that a front view of the grid appears to be completely 
blocked.  The total volume of the spacer that the aerosol goes though is 33.7 cm3, 
which is similar to the volume after the aerosol meets the airflow in Spacer 1 (33.5 cm3).  
In the Spacer 2 design, the straight mixing section has a diameter and length of 30 mm 
and 80 mm, respectively.  This mixing section then smoothly connects to a 4 mm tubing 
outlet over a length of 55 mm. 
Both spacers consist of inlet, straight mixing, and outlet sections.  These sections 
were connected using threaded overlaps designed and prototyped onto the pieces and 
sealed using two o-rings for each connection.  The devices were also connected to the 
spacers using a threaded connection to match the luer-lock style threads on the device 
outlets. 
 
Streamlined Components 
 Previous studies have demonstrated that with noninvasive ventilation systems, 
sites of flow expansion and contraction as well as sudden direction changes are 
responsible for high depositional losses of aerosol (Longest et al. 2013a, Longest et al. 
2013c).  Our group has proposed a “streamlined” design concept in which all conduit 
sudden expansions and contractions are eliminated and direction changes are restricted 
to a minimum radius of curvature (Longest et al. 2011b, Longest et al. 2013a, Longest 
et al. 2014a, Longest et al. 2014b).  This streamlined component approach has 
previously shown significant increases in aerosol transmission efficiency in both high 
flow (Behara et al. 2014c) and low flow (Longest et al. 2014b) N2L delivery systems.  
Based on the study of Longest et al. (2014b), an optimized streamlined nasal cannula 
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and Y-connector were implemented in this study as shown in Figure 7.4.  Both devices 
utilize 4 mm internal diameter tubing, which is consistent with the 2 – 4 mm range of 
commercial LFNC systems.  Luer-lock style connectors were included in the connection 
components to facilitate assembly and disassembly of an airtight system for determining 
sectional aerosol deposition.  These relatively bulky connectors will not be needed in a 
final design for clinical use. 
 
LFNC System Setup 
 The 4 mm diameter tubing, shown in Figure 7.5, connecting the Y-connector to 
the cannula was ~60 cm long to simulate the length needed to curve the tubing around 
the ears and allow the spacer to reside sufficiently far from the patient.  A simulated 
patient with the nasal cannula in place is shown in Figure 7.6a.  Figure 7.6b shows the 
device/spacer setup, while connected to ventilation gas using a standard barb fitting, 
and connected to the Y-connector.  All tubing connections were sealed using a similar 
sealing system to the device, where the male connector is inserted (with two o-rings for 
sealing) into the corresponding female connector (either on the cannula or Y-connector) 
and twisted 30° to lock into place. 
 
Evaluation of Devices, Spacers, and Full Delivery System 
Aerosolization performance of the LV-DPIs was characterized using 10 mg of 
EEG-AS powder formulation, which was accurately weighed and manually filled into 
size 0 capsules.  This 10 mg mass of powder filled approximately 3% of the capsule 
volume.  It is estimated that the capsules can hold approximately 100 mg without 
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powder contacting the capillaries when the device is operated in the intended horizontal 
position.  Loaded capsules were placed in one half of the LV-DPI device and pierced 
when the two device halves were sealed together with a 30° turn. After the devices were 
assembled, a 10 mL syringe was filled with room air and then connected via the luer-
lock onto a 3-way stopcock that was connected to the LV-DPI inlet.  To maintain a 
consistent distance from the outlet of the devices to the inlet of the NGI for aerosol 
sizing, a custom adaptor was fabricated which held the LV-DPIs approximately 3 cm 
away from the NGI preseparator inlet. The powders were then aerosolized with the LV-
DPI in a horizontal position.  As minimal size change is expected in the aerosol under 
ambient temperature and relative humidity (RH) conditions, experiments were 
conducted with ambient air (T = 22 ± 3 oC and RH = 50 ± 5 %) with the NGI at room 
temperature.  To allow for horizontal positioning of the inhaler, the NGI was positioned 
on its side (oriented vertically). The NGI was operated at 45 L/min and the preseparator 
and individual stages were coated with MOLYKOTE® 316 silicone spray (Dow Corning, 
Midland, MI) to minimize particle bounce and re-entrainment.  The flowrate of 45 LPM 
was chosen to ensure collection of the aerosol and maintain reasonable stage cutoff 
diameters for evaluating a small size aerosol.  To actuate the DPI, the plunger of the 
syringe was depressed quickly (~0.2 seconds to empty) to aerosolize the powder into 
the inlet of the NGI.  The stopcock valve was then turned to the off position for the 
device and the syringe was refilled with room air through the open port for a total of 5 
actuations.  Syringe emptying times were determined in our previous work using a 
single operator and high speed photography at 1000 frames/sec (Farkas et al. 2017).  
All measurements were made with three replicates for each design configuration. 
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After the best case device was chosen, the spacer was optimized using the same 
device for comparison.  The spacers were tested in the horizontal position using the 
same adapter designed to hold the devices 3 cm away from the inlet of the NGI, as 
described above.  After each replicate, the spacer was disassembled, and the sections 
were assayed separately.  The spacer ED is defined as the percentage of the loaded 
dose that was not retained in both the device and spacer after 5 actuations. 
For steady state testing, the powder exiting the cannula was directed in the NGI 
while being held in place by a clamp.  The cannula was not sealed to the NGI and it was 
expected that the NGI flow rate of 45 LPM was sufficient to capture all aerosol exiting 
from the cannula.  A similar curvature to the tubing shown in Figure 7.6a was used to 
allow the spacer and device to be used horizontally on the benchtop.  Images showing 
the powder exiting the cannula are shown in Figure 7.7 while flowing into an open 
environment.  After testing, all of the components were disassembled and assayed 
separately with the cannula ED being defined as the percentage of the loaded dose that 
made it through all of the components and into the NGI. 
 
Aerosol performance characterization methods 
After aerosolization, drug masses retained in the capsule, device, spacer, and 
system components (tubing, Y-connector and cannula), and the drug collected on the 
preseparator, impaction plates and the filter of the NGI were recovered by washing with 
appropriate volumes of deionized water and quantified by HPLC analysis.  The mass of 
AS retained in the capsule, device, spacer, and system components, determined by 
HPLC, was expressed as a percentage of the nominal AS dose. The device emitted 
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dose (device ED) was calculated by subtracting the mass of AS retained in the capsule 
and device from the loaded AS dose.  The spacer ED was calculated by subtracting the 
mass of AS retained in the capsule, device, and spacer from the loaded dose.  
Likewise, the cannula ED was calculated by subtracting the AS retained in all of the 
components from the loaded dose. 
In order to determine the nominal dose of AS in the EEG-AS formulation, known 
masses of the formulation were dissolved in 50 ml of water and the mean amount of AS 
per mg of formulation was determined using HPLC analysis. For each aerosolization 
experiment, the measured formulation AS content and the mass of formulation loaded 
into the capsule was used to determine the nominal dose of AS.  
The cut-off diameters of each NGI stage at the operating flow rate of 45 LPM 
were calculated using the formula specified in USP 35 (Chapter 601, Apparatus 5) and 
were used to calculate MMAD and fine particle fractions of the delivered aerosol. Fine 
particle fraction of the EEG formulation (FPF<5µm/ED) and sub-micrometer FPF 
(FPF<1µm/ED) were defined as the fraction less than 5 µm and 1 µm, respectively, 
expressed as a percentage of the ED.  MMAD, FPF<5µm/ED and FPF<1µm/ED were 
calculated by linear interpolation using a plot of cumulative percentage drug mass vs. 
cut-off diameter. 
 
7.4 Results 
EEG Formulation Dispersion Characterization 
 The dispersion characteristics for the batch of EEG-AS formulation used in this 
study was determined using a Sympatec laser diffraction system using an 
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ASPIROS/RODOS unit for comparison to previous studies as well as comparison to the 
aerosolization performance of the devices in this study.  The geometric diameters given 
by the laser diffraction system were converted to aerodynamic diameters using the 
theoretical particle density of 1.393 g/cm3 (Longest et al. 2011a).  The MMAD was 
calculated to be 1.18 µm while the FPF<5µm/ED and FPF<1µm/ED values were found to be 
100% and 38.2%, respectively.  The results of this test show that the powder is highly 
dispersible when using a benchtop dispersion unit that operates at high pressures. 
 
Device Optimization 
 Two capillary inlet configurations were tested in this study to optimize the 
straight-through (ST) design: an inlet containing a single 0.6 mm diameter capillary and 
an inlet containing three 0.6 mm capillaries spaced evenly around the long axis of the 
device.  Performance results of the ST designs are given in Table 7.1.  The first inlet 
configuration tested was the original inlet from our previous work (Farkas et al. 2017), 
the single 0.6 mm inlet.  The performance, which was comparable to the previous study, 
included an ED of 63.1% and an MMAD of 1.56 µm.  To attempt to decrease the 
amount of powder left in the capsule, the number of inlet capillaries was increased to 
three in a circular pattern around the long axis of the device.  With an ED of 62.1% and 
MMAD of 1.66 µm, there was no significant difference found between the single and 
three inlet devices. 
It was observed through device testing that powder was being lost on the inlet side 
of the devices, in places the jet from the inlet capillaries would not impact.  To prevent 
this, the capillaries were retracted by no more than 4 mm to give a consistent piercing of 
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2 mm inside the capsule.  These devices with retracted capillaries are denoted as 
0.6mm_v2 and 3x0.6mm_v2.  Both devices showed a significant increase in ED, with 
the 0.6mm_v2 LV-DPI producing a mean device ED of 84.6% and the 3x0.6mm_v2 LV-
DPI producing a mean device ED of 78.1%.  Both devices showed an increase in 
MMAD (1.77 µm) and a slight decrease in FPF<1µm/ED values (20%), but the ~20% 
higher ED was considered to offset the small size increase.  Because no significant 
differences were found between the 0.6mm_v2 and 3x0.6mm_v2 LV-DPIs, the simpler 
of the two designs, 0.6mm_v2, was chosen as the best case for further study.  Further 
details of device performance and statistical comparisons are provided in Table 7.1. 
 
Comparison of Spacer Designs 
 Two spacer designs were chosen for investigation for this study with the function 
of controlling the aerosol plume exiting the device to allow for transport of the powder 
through the delivery system.  Spacer 1, which is shown in Figure 7.3a, was designed to 
keep the incoming airflow separate from the aerosol plume while allowing the plume to 
expand.  Once the plume had expanded, the airflow would then meet with the plume 
through a 1 mm wide slit around the circumference of the flow path of the spacer.  This 
design had a mean spacer retention of 12.2% with the MMAD increasing to 2.28 µm, 
which is 0.51 µm larger than the size exiting the LV-DPI device (Table 7.2).  
Corresponding FPF<5µm/ED and FPF<1µm/ED values decreased from the values leaving the 
device to 89.4% and 12.2%, respectively.  The second spacer design (Spacer 2), shown 
in Figure 7.3b, included six rod array inserts, each rotated 90 degrees from the next, 
composed of equally spaced cylindrical rods.  These inserts were designed to help 
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produce a uniform inlet airflow to help reduce losses in the spacer.  In addition, this 
design also introduced the aerosol to the airflow as it exited from the device.  This 
spacer saw a slight reduction in losses to produce a mean spacer retention value of 9% 
with a similar size to Spacer 1 (MMAD = 2.31 µm) and with similar FPF values: 86.5% 
<5 µm and 13% <1 µm.  Spacer 2 was then chosen to investigate further by connecting 
it to the full LFNC delivery system (Figure 7.5). 
 
Effect of Flow Rate on Aerosol Characteristics 
 The original flow rate, 5 LPM, which was used to choose the best spacer option, 
served as the starting point to observe the aerosol characteristics exiting the cannula 
with the results given Table 7.3.  With the best-case device and spacer (0.6mm_v2 and 
spacer 2), the mean cannula ED was 64.6% with a mean MMAD of 2.41 µm, mean 
FPF<5µm/ED of 84.4%, and FPF<1µm/ED of 11.3%.  In an attempt to decrease either 
hygroscopic growth or electrostatic attraction losses of smaller particles in the very 
narrow tubing, which were thought to be potential sources of the size increase from the 
outlet of the device to the outlet of the cannula, the flow rate was increased to 8 LPM.  
The increase in flow rate decreases the retention time of the powder in the system to 
allow either less time for hygroscopic growth or less time for the static charge to attract 
the small particles to the walls.  The cannula ED at 8 LPM of 63.4% was not affected by 
the flow rate change.  However, the cannula emitted size decreased significantly to 1.93 
µm at 8 LPM, which provides an absolute difference of 0.48 µm (20% smaller).  Fine 
particle fractions also increased at 8 LPM as FPF<5µm/ED was 92.4% and FPF<1µm/ED was 
16.2%, indicating a smaller aerosol. 
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7.5 Discussion 
Through careful optimization of the LV-DPI, device ED was increased from 62.1% 
to 84.6%.  While the device emitted MMAD was increased to 1.77 µm, dispersion of the 
powder remained high with FPF values of 95.2% < 5 µm and 20.2% < 1 µm.  
Introduction of a new inline spacer enabled the aerosol to be combined with the LFNC 
delivery line with minimal loss and maintained separate ventilation and DPI actuation 
gas streams.  Optimization of the spacer design reduced spacer loss from 12.2% 
(concentric design) to 9% (uniform flow design).  A low total spacer volume was 
maintained (< 33.7 cm3) to provide an acceptable time delay between device actuation 
and transmission through the nasal cannula.  The aerosol exiting the nasal cannula was 
larger than exiting the LV-DPI device and was greater than 2 µm, which is larger than 
the ~1.5 µm MMAD that was desired.  However, aerosol transmission efficiency out of 
the cannula (i.e., cannula ED) achieved the targeted >60% goal and was as high as 
65% under optimized conditions. 
One surprising outcome of this study was that aerosol size increased through the 
LFNC system resulting in a greater than 2 µm outlet MMAD at a LFNC flow rate of 5 
LPM.  Increasing the LFNC flow rate to 8 LPM produced approximately the same overall 
system depositional loss, but reduced the ex-cannula MMAD to 1.93 µm.  One possible 
explanation of this size increase is hygroscopic growth of the EEG aerosol, which is a 
time dependent process (Longest et al. 2012a).  Longer residence time with 5 LPM flow 
allows for more growth and a larger outlet aerosol.  However, the LFNC gas is assumed 
to be almost completely dry.  The humidity for aerosol growth would then come entirely 
from the 10 ml of room air injected into the system with each actuation, which seems 
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unlikely.  An alternative explanation may be aerosol charge.  Dry powder aerosols are 
known to have an electrostatic charge, especially in dry environments (Byron et al. 
1997, Kwok et al. 2009).  Smaller particles are also likely more influenced by charge 
than larger particle (Vinchurkar et al. 2009).  Hence, the electrostatic charge on the 
small particles may cause a disproportionate loss of the small particle size fraction at 5 
LPM thereby increasing the overall size of the aerosol.  Importantly, with either 
scenario, the net aerosol transmission efficiency through the cannula is high and in the 
range of 63-65%.  If a smaller aerosol with MMAD < 2 µm is desired at the cannula 
outlet to minimize nasal depositional loss, then increasing the gas flow to 8 LPM for the 
short time of aerosol administration provides a reasonable option. 
The aerosol size exiting the cannula will primarily affect nasal depositional loss 
(Garcia et al. 2009, Schroeter et al. 2015) as well as the final droplet size achieved by 
the EEG aerosol (Longest et al. 2011a).  The degree of nasal deposition will depend on 
the nasal inhalation flow rate and may be different from ambient inhaled aerosols due to 
the presence of the nasal cannula (Walenga et al. 2014).  From previous experiments 
with nasal aerosols with a nasal cannula interface, depositional loss with a 2 µm particle 
at a nasal inhalation flow rate of 30 LPM is expected to be approximately 10% or less.  
As a result, the estimated lung delivery efficiency including nasal losses will be ~50-60% 
of the initial loaded dose.  Furthermore, depending in the lung region to be targeted, it 
may be beneficial to start the EEG particle size at ~ 2 µm in order to achieve a larger 
final droplet size (Longest et al. 2011a, Tian et al. 2014b).  Based on the study of 
Longest et al. (2011a), a 2 µm initial EEG particle can achieve a final size > 6 µm within 
the lungs. 
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Perhaps more important to total lung deposition than the inhaled 2 µm MMAD 
aerosol is the fact that the aerosol is delivered very rapidly.  The transit time (the time 
required for the aerosol to reach the cannula after syringe actuation) of the delivery 
system was similar for 5and 8 LPM and is approximately 0.2 s for both flow rates.  
However, delivery duration (the duration of time that aerosol is exiting the cannula) from 
the cannula was affected by the flow rate and at 5 and 8 LPM is approximately 0.75 and 
0.5 s, respectively.  This compact time window should enable actuation with the start of 
nasal inspiration.  A simple pressure monitor or flow direction element on the cannula 
can be used to sense inspiratory or expiratory flow.  Ideally, conscious subjects can be 
instructed to inhale deeply through the nose for a period up to 3 s, enabling all of the ex-
cannula dose to enter the nose.  Synchronization with inspiration and nasal depositional 
losses will be considered in future studies. 
Optimization of the device in this study provided a significant improvement in ED 
compared with the previous LV-DPI development study (Farkas et al. 2017).  The 
primary device change that enabled this improvement was retracting the capillaries 
approximately 4 mm each.  Physically, this retraction maintained higher velocity near 
the capillary walls and prevented powder deposition near the capillary bases.  A slight 
increase in aerosol size was observed to a device outlet MMAD of 1.77 µm for the best 
case design.  This size increase of 0.21 µm is likely due to both more of the powder 
being aerosolized and reduced shear forces associated with the capillary outlet 
positioned closer to the capsule wall.  Other design improvements to increase ED were 
less effective.  Due to no significant difference in the 0.6 mm and 3x0.6 mm inlet 
designs, the simpler, single 0.6 mm capillary inlet was chosen for further study.  Both 
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the optimization of the spacer and flow rate selection for cannula delivery used the 
same device for comparison. 
Previous studies evaluating N2L aerosol delivery using small diameter cannula 
consistent with LFNC systems are rare.  Perry et al. (Perry et al. 2013) previously 
considered transmission efficiency of an Aeroneb Solo mesh nebulizer at multiple flow 
rates through a nasal cannula system.  At an airflow rate of 5 LPM the percentage of 
nominal dose exiting adult, pediatric and infant small bore cannula were 2.5, 0.6 and 
0.6%, respectively.  The aerosol MMAD exiting the adult cannula at 5 LPM was 0.48 µm 
(Perry et al. 2013).  Particles in the size range of 0.5 µm are expected to have limited 
lung deposition and be largely exhaled (Kim et al. 2000).  In contrast, the newly 
developed LV-DPI system delivered 65% of the initial dose through the cannula, 
resulting in a 26-fold increase compared with the conventional mesh nebulizer system 
and adult cannula size of Perry et al. (Perry et al. 2013).  Furthermore, the exiting 
aerosol size of 2 µm and use of EEG particles are expected to enable lung targeted 
deposition and minimal exhaled aerosol loss (Tian et al. 2013). 
Limitations of the current study include the need for additional device 
improvements, addition of a nasal cavity model and breathing waveform, evaluation of 
flow synchronization and consideration of lung deposition and exhaled dose.  
Considering device improvements, currently the syringe must be removed with each 
actuation and refilled with room air.  This limitation will be overcome with the 
introduction of a one-way valve that enables device refilling while assembled.  Inclusion 
of a nasal model is needed to verify high transmission of the aerosol to the lungs.  It is 
expected that the back pressure introduced with the spacer and nasal cannula interface 
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marginally reduced performance.  Therefore, including a breathing subject may improve 
cannula ED and aerosol size.  Aerosol transmission measurements were made to 
evaluate the potential for flow synchronization.  However, experiments with a breathing 
waveform are still needed.  Finally, many studies equate tracheal filter deposition with 
lung deposition, which ignores the exhaled aerosol fraction.  Improved lung deposition 
and reduced exhaled dose expected with EEG aerosols (Tian et al. 2014b) need to be 
confirmed. 
In conclusion, this study has successfully improved the LV-DPI and applied the 
device to achieve high efficiency delivery of a dry powder aerosol in a LFNC system.  
Device modifications were implemented to improve ED and reduce spacer depositional 
loss.  Transmission efficiency of loaded drug mass through the optimized system was 
65%, which represents a 26-fold increase compared with similar commercial systems 
(Perry et al. 2013).  Application of this technology to other less challenging systems with 
larger tubing diameters will further increase transmission efficiency.  A primary 
advantage of using a dry powder device is the large powder mass that can be 
administered in a short amount of time.  The developed system delivered a 10 mg 
powder mass in approximately 38 s (assuming a 7.5 s breathing cycle for deep 
inspiration) compared to a minimum 7 min with a mesh nebulizer at a 0.5% 
concentration, not accounting for system losses.  Potential applications of this device 
include high dose inhaled medications such as inhaled surfactants, antibiotics, 
mucolytics, and anti-inflammatories.  Further studies are needed to verify the potential 
for synchronization with inhalation, high lung transmission efficiency, and low exhaled 
dose.  
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7.6 Abbreviations 
AS Albuterol sulfate 
DPI Dry powder inhaler 
ED Emitted dose 
EEG Excipient enhanced growth 
ETT Endotracheal tube 
FPF Fine particle fraction 
HPLC High performance liquid chromatography 
HPMC Hydroxypropyl methylcellulose 
ID Internal diameter 
LFNC Low flow nasal cannula 
LPM Liters per minute 
LV Low volume 
MMAD Mass median aerodynamic diameters 
N2L Nose-to-lung 
NGI Next Generation Impactor 
RH Relative humidity 
ST Straight-through 
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Figure 7.1 Mid-plane cross-sectional view of the LV-DPI devices with inlet-outlet 
capillary diameters and needle insertions: a) 0.6mm-0.89mm_v1, b) 3x0.6mm-
0.89mm_v1, c) 0.6mm-0.89mm_v2, d) 3x0.6mm-0.89mm_v2, e) 3x0.6mm-0.89mm; 
and, inlet capillary patterns drawn to scale for the (e) single inlet and (f) three capillary 
inlet. 
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Figure 7.2 Semi-transparent 3D rendering of the ST-0.6mm_v2 device. 
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Figure 7.3 Section views of the two spacer designs: a) Spacer 1, b) Spacer 2. 
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Figure 7.4 3D renderings of the streamlined components from the delivery system: a) 
Cannula, b) Y-Connector 
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Figure 7.5 Schematic drawing showing the overall layout of the delivery system with 
each component labelled. 
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Figure 7.6 Complete LFNC plus LV-DPI delivery system: a) tubing and cannula 
mocked up on a mannequin head, b) assembly of the syringe, device, spacer, and y-
connector. 
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Figure 7.7 Still images of powder leaving the cannula at different times during 
administration: a) just before powder exits, b) powder beginning to exit, c) midway 
through dose, d) just as powder stops exiting. 
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Table 7.1 Optimization of Straight-Through (ST) LV DPI device.  Mean aerosol 
characteristics with standard deviations (SD) shown in parenthesis [n=3]. 
Description 
Inlet Capillary Dimensions 
0.6mm_v1 3x0.6mm_v1 0.6mm_v2 3x0.6mm_v2 
     
Device ED (%)* 63.1 (4.8) 62.1 (1.5) 84.6 (6.3)**,*** 78.1 (3.0)**,*** 
     
Capsule (%)* 30.4 (6.1) 28.6 (3.9) 14.4 (5.8)**,*** 18.7 (1.8)**,*** 
Device (%)* 6.4 (3.1) 9.3 (2.5) 1.0 (0.6)*** 3.2 (1.2)*** 
     
FPF<5µm/ED (%)* 97.8 (0.1) 95.7 (1.5) 95.2 (0.4) 93.5 (1.5)** 
FPF<1µm/ED (%)* 23.9 (0.5) 21.3 (1.0) 20.2 (1.7)** 20.1 (1.0)** 
MMAD (µm)* 1.56 (0.01) 1.66 (0.04) 1.77 (0.08)** 1.77 (0.03)** 
*p<0.05 significant effect of device configuration on % ED and % capsule drug retention 
(one-way ANOVA).  
 
**p<0.05 significant difference compared to 0.6mm_v1 (post-hoc Tukey). 
***p<0.05 significant difference compared to 3x0.6mm_v1 (post-hoc Tukey). 
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Table 7.2 Optimization of LV-DPI Spacer.  Mean aerosol characteristics with 
standard deviations (SD) shown in parenthesis [n=3]. 
Description Spacer 1 Spacer 2 
   
Capsule (%) 10.7 (4.9) 7.6 (0.2) 
Device (%) 2.2 (1.3) 1.2 (0.1) 
Device ED (%) 87.1 (5.9) 91.2 (0.2) 
   
Spacer (%)* 12.2 (1.3) 9.0 (1.8) 
Spacer ED (%)* 74.8 (5.8) 82.2 (1.6) 
   
FPF<5µm/ED (%) 89.4 (3.9) 86.5 (3.1) 
FPF<1µm/ED (%) 12.2 (1.1) 13.0 (0.7) 
MMAD (µm) 2.28 (0.18) 2.31 (0.11) 
*p <0.05 significant difference between Spacer 1 and 2 (t-test). 
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Table 7.3 Comparison of entire delivery system at 5 LPM and 8 LPM.  Mean aerosol 
characteristics with standard deviations (SD) shown in parenthesis [n=3]. 
Description 5 LPM 8 LPM 
   
Capsule (%) 15.0 (2.3) 12.5 (3.3) 
Device (%) 2.0 (0.2) 3.1 (0.9) 
Device ED (%) 83.0 (2.1) 84.5 (2.6) 
   
Spacer (%) 6.7 (0.3) 5.9 (1.0) 
Spacer ED (%) 76.2 (1.8) 78.6 (2.7) 
   
Y-Connector (%) 2.9 (0.6) 4.5 (1.2) 
Tubing (%) 3.9 (0.7) 4.5 (1.3) 
Cannula (%) 4.8 (0.7) 6.2 (3.1) 
Cannula ED (%) 64.6 (1.1) 63.4 (3.1) 
   
FPF<5µm/ED (%)* 84.4 (1.8) 92.4 (3.7) 
FPF<1µm/ED (%)* 11.3 (0.3) 16.2 (0.7) 
MMAD (µm)* 2.41 (0.05) 1.93 (0.09) 
*p <0.05 significant difference between 5 LPM and 8 LPM (t-test). 
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Chapter 8 Conclusions and Future Work 
  
The objectives described in Chapter 1 have each been accomplished.  A 
summary of the tasks accomplished is as follows: (1.1) two prototype devices (CC1-3D 
and CC90-3D) were designed around the 3D rod array technology and tested using in 
vitro methods; (1.2) inlet hole position of the CC1-3D device developed in Task 1.1 was 
investigated using high-speed photography and linked to device performance with in 
vitro testing; (1.3) alternate materials were studied for the 3D rod array and the effect on 
aerosolization performance was quantified; (2.1) a device using a critical orifice to 
control flow rate with positive pressure applications was designed and optimized for 
usage in high flow nasal cannula (HFNC) and low flow nasal cannula (LFNC) therapy; 
(3.1-3.2) a high dose device, based on a fluidized bed design, that was capable of 
delivering up to 100 mg of powder was designed to operate with both adult and pediatric 
patients and the aerosolization performance was compared with the CC90-3D device 
developed in Task 1.1; (3.3) the mixing spheres that the fluidized bed initially included 
were removed, leaving only the dose sphere as the main source of deaggregation, in 
order to reduce device retention; (4.1) prototype devices were designed to deliver 
loaded doses up to 50 mg and powered by a small volume of air provided by a syringe 
or placebo MDI; (4.2) the devices from Task 4.1 were tested to discover the optimized 
device and air source (syringe); (4.3) the device optimized in Task 4.2 was used to 
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develop a delivery system to be used in LFNC delivery in steady state conditions.  
Conclusions and possible future studies, identified based on the results of these 
objectives, are summarized below in more detail. 
 
8.1 Objective 1: Development of a High Efficiency Dry 
Powder Inhaler 
The poor performance of DPIs currently available on the market limit the 
available medications and therapies that can be safely administered.  Drugs requiring a 
specific dose to be delivered, for effectiveness and prevention of side effects, are 
difficult to use with standard DPIs because of large dose variabilities between patients.  
This study has described new strategies for increasing the lung dose and decreasing 
the dose variability in patients.  The CC1 device was shown to work well for an adult 
patient, while the CC90 device performed similar across a range of flow rates that 
simulate use by children, adults, or patients with lung diseases causing less than ideal 
inhalation conditions. 
While the devices in this study have performed well, future modifications to the 
designs could still be beneficial to both performance and manufacturability of the 
devices.  Integration of a capsule piercing mechanism is a concern because the location 
of the optimal capsule piercings makes it difficult to pierce in a single motion.  A simpler 
piercing location needs to be tested before designing a mechanism.  With the work 
done in Objective 4, it was proven that a small air volume passing through the capsule 
can produce a high ED and small MMAD.  An alternative to a piercing mechanism that 
pierces, then retracts back into the device, is to design the device to use hollow 
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capillaries to pierce the capsule and stay in place to provide the inlet and outlet air.  
Extrathoracic (mouth-throat or nasal) deposition studies also need to be performed to 
test the efficacy of the devices with the AS formulation as well as with other 
medications. 
 
8.2 Objective 2: Development of an Inline DPI System using 
3D Rod Array Technology 
The effectiveness of DPIs in producing an aerosol capable of delivering 
medication to the lungs using N2L delivery was shown in this study.  With flow rates in 
the range of 5-45 LPM investigated, small particle sizes and low losses were observed 
which should correspond with low losses in the NMT region and high lung doses.  The 
active devices investigated should be especially helpful for delivering aerosols to 
patients that lack the ability to produce a flow rate high enough to use passive devices, 
as well as to patients on mechanical ventilation with HFNC therapy. 
Future work to improve this technology includes modifying the design to reduce 
device losses to below 20%, as well as adding an inhalation sensor and an activation 
switch for detection and delivery during inhalation only.  A challenge posed by capsule-
based delivery in a positive pressure system is the need for a well sealed piercing 
mechanism to prevent air leaks.  The mechanism needs to be simple and easy to use in 
order to prevent improper usage by the patient.  Delivery using a NMT model and 
realistic breathing profiles should also be investigated to confirm the efficacy of these 
devices. 
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8.3 Objective 3: High-Dose Dry Powder Inhaler Development 
The classic deaggregation method of a fluidized bed (FB) was implemented in a 
compact hand-held oral inhaler for the first time and optimized for the delivery of high 
dose dry powder aerosols.  Based on previous performance of new high efficiency 
inhalers originally designed for lower doses, the optimized FB-DPI provided excellent 
deaggregation of the aerosol but decreased ED under adult and pediatric inhalation 
conditions (Behara et al. 2014a, Behara et al. 2014b).  Removal of the mixing balls 
improved emitted dose while maintaining excellent deaggregation, such that the 
combination of the powder formulation with the mixing chamber and dose sphere is 
likely most responsible for the high quality aerosol that was produced.  Still, the 
combination of the FB-DPI and EEG powders with or without the mixing balls achieved 
MMADs and FPFs that are far superior to currently available products.  Compared with 
the newly proposed high dose Orbital inhaler, the strength of the FB-DPI is its improved 
aerosolization (Young et al. 2013).  However, the Orbital device is currently capable of 
delivering 400 mg, which may be advantageous in some applications.  Our approach is 
to instead load 100 mg and be four times more efficient at targeted lung delivery, which 
is to be determined in future studies.  Analysis of the fluidized bed design indicated that 
removal of the mixing balls and maintaining the newly designed dosing sphere and 
chamber increased ED to 73.8% while maintaining excellent aerosolization 
performance.  As a result, it is concluded that the FB-DPI is highly effective but can be 
simplified by maintaining only the newly designed dosing sphere and inhaler chamber.  
Future studies will seek to optimize the simplified new design for high dose DPI delivery 
to both adults and children.  This simplified design will then need to be tested in a MT 
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model for adults and children to show the efficacy of the devices in reducing losses with 
large masses of powder. 
 
8.4 Objective 4: Development of a low-volume capsule-
based Dry Powder Inhaler and Nose-To-Lung Delivery 
Platform 
The results of this study show that a high quality aerosol can successfully be 
generated using a low volume of air on the order of approximately 10 mL.  While the 
results do not meet all of the desired performance metrics for high efficiency EEG 
aerosol delivery, this device provides a substantial advance.  The device successfully 
outperformed more complex devices (Tang et al. 2011, Pohlmann et al. 2013, 
Hoppentocht et al. 2014b), while still being easy to load and operate.  The LV devices 
also compared well with the inline DPIs our group has developed, with improved ED 
and FPF<5µm/ED values higher than obtained with current 3D rod array inline devices 
while using 2 orders of magnitude less air (Behara et al. 2014c).  Higher drug masses 
on the order of 50 mg marginally decreased aerosol performance; however, it is 
expected that improved performance can be obtained by optimizing the device for 
operation with a known mass of powder for a specific application.  Furthermore, we 
expect that a quantitative analysis and design approach (Longest et al. 2009, Hindle et 
al. 2013) implementing computational fluid dynamics (CFD) (Longest et al. 2013b) and 
additional prototyping can be used to meet all of the high performance aerosol delivery 
metrics that were initially set. 
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 With the redesign of the straight-through (ST) device, great progress was shown 
in delivery of an aerosol through a LFNC system using steady state conditions.  While a 
NMT model was not used to determine losses after the cannula exit, the high FPF 
values and low MMAD obtained with this device should be able to avoid depositional 
losses in the nasal passages and achieve a high lung dose.  Future work with this 
device will need to include the addition of at NMT model and realistic breathing profiles 
to show that the delivery of the aerosol can be synced to the inhalation time of the 
patient to prevent aerosol being delivered at the wrong time.  The LV device was also 
designed to accept a higher mass of powder in the capsule and this was tested with the 
SS-0.89mm device previously.  The redesigned ST 0.6mm_v2 device was not tested 
with the larger mass, but considering the performance of the device was significantly 
better with the 10 mg fill mass, the larger powder mass should also perform better. In 
addition, the LFNC system developed in this study is designed to work with an adult 
patient.  Because of the flexibility of the LV device, it can also be adapted to deliver 
aerosols to infants and children, but a new interface would have to be adapted to work 
with the reduced flow rates and tidal volumes of these potential patients.  With the 
PennCentury DP-4 devices no longer available, there is a need for devices able to 
deliver aerosols to test animals.  The LV devices explored in this study could be a prime 
candidate for use in testing environments because of its ease of use and high 
performance with air volumes that would need to be used in these animals. 
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8.4 Lessons Learned 
There have been many takeaways from the research conducted in these studies.  
Firstly, the coupling of device development and formulation development was found to 
achieve optimal delivery conditions.  Compared to devices/formulations on the market, 
this is a major change, as current commercial devices are inefficient.  While some 
commercial devices have reasonable deaggregation capabilities, when paired with a 
less dispersible powder formulation, they do not perform well.  Likewise, if a highly 
dispersible powder is used in a poor device, poor aerosolization results can be 
expected. 
If the powder formulation used is highly dispersible, as with the case of the EEG 
powders studied in this research, device over complexity adds unnecessary 
complications to design and usage.  A simpler device design that focuses on the a 
single deaggregation method together with ease-of-use may be advantageous.  For 
example, the original design of the high-dose oral inhaler attempted to use a fluidized 
bed to disperse the power because it was expected that the small holes in the dosing 
sphere would not create the needed amount of dispersion.  When the mixing spheres 
were removed, however, it was shown to be just as efficient in aerosolization, but 
without the added complexity of the mixing balls contributing to the device retention. 
In regard to the LV devices, small changes to the capillaries used in the devices 
were shown to produce large changes in the efficiency of the devices.  A 20% increase 
in outlet capillary diameter was shown to increase the size on the order of 50% when 
leaving the device.  This speaks to the simplicity of the device, as the only variables 
changed were the outlet diameter and capillary insertion length to move from a less 
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efficient to a highly efficient device.  Also, positive pressure devices as a whole have 
been studied previously, but most have been dismissed as having poor efficiency.  This 
research shows that positive pressure devices can indeed be efficient when used in the 
right circumstances and can even be highly adaptable delivery systems. 
 
8.5 Contributions to Science 
The phases of graduate student education shown in this work include training in 
the research area, application of ideas, and innovation showing state-of-the-art 
solutions to complex problems.  The areas of study that are the focus of this research 
include aerosol science, device development and design, and respiratory drug delivery.  
During the training an application phases, the development of the 3D rod array system 
as a means to disperse an aerosol was the primary focus.  This includes the 
development of both the CC1 and CC90 devices for oral delivery, as well as the inline 3D 
rod array devices for EEG N2L delivery in both HFT and LFT.  During this time, it was 
shown that device design must be coupled with formulation design to truly optimize 
delivery.  The application phase also consisted of the high dose oral inhaler design 
based on the technology of a fluidized bed, which had previously not been used in an 
inhaler.  This design provides an alternative to the load-dose-repeat cycle that is 
required when using a capsule-based device that is unable to handle high doses of 
powder.  Innovation produced in this research includes the design of a simple, easily 
adaptable, solution to aerosol delivery using a low air volume very efficiently, i.e., the 
LV-DPI device.  This device provides a new strategy for aerosol administration during 
non-invasive ventilation, to children who are unable to use a DPI, and to infants in cases 
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of respiratory distress.  While not directly studied in this work, this innovative design will 
also allow for use in test animals for pharmaceutical research. 
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